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General introduction and outline
Introduction
Around 1970 computed tomography (CT) entered the field of clinical imaging tools. 
In those days both the spatial and temporal resolution of CT were insufficient for 
cardiac imaging. With the introduction of 4-slice CT in the late 1990s, visualization 
of coronary arteries became feasible. Nowadays computed tomography coronary 
angiography (CTA) is considered a suitable non-invasive method for the assessments 
of coronary atherosclerosis; its clinical applicability is widely incorporated in current 
guidelines.1, 2 Coronary stenosis severity on CTA is strongly correlated with invasive 
coronary angiography, and the diagnostic accuracy for the presence of coronary 
artery disease (CAD) is excellent. Especially the high sensitivity (~ 98%) allows 
for accurate rule-out of disease in patients with suspected CAD.3 Additionally, the 
prognostic value of CTA has been established in the past years.4 The prognosis of 
patients is decreased with increasing number of obstructive (≥50% stenosis) lesions.5 
Most importantly, the prognosis of patients without CAD on coronary CTA is excel-
lent. Moreover, it has been noted, that also the presence of non-obstructive CAD 
is associated with impaired prognosis.6 This has led to an increasing interest in the 
clinical value of coronary atherosclerosis burden in addition to only assessing the 
presence of obstructive CAD. On coronary CTA, plaque composition can also be 
assessed. Traditionally, coronary plaque is classified as non-calcified, partially plaque 
or calcified plaque. In several studies, the prognostic implications of the presence 
of different plaque types have been established.7, 8 Patients with non-calcified and 
partially calcified plaque have a worse prognosis compared to patients with only 
calcified plaques. Currently the field of research in cardiac CT is shifting towards 
assessment of overall atherosclerotic burden and incorporating additional features of 
coronary CTA, besides obstructive CAD, for risk stratification of patients. 
Quantification of coronary atherosclerosis.
In current practice the assessment of CAD on coronary CTA is performed visually. 
However, for accurate and reproducible assessment of the dimension and com-
position of coronary atherosclerosis, a quantitative approach would be favorable. 
Recently, novel software algorithms have become available which allow for such a 
quantitative analysis.9  Using this software, the burden of coronary atherosclerosis, 
the three-dimensional dimensions (i.e. diameters and volumes) and the exact de-
gree of stenosis can be quantified. Moreover, this software allows for assessment of 
composition of coronary atherosclerosis using Hounsfield Unit (HU) thresholds. The 




This thesis further investigates the accuracy of this software, especially for quan-
tification of coronary plaque composition. Additionally, the clinical value of this 
quantification algorithm will be explored.  
Diabetic patients without chest pain syndrome.
Cardiovascular death is the main cause of death in patients with diabetes mellitus 
(DM).11 Additionally, patients with DM often have silent myocardial ischemia and 
CAD in an advanced stage before becoming manifest.12 However, in these patients 
traditional cardiovascular risk factors fail to accurately predict diabetic patients’ 
risk.13 In the past years the value of different imaging modalities in the specific setting 
of asymptomatic patients with DM has been addressed.14  
This thesis explores the prognostic value of coronary CTA in these high risk diabetic 
patients. Furthermore, the change in ischemia over-time is investigated, focusing on 
the role of coronary CTA to predict these changes. 
Outline
This thesis focuses on the clinical value of quantification of coronary atherosclerosis 
on coronary CTA. Moreover, the value of coronary CTA in high risk diabetic patients 
without chest pain syndrome in clinical practice is assessed. This thesis is preceded 
by Chapter 2 which provides an overview of the clinical use of computed tomography 
coronary angiography (CTA) and the application in acute cardiac care. 
Part 1 of this thesis focuses on the quantitative assessment of coronary atherosclerosis 
on coronary CTA. 
Chapter 3 describes the different imaging techniques for analysis of coronary 
atherosclerosis. In Chapter 4 the feasibility of an automatic algorithm for coronary 
atherosclerotic tissue characterization is established and compared to IVUS VH. 
Chapter 5 continues the study of Chapter 4 and discusses a novel method to enhance 
the characterization of calcified areas in IVUS VH by quantification of the acoustic 
shadow. This acoustic shadow is the result of the inability of the IVUS signal to 
penetrate calcium, and considered a major limitation of this technique. Chapter 6 
assesses the accuracy of a novel algorithm to automatically detect and quantify the 
Agatston coronary artery calcium score on contrast CTA. In Chapter 7 the param-
eters of coronary atherosclerosis as derived from quantitative coronary computed 
tomography (QCT) are correlated to the presence of myocardial ischemia on gated 
myocardial perfusion single photon emission computed tomography (SPECT). In 
Chapter 8, a novel CTA risk score is introduced which integrates the location, severity 
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and composition of coronary atherosclerosis on CTA in one score. The value of this 
automated QCT-derived risk score for risk stratification is assessed in patients with 
suspected coronary artery disease. In Chapter 9, the value of CTA for serial imaging 
of coronary atherosclerosis is investigated. For this purpose, QCT is performed in 
patients who underwent serial CTA with a 2-year interval.
Part 2 of this thesis focuses on the clinical aspects of coronary atherosclerosis on 
coronary CTA in high risk diabetic patients without chest pain syndrome. 
Chapter 10 investigates the changes in ischemia over time as assessed with SPECT 
myocardial perfusion imaging in relation to characteristics of coronary atherosclero-
sis on coronary CTA. In Chapter 11 the long-term prognostic value of coronary CTA 
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Computed tomography angiography and 
other applications of CT
de Graaf MA, Scholte AJ, Kroft LJ, Bax JJ.




Patients presenting with acute chest pain constitute a common and important di-
agnostic challenge. This has increased interest in using computed tomography (CT) 
for non-invasive visualization of coronary artery disease in patients presenting with 
acute chest pain to the emergency department; particularly the subset of patients who 
are suspect of having an acute coronary syndrome, but without typical ECG changes 
and normal troponin levels at presentation. As a result of the rapid developments 
in coronary CT angiography technology, high diagnostic accuracies for excluding 
coronary artery disease can be obtained. It has been shown that these patients can 
be discharged safely. The accuracy for detecting a significant coronary artery stenosis 
is also high, but the presence of coronary artery atherosclerosis or stenosis does 
not necessarily imply that the cause of the chest pain is related to coronary artery 
disease. Moreover, the non-invasive detection of coronary artery disease by CT has 
been shown to relate with an increased use of subsequent invasive coronary angiog-
raphy and revascularization, and further studies are needed to define which patients 
benefit from invasive evaluation following coronary CT angiography. Conversely, the 
implementation of coronary CT angiography can significantly reduce the length of 
hospital stay, with a significant cost reduction.
Additionally, CT is an excellent modality in patients whose symptoms suggest other 
causes of acute chest pain such as aortic aneurysm, aortic dissection, or pulmonary 
embolism. Furthermore, acquisition of the coronary arteries, thoracic aorta, and 
pulmonary arteries in a single CT examination is feasible, allowing ‘triple rule-out’ 
(exclusion of aortic dissection, pulmonary embolism and coronary artery disease). 
Finally, other applications such as the evaluation of coronary artery plaque composi-
tion, myocardial function and perfusion or fractional flow reserve are currently being 
developed and may also become valuable in the setting of acute chest pain in the 
future.
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General aspects of cardiac CT
Introduction
The present chapter is an update of the previous book chapter.1 Those parts on which 
new literature is available have been updated, whereas other parts have been in-
serted unchanged. Since the introduction of CT in the early 1970s the technique 
has evolved into an essential imaging tool in general medicine. With this technique, 
non-invasive high resolution cross-sectional imaging of internal structures such as 
the brain, thorax and abdomen was permitted, thereby gradually replacing the more 
invasive radiographic techniques.2 Moreover, CT angiography has evolved as a very 
accurate tool for visualization of the aorta and pulmonary arteries. However, high-
quality imaging of the coronary arteries remained challenging because of their small 
vessel size, movement, and tortuous anatomy requiring high temporal, spatial and 
contrast resolution. In the late 1990s, the first 4-slice spiral CT scanner was developed 
with sufficient resolution to allow visualization of the coronary arteries, establishing 
the potential of multi-slice CT for detecting significant coronary artery stenosis in 
comparison to invasive coronary angiography (ICA).3-5 Since then, multi-slice CT 
coronary angiography has developed into a promising non-invasive alternative to 
ICA. With each successive generation of scanners from 4-slice to the present 64-, 
256- and 320- slice scanners, temporal and spatial resolution improved markedly due 
to faster gantry rotation times, thinner detectors, and volumetric coverage. These new 
developments currently allow motion-free visualization of the entire coronary artery 
tree with high diagnostic accuracy for detecting coronary artery stenosis.6, 7 Thanks to 
these rapid developments, interest has been raised in using CT for the evaluation of 
patients presenting with acute chest pain. In the intensive cardiac care unit (ICCU), 
acute chest pain is the most common clinical presentation of coronary artery disease 
(CAD). The diagnosis of acute coronary syndrome (ACS) is straightforward in high risk 
patients with typical chest pain, typical ECG changes, and elevation of serum cardiac 
markers (enzymes), whereas it is difficult in patients presenting with atypical chest 
pain, non-diagnostic or normal ECG, and normal markers on presentation. Indeed, up 
to 8 % of patients with ACS are misdiagnosed and inappropriately discharged home.8 
Conversely, only a minority of ‘low risk’ patients (i.e. those with initially normal 
ECGs and cardiac enzymes) actually suffer from myocardial ischemia.9 Therefore, the 
conventional approach for patients with acute chest pain leads to many unnecessary 
hospital admissions and is both time-consuming and expensive and thus, resource-
intensive. Therefore, a non-invasive and rapid examination to establish or exclude 
CAD as the underlying cause of symptoms could substantially improve the clinical 
care of patients admitted to the ICCU, reducing hospital admissions and costs. This 
chapter focuses on the evolving role of coronary CT angiography (CTA) (includ-
ing coronary artery calcium (CAC) scoring) in the diagnosis of patients presenting 
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with acute chest pain. An overview of a wide range of other CT applications is also 
provided, including triple rule-out, evaluation of plaque composition, myocardial 
function, and perfusion.
CT coronary angiography: patient preparation, 
acquisition, post-processing
CT is an imaging modality which has an X-ray source (tube) and detectors on opposite 
sides of a gantry that continuously rotates around the patient. During the CT scan the 
patient is moved through the gantry. Subsequently, the X-ray source emits photons 
collimated into a fan beam which are, after partial absorption and dispersion, reab-
sorbed by the detectors. Computer systems process these data into three-dimensional 
(3D) volumetric information, which can be transferred to CT workstations and evalu-
ated using multiple post-processing techniques.
Patient preparation
Proper patient preparation is important for obtaining diagnostic image quality. There-
fore, before referring a patient for coronary CTA, a short patient history should be 
obtained. Overall, a history of a severe allergic reaction to contrast agents, impaired 
renal function (glomerular filtration rate <30 mL/min), presence of atrial fibrillation, 
and pregnancy are considered contraindications. The patient should refrain from 
food and liquids preferably 3 hours before the examination, to prevent nausea as a 
reaction to the contrast agent. Moreover, a low and stable heart rate in the range of 
approximately 50–60 beats/min is preferred during image acquisition. To achieve a 
low and stable heart rate, a β-blocker is frequently administered prior to the examina-
tion, unless contraindicated. Preferably, sublingual nitrates (0.4mg) are administered 
to the patient. The resulting vasodilatation facilitates the assessment of small coronary 
arteries.10 Lastly, to ensure rapid delivery of the contrast agent bolus for coronary 
CTA, an intravenous catheter should be present for delivery of the contrast agent, 
preferably in the right antecubital vein (18–20 gauge).
Acquisition
The scan range of the current 64-slice scanners is not large enough to cover the 
entire heart in one rotation and therefore several heart cycles are needed to image 
the entire heart. To compensate for cardiac motion and synchronize the start of the 
systole, ECG gating is needed to obtain phase-compatible images. Currently, the 
majority of cardiac CTs are acquired using prospective triggering, in which the start 
of scanning is triggered by the preceding R-wave. Most often the scan is triggered in 
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the relatively motion-free phase of mid diastole (70–80 % of the R–R interval) to mini-
mize motion artefacts. Depending on the scanner type, imaging can be performed in 
helical (‘spiral’) mode with continuous table movement and modulated acquisition, 
or in step-and-shoot mode with multiple volumetric acquisitions reconstructed into 
a single data set. A wide-volume detector allows full cardiac acquisition in a single 
gantry rotation, e.g. a 256- or 320-detector-row scanner that allows a maximum of 
16 cm scan range in a single rotation.11, 12 Novel dual-source CT scanners, equipped 
with two X-ray tubes and two detectors at a 90 degree angle provide high temporal 
resolution. As a result, these scanners are able to produce images of high quality in 
patients with high heart rates. Besides, with these 64-slice dual-source CT scanners, 
using a high-pitch spiral technique, the entire heart can be depicted in one cardiac 
cycle with ultra-low radiation dose (<1mSv).13
For CAC scoring, a low-dose ECG triggered non-contrast-enhanced scan is per-
formed before the contrast-enhanced CT examination and reconstructed to 3-mm 
slices. Additionally, this scan can be used to determine the proper location and scan 
range for coronary CT imaging. For a regular CTA, a rapid infusion of 60–100 mL of 
contrast material with a flow rate of 5 mL/s is used, followed by a saline flush. Typical 
scan parameters are a pitch of 0.375, rotation time of 333–500 ms, tube voltage of 
100 or 120 kV and tube current of 300-500 mA (depending on body mass index). 
However, with novel iterative reconstruction algorithms, lower radiation exposure 
can be achieved by lowering tube voltage and current with preserved image quality. 
When using a bolus-triggered start of the CT scan, the start is automatically initiated 
if the preset contrast-enhancement threshold level in the descending aorta is reached. 
Alternatively, a test bolus injection can be used to determine the contrast transit time. 
Subsequently, data acquisition is performed at half-inspiratory breath hold of ap-
proximately 10 s.
Post-processing
After data acquisition, images are reconstructed and sent to a dedicated worksta-
tion for post-processing. Commonly, coronary CTA data sets are reconstructed with 
continuous images using thin increments (typically 0.5–0.6 mm slice thickness). For 
post-processing, various types of algorithms are available.
· The thin axial slices, as depicted in Figure 1, are considered the source informa-
tion of CT imaging. Accordingly, the cardiac structures and coronary arteries can 
easily be evaluated by scrolling through the images in axial direction.
· Curved multiplanar reconstructions (MPR) allow visualization of the entire coro-
nary artery in a single image which is useful for depicting the entire coronary 
lumen and evaluating degree of stenosis.
Chapter 2
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· Maximum intensity projections (MIP) can be reconstructed which represent 
a series of contiguous CT slices stacked into a single image (‘slab’). Moreover, 
MIPs are very suitable for assessment of longer length of vessel segments and may 
facilitate in evaluating the degree of stenosis.
· 3D volume rendering provides a 3D image of the heart and vessels. An excellent 
overview of the coronary anatomy is provided, although 3D volume rendering is 
generally not used for assessing the stenosis severity. Figure 2 provides an example 
of a 3D volume rendered image.
Figure 1. Typical example of axial contrast-enhanced images. 
This image with a 0.5-mm slice thickness, can be used to evaluate cardiac structures (such as the left 
ventricle (LV), left atrium (LA), right ventricle (RV), and aorta (Ao)) and coronary arteries by scrolling 
through the slices in the cranio-caudal direction. Four images have been selected to demonstrate the 
anatomy of the heart. A. Axial image showing the left main (LM) coronary artery at the level of the 
ostium which arises from the left coronary cusp and bifurcates first into the left anterior descending 
coronary artery (LAD). B. Slightly more distal axial image showing the left circumflex coronary artery 
(LCx) and the first diagonal branch (D1) which has originated from the LAD. C. Axial image demonstrat-
ing the origin of the right coronary artery (RCA) from the right coronary cusp and the mid segments of 
the LCx, LAD, and D1. (D) Axial image at midventricular level which shows the mid segment of the 
right coronary artery (RCA) and distal segments of the LAD and LCx (the latter is seen in the left atrio-
ventricular groove).
23
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Interpretation of coronary artery disease on 
coronary CT angiography
A systematic approach is important when evaluating a coronary CTA. If CAC scoring 
has been performed, the Agatston score is reported on a patient and vessel basis. 
Thereafter, the coronary CTA is interpreted to assess coronary atherosclerosis and 
stenosis severity. In addition to the analysis of the coronary arteries, the entire scan 
range should be examined to detect potential extra-cardiac findings.
Coronary artery calcium score
For quantification of the coronary calcifications, the Agatston method (a method that 
multiplies the calcified area by a density factor based on the highest Hounsfield 
values within this area) is routinely used.14 Total CAC scores are generally stratified 
into normal (zero calcium), mild (1–100), moderate (101–400), and severe (> 400).15 
Several population based studies have demonstrated that the CAC score increases 
with higher age, thereby reflecting the natural progression of atherosclerosis. In ad-
dition, men tend to have higher CAC scores than women of similar age. Therefore, 
the CAC score should be ranked in percentiles according to the distribution within 
age and gender16, 17 Although newer quantification methods have been introduced 
(calcified volume (mm3) and mass (mg) measurements), these metrics are not com-
monly used in clinical practice.18 With novel algorithms the quantification of CAC on 
contrast enhanced scans is feasible.19 However, these techniques are currently not 
used in clinical practice.
Figure 2. Surface-rendered volumetric 3D images of the coronary arteries and side branches. 
This type of image provides a 3D overview of the coronary artery tree and their relative position to the 
underlying cardiac structures, including the left ventricle (LV) and right ventricle (RV). A. Anterior view 
of the left circulation demonstrating the left anterior descending coronary artery (LAD) with first diago-
nal branch (D1). In addition, the left circumflex coronary artery (LCx) can be identified. The left atrium 
(LA), aorta (Ao), and right ventricular outflow tract (RVOT) can be also appreciated in this view.B. Cra-
nial view demonstrating a volume-rendered image of right coronary artery (RCA) and left main coronary 
artery (LM) and their main branches originating from the right and left coronary cusp, respectively. C. 




With regard to the coronary CTA, the quality of the scan should be mentioned as 
this influences the diagnostic certainty of the study. Findings are commonly reported 
similar to the reporting of invasive coronary angiography (ICA). Typically, each coro-
nary segment of the American Heart Association 17-segment model20 is described as 
normal, mild (<30% wall irregularities), non-significant (30–50% stenosis), signifi-
cant (>50% stenosis), severe stenosis (> 70%), and occlusion. In addition to stenosis 
severity, the plaque composition of each lesion should be described as non-calcified, 
calcified, or mixed (i.e. a combination of calcified and non-calcified plaque). Pres-
ence and patency of stents and bypasses are reported, if evaluable. Segments that are 
uninterpretable due to severe calcifications, motion, or breathing artefacts should be 
mentioned as such in the report.
Extra-cardiac findings
Beyond evaluating the coronary arteries, other cardiac findings and/or extra-cardiac 
findings may be identified during coronary CTA. Interestingly, extra-cardiac findings 
provide an explanation for chest pain complaints in 4–8% of patients or may be 
incidental findings not related to chest complaints.21, 22 Clinically important findings 
that require immediate therapy, intervention, additional diagnosis, or follow-up 
are reported in approximately 13% of cardiac CT examinations.23, 24 These include 
suspected malignancy which may necessitate immediate therapeutic actions, or the 
presence of acute pulmonary embolism or pneumonia.21, 25-27 Incidental lung cancers 
are found in 0.24% of patients.23 For coronary artery assessment, a zoomed-in small 
field of view focused on the heart is reconstructed to obtain maximal spatial resolu-
tion for evaluation. However, this focused view reveals only 36% of the total chest 
volume, whereas 70% of the total chest volume has been exposed to radiation.27 
Substantially more significant extra-cardiac pathology is found on maximum full-field 
reconstructions than on small-field reconstructions.23 Therefore the maximum full-
field reconstructions should be reviewed for optimal identification of extra-cardiac 
pathology.21, 23, 25, 27, 28
Patients with non-acute chest pain
Coronary artery calcium score
It has been widely verified that the presence of coronary artery calcification only 
occurs in the presence of coronary artery atherosclerosis.29 Both electron beam CT 
(EBCT) and multi-slice CT have been used over the past years for the noninvasive 
evaluation of coronary artery calcifications, both demonstrating high sensitivities 
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for the detection of CAD indicating that a large proportion of patients with CAD 
are accurately detected by CAC scoring.17, 30 The relation between the presence of 
obstructive CAD and the presence and extent of CAC has been extensively studied.31 
The CAC score has a high sensitivity and negative predictive value for the presence 
of obstructive CAD, but its specificity is limited.31, 32 The high negative predictive 
value indicates that patients without CAC virtually never have obstructive CAD. In 
contrast, the lower specificity indicates that patients without obstructive CAD still 
often present with CAC. For instance, Haberl et al. evaluated 1,764 patients who 
underwent both EBCT (CAC score) and ICA. The absence of CAC was associated with 
an extremely low probability of disease (<1%) and thus highly accurate to exclude 
obstructive CAD. However, specificity was only 23% in men and 40% in women. 
Therefore, the technique may be more suited to provide an estimate of total plaque 
burden rather than stenosis severity.
Furthermore, numerous investigations have shown that the extent of CAC provides 
prognostic information. CAC scoring has therefore been proposed as a tool for cardiac 
risk stratification. Several large trials have reported that elevated CAC scores have 
predictive value for cardiovascular events, both independently and incrementally to 
cardiovascular risk factors.33, 34 Budoff et al. assessed the prognostic value of CAC 
scoring in 25,253 asymptomatic individuals over a mean follow-up period of 6.8 
years. The survival of individuals without CAC was excellent (99.6%), with a gradual 
reduction in survival rates with increasing CAC score.33
Coronary CT angiography
With the current generation 64-slice CT scanners, with improved temporal and 
spatial resolution, a good diagnostic accuracy for detection of obstructive CAD has 
been reported, both for the proximal as well as the distal part of the coronary arteries. 
In comparison with ICA, a high sensitivity (85–99%) and high specificity (83–90%) 
has been reported for the detection of obstructive stenoses.6, 7 More importantly, as 
demonstrated by the high negative predictive value, coronary CTA is an excellent 
tool to exclude significant CAD. This implies that in the presence of normal coronary 
arteries on coronary CTA, no further testing is required and patients can be reas-
sured. The positive predictive value however, is lower (64–93%), and the severity of 
atherosclerotic lesions is frequently overestimated on coronary CTA.
Recently, new low-radiation-dose algorithms have been introduced, which resulted 
in a significant reduction in radiation, A meta-analysis of these studies confirmed the 
diagnostic accuracy35; pooled data from 15 studies (with varying novel CT scanners) 
included 960 patients, reported a sensitivity of 100% with a specificity of 89%. The 
NPV was 99%, with a PPV of 93%, indicating overestimation of stenosis severity in 
7% of patients. Moreover, the diagnostic performance of coronary CTA is influenced 
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by the pretest likelihood of obstructive CAD. Indeed, as shown in Table 1, the benefit 
from CT is highest in patients with a low to intermediate pretest likelihood for CAD 
due to the high accuracy to exclude obstructive CAD.36
In line with these observations, Henneman et al. demonstrated that coronary CTA 
was able to exclude coronary artery atherosclerosis in 58% of patients with low pretest 
likelihood of CAD, with no need for further routine visits to the outpatient clinic.37 
Conversely, coronary CTA demonstrated atherosclerosis and/or stenosis in 83% of 
patients with a high pretest likelihood of CAD. These patients may thus benefit more 
from non-invasive testing for ischemia and/or direct ICA with fractional flow reserve 
assessment, to determine optimal therapy (medical management or revascularization. 
Indeed the recent European Society of Cardiology guidelines for stable CAD indicate 
that coronary CTA is particularly useful in patients with low-intermediate pretest 
likelihood of CAD (recommendation class IIa).38
In addition to the diagnostic value, coronary CTA provides prognostic informa-
tion. Chow et al. reported in the CONFIRM (Coronary CT Angiography Evaluation 
for Clinical Outcomes) registry (with 14,064 patients in 12 different centers) that a 
normal coronary CTA was associated with an annual mortality rate of 0.65% over 
a mean follow-up of 22.5 months (Figure 3).39 Conversely, patients with obstructive 
CAD had an annual mortality rate of 2.9%, which increased to almost 5% in patients 
with 3-vessel, left-main and or proximal LAD disease. It is important to realize that 
the annual mortality in the CONFIRM registry was only 1.1%, indicating a relatively 
low risk population.
A recent meta-analysis by Bamberg et al. focused on the prognostic value of 
coronary CTA, and included 9 studies with 3,760 patients with an average follow-up 
varying from 14 to 78 months.40
The overall event rate was 6.8%, but it should be noted that two-third of the events 
were coronary revascularizations. (Early) Revascularization is not an ideal end-point 
since the findings on coronary CTA may have triggered the revascularization. Patients 
with a normal coronary CTA had an event rate of 0.4%. Patients with obstructive CAD 
had a 6-fold increased risk for death, infarction or ACS. Importantly, a significant 
Table 1. Diagnostic accuracy of 64-slice coronary CT angiography for detection of significant stenosis 
(≥ 50%) categorized according to pretest probability. 
Pretest probability N Sens(%) Spec(%) PPV(%) NPV(%)
Low 66 100 93 78 100
Intermediate 83 100 84 80 100
High 105 98 74 93 89
Data adapted from Meijboom et al.36 
Abbreviations: NPV: negative predictive value, Sens: sensitivity, Spec: specificity, PPV: positive predic-
tive value
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stenosis on coronary CTA remained predictive of events after correction for CAC 
score and cardiovascular risk factors.
Patients with suspected acute coronary 
syndrome
Coronary artery calcium score
The prognostic value of the CAC score has been widely established in patients with 
stable angina, but some studies evaluated the use of CAC score in patients with acute 
chest pain. Earlier studies with EBCT reported a high negative predictive value of 
the CAC score, demonstrating that patients with a CAC score of 0 had an excellent 
prognosis.41-43 Georgiou et al. reported in 192 patients with acute chest pain that 
the absence of coronary artery calcifications had a very low risk for future cardiac 
events (<1%), whereas the presence of CAC was a strong predictor of events41. More 
recently, Nabi and co-workers reported on the use of CAC score in 1031 patients with 
acute chest pain using 16-slice CT.44 In the 625 (61%) patients with zero CAC score, 
the cardiac event rate was <1%, whereas the event rate increased in parallel with 
an increasing CAC score. The various prognostic studies using CAC score in patients 
with acute chest pain and/or suspected ACS are summarized in Table 2. The results 
of six studies, with a total of 3035 patients were included in the pooled analysis.45 
In total, 62% of patients with acute chest pain or suspected ACS presented with a 
CAC score of 0 (indicating relatively low risk populations). However, there was a 
large variation in incidence of CAC score of zero between studies, ranging from 36% 















Figure 3. Bar graph illustrating the prognostic value of coronary CTA for the prediction of all-cause 
mortality. 
Non-obstructive CAD was defined as <50% stenosis, non-high risk CAD was defined as ≥50% stenosis 
and high risk CAD included left main stenosis (≥50%) or 3-vessel disease (≥70%) or 2-vessel disease 
(≥70%) including the proximal left anterior descending artery.
CAD: coronary artery disease
Adapted from Chow, Circulation Cardiovascular Imaging 2011
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to 76%. The pooled analysis demonstrated a negative predictive value of 99% for 
the occurrence of future events. In contrast, the positive predictive value was only 
14%. The long-term prognostic value of CAC score patients with suspected ACS has 
also been evaluated. Forouzandeh and colleagues acquired long-term follow-up data 
(median 3.3 years) in 760 patients presenting with acute chest pain who underwent 
16-slice CT.46 Events occurred in 45 (6%) patients; the long-term event rate was 0.4% 
in patients without CAC, and increased to 11% in patients with a CAC score >400. 
Although a CAC score of zero has been associated with an excellent prognosis, it 
has simultaneously been observed that patients with ACS or acute infarction can 
present without CAC in the culprit vessel47. Thus, particularly in the acute setting, 
the absence of CAC may not always imply the absence of atherosclerotic plaque. 
This was demonstrated by Chang et al showing that obstructive atherosclerosis was 
present in 17 of 795 (2%) patients with a suspected ACS and CAC 0. 48 In addition, 
12% of the patients with a CAC 0 had non-obstructive CAD. Accordingly, Biegel et 
al. performed coronary CTA in 785 consecutive patients with acute chest pain.49 Of 
the 255 patients with CAC score 0, significant CAD was observed on ICA in 2.7% of 
patients. Figure 4 provides an example of a patient with an obstructive non-calcified 
plaque despite a CAC score of zero.
Coronary CT angiography
Previous studies have demonstrated that coronary CTA has a high sensitivity and 
specificity for the detection of CAD compared to ICA in patient with stable CAD. 
More importantly, due to the high negative predictive value, coronary CTA can reli-
ably exclude significant CAD, which is of potential value in patients presenting with 
Table 2.  Diagnostic accuracy of a coronary artery calcium score of 0 for the prediction of acute 
coronary syndrome or events.
Author N No. (%) 
CAC=0
Follow-up Sens(%) Spec(%) PPV(%) NPV(%)
Chang et al48 1047 795 (76) Prospective, 30 days 67 77 4 99
Georgiou et 
al41 192 76 (40)
Prospective, 50 ± 10 
months 97 64 48 97
Hoffman et al51 368 197 (54) Prospective, 6 months 97 58 18 99
Laudon et al42 263 133 (51) Prospective, 6 months 97 57 23 99
McLaughlin 
et al43 134 48 (36) Prospective, 30 days 88 37 8 98
Nabi et al44 1031 625 (61) Prospective, 6 months 94 62 7 99
Pooled * 3035 1874(62) - 93 65 14 99
*Data adapted from Tota-Maharaj et al.45
Abbreviations: CAC: coronary artery calcium, NPV: negative predictive value, Sens: sensitivity, Spec: 
specificity, PPV: positive predictive value
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suspected ACS in the emergency room, but without specific ECG abnormalities and 
serum troponin levels in the normal range on admission. Limited studies are avail-
able that assess the diagnostic value of coronary CTA for the detection of significant 
CAD compared to ICA in patients presenting with suspected ACS. Meijboom et al. 
evaluated 104 patients with non-ST elevation ACS using 64-slice CTA compared with 
ICA.36 In total 88 patients (85%) presented with significant CAD on ICA. Reported 
sensitivity and specificity of coronary CTA for detecting or excluding significant coro-
nary artery stenosis were 100% and 75% respectively. Figure 5 shows an example of 
a patient presenting with suspected ACS with a significant stenosis in the RCA. More 
importantly, several investigations have addressed the predictive value of coronary 
CTA for the detection of ACS in patients with acute chest pain. Table 3 demonstrates 
the diagnostic accuracy of coronary CTA for the detection of ACS. In the most of 
these studies ACS is defined as either acute myocardial infarction or unstable angina 
pectoris according to the ACC/AHA-criteria50, preferably with evidence of myocardial 
Figure 4. Example of a patient presenting with suspected ACS.
In this patient coronary artery calcium (CAC) scoring and contrast-enhanced coronary CT angiography 
were performed to exclude CAD. Although the CAC score was zero (A), an obstructive non-calcified 
plaque with a superimposed thrombus in the right coronary artery (RCA) was detected on coronary CT 
angiography (B, C). The volume-rendered 3D reconstruction (B) and curved multi-planar reconstruction 
(C) show an occlusion in the mid segment of the RCA (white arrows). (D) This finding was confirmed on 
invasive coronary angiography (white arrow). Ao, aorta; LAD, left anterior descending coronary artery; 
LCx, left circumflex coronary artery. From Henneman MM, Schuijf JD, Pundziute G, et al. Noninvasive 
evaluation with multislice computed tomography in suspected acute coronary syndrome: plaque mor-




ischemia on functional testing.51 In the ROMICAT I study, 368 patients presenting 
with chest pain and possible ACS (but normal initial troponin and non-ischemic ECG) 
underwent 64-slice CTA.51 Of these 368 patients, 8% eventually developed an ACS 
according to the definition described above. On 64-slice CT, 183 did not have any 
coronary atherosclerosis (no CAD), whereas 117 had non-obstructive coronary artery 
Figure 5. Example of non-invasive coronary angiography with CT in a patient presenting with sus-
pected ACS. 
In (A), a 3D volume-rendered reconstruction is provided, showing a large dominant right coronary ar-
tery (RCA) with signs of luminal narrowing (white arrow). B. A curved multiplanar reconstruction (MPR) 
of the RCA is shown demonstrating the presence of significant luminal narrowing in the mid segment 
(arrow). C. Another curved MPR in a different view, revealing the presence of significant stenosis (ar-
rows). Cross-sectional CT images (inlays) show the presence of calcified plaque proximal to the stenosis 
(a), exclusively non-calcified plaque within the stenosis (b), and no coronary plaque distal from the 
stenosis (c). D. Conventional coronary angiography confirming the presence of significant luminal nar-
rowing of the RCA (arrow).
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stenoses. Of these 300 patients, only 7 (2%) were diagnosed with ACS, yielding a 
NPV of 98%. Conversely, 68 patients had obstructive CAD on CTA, and 24 developed 
an ACS; accordingly the PPV was 35%. Similarly, Gallagher et al. evaluated 85 pa-
tients with suspected ACS using 64-slice CTA; 73 patients had non-obstructive or no 
CAD on the CT scan and 1 of these developed an ACS, resulting in a NPV of 99%. On 
the other hand, 6 of the 12 patients with obstructive CAD on the CT scan developed 
an ACS, yielding a PPV of 50%. Meta-analysis combining the results of 10 studies 
with a total of 917 patients confirmed a NPV of 98%, with a lower PPV of 64%. 
The high NPV permits rule out of future development of ACS. In contrast, significant 
CAD on coronary CTA has lower predictive value for the development of ACS. These 
observations indicate that absence of significant CAD on coronary CTA can rule out 
development of ACS, but the presence of significant CAD does not indicate that these 
patients will always develop an ACS.
In addition, coronary CTA has been used for prediction of short- and long-term 
outcome of patients presenting to the emergency room with suspected ACS. In the 
ROMICAT I study, none of the 300 patients with a ‘negative coronary CTA’ (defined 
as no coronary atherosclerosis or non-obstructive CAD) experienced a subsequent 
cardiovascular event during a 6 months follow-up period.51 Based on these initial 
observations, subsequent studies have focused on the potential implementation of 
coronary CTA in management of patients presenting to the emergency room with 
suspected ACS (but with normal troponins and non-ischemic ECG). For example, Lit 
et al. performed a randomized controlled trial (RCT) in 1370 patients with suspected 
ACS.52 Patients were randomized to either CTA or standard care. Of the 908 patients 
referred for CTA, 640 (70%) had a negative CTA (no atherosclerosis or non-significant 
CAD). These patients were discharged, and none of these patients died, or presented 
with myocardial infarction within the next 30 days.
At present, four large RCTs have been conducted to assess the value of a CTA-based 
strategy compared to standard care. The results of these four trials have been pooled 
in a meta-analysis by Hulten et al.53 This meta-analysis analysis included the results of 
1,869 patients undergoing coronary CTA and 1,397 patients receiving standard care. 
Of the 1,869 patients undergoing CTA, only 4.2% had a significant coronary artery 
stenosis (≥70% luminal narrowing) on CTA. None of the patients died during the 
trials. In total, 142 (7.6%) of the patients in the coronary CTA group underwent ICA, 
of which 76 (4.1%) were revascularized. Patients referred to coronary CTA more often 
underwent ICA than patients receiving standard care. As depicted in Figure 6, the ICA 
referral rate was 6.3% in patients receiving standard care as compared to 8.4% in 
patients randomized to CTA (P = 0.003). The absolute increase in ICA for a coronary 
CTA based strategy was 21 per 1,000 patients.53 Of interest, the majority of these 
downstream referrals for ICA were during the index hospitalization. Similar to the 
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increase in ICA in the coronary CTA group, a significant increase in revascularization 
was observed in this group (both PCI and CABG).The revascularization rate was 2.6% 
in patients receiving standard care as compared to 4.6 % in patients randomized to 
coronary CTA (P = 0.004). The absolute increase in revascularization for a coronary 
CTA based strategy was 20 per 1,000 patients.
The information from these 4 RCTs underscores the value of coronary CTA in the 
emergency room for patients presenting with acute chest pain, suspect of ACS in the 
emergency room, namely exclusion of CAD. At the same time however, this approach 
is associated with an increased use of ICA and subsequent revascularization.
At the same time, the coronary CTA based strategy resulted in a significant reduction 
in the length of stay (emergency department or hospital stay) by 3.4–11.6 hours as 
compared to patients receiving standard care.52, 54-56 For example, 50% of the patients 
randomized to coronary CTA in the ROMICAT II study could be safely discharged 
within 8.6 hours as compared to 26.7 hours for the patients receiving standard care 
(Figure 7).55 Moreover, a coronary CTA based strategy positively affected emergency 
department costs: in three of the four trials a significant reduction in costs was ob-
served in the group of patients randomized to CTA, ranging from $286 to $1321.
The number of post discharge hospitalizations for ACS is extremely low in these 
4 trials (ranging from 0 to 3.1%), which further supports the safety of coronary CTA 
guided discharge of patients.













Figure 6. Difference in referral rate for invasive coronary angiography and subsequent revasculariza-
tion between patients randomized to either a coronary CTA based strategy or standard care. 
Adapted from Hulten et al. 53
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CT angiography of aorta and pulmonary arteries
Non-cardiac causes of acute chest pain concerning vascular structures in the thorax 
such as in acute aortic syndrome and pulmonary embolism can be easily visual-
ized by CT. CT angiography of other vascular beds than the heart is less complex 
if non-ECG gating techniques are used. ECG gating may be used to improve image 
quality. In addition, contrast enhancement in the blood pool is required to visualize 
the vascular structures, and thus intravenous contrast is still needed. Several common 
principles should be applied to all imaging protocols to provide optimal diagnostic 
image quality such as bolus timing for optimization of contrast delivery in the vessel, 
fast high resolution acquisition, and administration of approximately 60–120 mL of 
contrast material (dependent on patient size, contrast agent used, and scanner type) 
injected at rapid infusion rates (4–5 mL/s).
Because of the availability, excellent image quality with good spatial resolution, 
high sensitivity, and fast imaging speed, multi-slice CT has become the first-choice 
imaging tool for the evaluation of acute aortic syndrome57 and traumatic aortic pa-
thology.58 multi-slice CT is also widely used in the evaluation of non-acute pathology 
such as aneurysm or aortic coarctation, inflammatory and infective aortic disease, 
and after aortic surgery.59
Figure 7. Difference in length of hospital stay between patients referred to CTA of standard care.
The horizontal line indicated the median length of stay in both study groups which was significantly 
different. 
From: Hoffmann et al. NEJM. 2011 
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Acute aortic syndrome encompasses a variety of life-threatening conditions that 
require emergency diagnosis and management, including aortic dissection (AD) (see 
Figure 8), intramural hematoma (IMH), penetrating aortic ulcer (PAU) and symptom-
atic aortic aneurysm. 
If a patient presents with suspected acute aortic syndrome, the CT protocol should 
include a non-contrast enhanced scan from the proximal part of the arch vessels 
to the diaphragm, followed by CTA from the proximal part of the arch vessels to 
the femoral arteries. The non-contrast scan is to evaluate possible presence of an 
IMH as aortic wall thrombus.59 IMH of the ascending aorta is clinically regarded at 
high risk for complication (evolving into dissection) and death, and surgery is usually 
indicated.60
PAU is usually located in the mid-descending thoracic aorta, where it presents as a 
mushroom-like contrast outpouching beyond the expected contours of the aortic lu-
men. PAU represents an atherosclerotic ulceration that penetrates the internal elastic 
lamina allowing hematoma formation within the aortic media, and may develop into 
IMH, aortic dissection, or vessel rupture.61
Thoracic aortic aneurysm
Aneurysm is defined as a permanent localized dilatation of an artery, having at least 
a 50% increase in diameter as compared with the normal diameter.60 In general, an 
ascending aortic diameter equal to or greater than 4 cm (in an individual less than 
60 years old) is considered an aneurysm. The size of the thoracic aorta increases 
with age and depends on sex and body size. The normal ascending aorta diameter is 
approximately 27 mm in 20-years old and 36 mm in 80-years old.60 Thoracic aortic 
Figure 8. Thoracic CT angiography showing a type A aortic dissection(A).
The right coronary artery is contrast enhanced and has its origin from the true lumen (arrow, B). The 
right coronary artery has double appearance due to motion artefacts in this non-ECG gated scan. The 
left main coronary artery stem (arrow, C) is also contrast enhanced and had its origin from the true lu-
men. Carotid and subclavian arteries as well as the visceral arteries all had their origin from the true 
lumen. Note the almost complete disruption between the true and false lumen of the descending aorta 
(arrowheads B, C). F, false lumen; T, true lumen.
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aneurysms can be true or false aneurysms. In a true aneurysm all three layers of the 
vessel wall are involved (intima, media, and adventitia) and is characterized by a 
fusiform shape. In a false aneurysm (or pseudo-aneurysm), the intima is disrupted and 
the blood is contained by the adventitia. Atherosclerosis is the most frequent cause of 
thoracic aneurysms (70%). Several genetic syndromes, vasculitis, and inflammatory 
diseases are also associated with aortic aneurysm and dissection.
Asymptomatic patients with an ascending aorta or sinus diameter larger than 5.5 
cm, a growth rate more than 0.5 cm per year in aorta aneurysm less than 5.5 cm, and 
patients with genetically mediated syndromes and thoracic aorta aneurysm exceed-
ing 4.0 to 5.0 cm, are candidates for elective surgical repair. Symptomatic patients 
suggestive of expansion of a thoracic aneurysm should be evaluated for prompt surgi-
cal intervention.60
CT angiography is the most robust tool for evaluating aortic aneurysms and some 
key features should be evaluated when using CT such as the maximal aortic diam-
eter, presence of thrombus, shape and extent of the aneurysm, involvement of aortic 
branches, relationship to adjacent structures, and presence of aortic calcifications. In 
23% of cases a thoracic aneurysm coexists with an abdominal aortic aneurysm, and 
thus evaluation of the entire aorta is indicated. Most importantly, CT shows excellent 
accuracy for characterizing important features of aneurysms.62
Pulmonary embolism
The well-known Wells’ clinical decision rule is used to risk stratify patients suspected 
of pulmonary embolism.63 This is a scoring method based on various clinical risk 
factors and stratifies patients as low, intermediate, or high risk. If a patient has a score 
of 4 or more, further testing is required. In routine clinical practice, multi-slice CT 
pulmonary angiography has become the first-choice imaging method for evaluating 
the pulmonary arteries when pulmonary embolism is suspected (see Figure 9).64 A 
normal CT pulmonary angiography can safely exclude pulmonary embolism without 
need for additional tests.65 On CT, pulmonary emboli are shown as filling defects 
of the contrast-enhanced central or segmental pulmonary arteries. In patients with 
pulmonary embolism, cloth burden is related to right ventricular dysfunction, where 
the measure of a right to left ventricular diameter ratio exceeding 1.0 is at risk for 
short term death.66
Triple rule-out CT
The concept of the ‘triple rule-out’ protocol is to simultaneously exclude all three 
potentially life-threatening causes of acute chest pain (ACS or infarction, acute aortic 
dissection or syndrome, and pulmonary embolism) in a single CT examination. A 
triple rule-out scan protocol includes coverage of the entire thorax cavity including 
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the aortic arch. State-of-the-art 64-slice scanners with wide anatomical coverage are 
able to scan the entire thorax including the pulmonary arteries, thoracic aorta, and 
coronary arteries in a single breath hold of approximately 15–20 s. An important 
technical challenge of a triple rule-out scan protocol is to ensure that high contrast 
enhancement is present simultaneously in both the pulmonary and systemic circula-
tion to evaluate the pulmonary arteries and aorta including the coronary arteries. 
Injection protocols should be adapted to scanner type and acquisition settings.
Triple rule-out approach may improve the triage of patients presenting to the emer-
gency department with acute chest pain, and provide a faster algorithm to make a 
diagnosis. However, it is crucial that patients should be carefully selected to ensure 
the appropriate use of a triple rule-out CT protocol. If the triple rule-out protocol in-
volves retrospective gating of the entire thorax, radiation dose is high, even more than 
the radiation dose observed in dedicated coronary CT angiography.67, 68 Prospective 
gating techniques strongly reduce radiation dose, but may not be applied effectively 
in patients with high or irregular heart rates. Therefore, patients with symptoms highly 
suggestive for ACS, acute pulmonary embolism, or acute aortic dissection, should 
be referred for a work-up specifically designed for this purpose (such as ICA if a 
patient has a high risk for ACS). As discussed before, the presence of a significant 
stenosis on coronary CTA does not automatically confirm the presence of ACS. In the 
remaining patients with uncertain cause of chest pain, a triple rule-out protocol can 
be considered.
Figure 9. Patient with acute pulmonary embolism and high embolus load. 
Massive emboli in the left and right pulmonary arteries can be observed (arrows, A). Note severe dilata-
tion of the right ventricle (RV, B) with interventricular septum shift to the left and compression of the 
left ventricle (LV) due to high embolus load. Normally the RV diameter does not exceed that of the LV.
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Initial studies suggest that a triple rule-out CTA protocol for evaluation of patients 
with acute chest pain is feasible and that quantitative parameters of image quality 
may be comparable to the conventional, dedicated coronary and pulmonary CTA 
protocol. 69, 70 A study evaluating the diagnostic value of triple rule-out with 64-slice 
CT in 55 patients admitted to the emergency department demonstrated that this 
technique facilitated the differential diagnosis of chest pain.70 Furthermore, the triple 
rule-out protocol could potentially identify a subset of patients with acute chest pain 
who can safely be discharged from the emergency department without adverse events 
during a 30-day follow-up.71 A recent study in 100 patients with acute chest pain and 
an intermediate cardiac risk profile used either coronary CTA or a triple rule-out pro-
tocol in case of elevated D-dimer levels. Based on a negative coronary CTA or triple 
rule-out findings, 60 of 100 patients were discharged the same day, without major 
cardiac events at 90-days follow up. Also, those patients with significant coronary 
artery stenosis were identified.72 The use of this protocol in intermediate cardiac risk 
profile patients was calculated to reduce the number of hospitalized patients and 
total health costs.73 Indeed, more RCTs are needed to determine how the triple rule-
out protocol is best applied to improve clinical decision making and justified use.
Technical developments
Coronary artery plaque quantification
Currently, assessment of stenosis severity on coronary CTA is performed visually. This 
requires however significant experience and is characterized by limited reproducibil-
ity.74 Novel software tools have become available to (automatically) quantify stenosis 
severity on CTA, so-called quantitative CTA (QCT).75, 76 These algorithms usually con-
sist of various steps. First, the coronary tree is extracted from the CTA dataset and a 
multiplanar reformation is created of each coronary artery or side branch. Thereafter, 
the lumen and vessel wall are delineated on these MPR images. Based on these 
segmented contours, the severity of coronary artery stenosis can be quantified, but 
also the amount of coronary atherosclerosis (the plaque burden) can be derived (see 
Figure 10.) Previous investigations using QCT have demonstrated a good agreement 
between stenosis severity as assessed with QCT compared to ICA and intravascular 
ultrasound (IVUS).75, 76 It was also shown that stenosis severity derived from QCT 
was related with the presence of ischemia on SPECT perfusion imaging.77 Besides 
these geometrical parameters, it is also feasible to automatically assess and quantify 
coronary plaque composition with QCT. In a head-to-head comparison between 
QCT and IVUS with virtual histology, a good agreement was shown for assessment 
of different plaque types (calcified, mixed or non-calcified).78 QCT will improve 
39
General aspects of cardiac CT
quantification of coronary stenosis and assessment of plaque composition and may 
be of particular value in serial evaluations to assess a potential effect of medication 
on atherosclerosis progression/regression and plaque composition.79 Recently, the 
incremental predictive value of these QCT parameters (over visual interpretation) for 
development of a subsequent ACS, has been established.80 Versteylen et al. compared 
the coronary CTA results in 25 patients who subsequently developed an ACS (over a 
mean follow-up period of 26 months) to 101 control patients without events. In the 
patients who developed an ACS, the total plaque volume, the plaque burden and the 
A B C 
D 
Figure 10. Example of quantitative CTA analysis of a 48 year old male patient referred for the evalu-
ation of stable chest pain. 
Panel A demonstrates a stretched multiplanar reformation (MPR)  of the LAD with a calcified lesion. 
QCT was used to detect both lumen (yellow) and vessel wall (orange) contours. Longitudinal lumen 
and vessel wall contours are shown in panel A; whereas transversal lumen and vessel wall contours 
at the level of the minimal lumen area (MLA) are shown in panel B. Panel C show the quantification 
of coronary plaque constitution. Calcium is labeled in white, fibrotic tissue labelled in dark green, 
fibro-fatty tissue in light green and necrotic core labeled in red. Quantification of the calcified lesion 
was performed using proximal (green) and distal (red) reference markers as well as lumen (yellow) and 
vessel wall (orange) reference lines, as illustrated in panel D. In this graph, the x-axis represents the 
distance from the coronary ostium in mm. The y-axis represents the area of either the lumen (lower part 
of graph) or the vessel wall (upper part of graph) in mm2. The part between the two graphs shows the 
plaque constitution. Stenosis severity was quantified as 35%.
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non-calcified plaque volume were significantly larger. Moreover, these quantitative 
CTA parameters provided incremental prognostic value over the clinical risk profile 
and the visual interpretation of the coronary CTA results.
Developments in CT scanners
The technology of the CT scanners is evolving rapidly. With the introduction of 256- 
and 320-slice scanners complete volume coverage of the heart becomes possible in 
a single heartbeat,11, 12 This may potentially reduce motion artefacts, particularly in 
patients with irregular heart rates or rhythm abnormalities. Moreover, dual-source CT 
scanners with 2 × 128 detector rows have been introduced and these systems dem-
onstrated a high temporal resolution of 75 ms (approximately half of the temporal 
resolution of the fastest 64-slice scanners) making possible to freeze cardiac motion 
and obtain diagnostic quality images of the coronary arteries regardless of heart rate 
or rhythm. Initial studies with dual-source coronary CT in patients presenting with 
chest pain have reported high negative predictive values approaching 100%, enabling 
to reliably excluded coronary artery stenoses also in patients with higher heart rates.81 
Very recently, high-pitch ECG triggered (‘Flash Spiral’) dual-source CT scanners have 
shown promising results.13 The novelty of this technique lies in the very high pitch 
which results in fast image acquisition without cardiac motion artefacts and a very 
low radiation exposure (<1 mSv).13 Currently only limited data in selected patients 
are available with these newer scanners, and larger studies are needed to determine 
the value of these novel equipment in routine clinical practice.
Novel applications of cardiac CT
Assessment of coronary artery plaque composition
Since coronary CTA allows for the visualization of the coronary vessel wall, coronary 
atherosclerosis on coronary CTA can be further characterized (beyond stenosis sever-
ity), permitting assessment of plaque composition. The plaques can be divided into 
non-calcified, calcified and mixed plaques. Interestingly, coronary plaque composi-
tion has been linked to clinical presentation: patients presenting with an ACS were 
shown to have more non-calcified and/or mixed plaques in the coronary arteries, 
whereas patients with stable CAD present with more calcified plaques.82 In addition, 
it has been suggested that plaque composition may provide prognostic information.
Specifically, non-calcified plaques with low attenuation values, positive remodel-
ing, and spotty calcifications have been associated with subsequent development of 
ACS.83 Moreover, Gaemperli et al. evaluated 220 patients with known or suspected 
CAD using 64-slice coronary CTA and demonstrated worse outcome of patients with 
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mixed or non-calcified plaques.84 This was further confirmed by Hou et al. in 4,425 
patients with suspected CAD with a follow-up period of nearly 3 years. The authors 
demonstrated that patients with non-calcified plaque were at 5 times higher risk for 
the combination of death, infarction or revascularization, as compared to patients 
with calcified plaques, and the risk of patients with mixed plaques was nearly 10 
times higher.85 Interestingly, it was shown in 163 patients with chest pain and sus-
pected CAD that mixed plaques were also correlated with the presence of ischemia 
on SPECT perfusion imaging.86
Evaluation of myocardial perfusion
Recent developments in CT scanner technology have enabled evaluation of left 
ventricular myocardial contrast attenuation enabling CT myocardial perfusion imag-
ing (of the left ventricle). This functional information is of particular importance to 
determine the hemodynamical significance of intermediate coronary artery stenoses 
(around 50% luminal narrowing). Standard CT perfusion (CTP) protocols include a rest 
study for the evaluation of the coronary arteries and the resting myocardial perfusion, 
followed by an adenosine-induced stress study to determine the stress perfusion.87 
Similar to perfusion imaging with SPECT or magnetic resonance imaging (MRI), re-
versible or fixed perfusion defects can be detected indicating ischemia or scar tissue 
respectively. 88-91 A major advantage of CTP is the combination of coronary artery 
anatomy (CTA) and function (CTP) in one examination. Blankstein et al. demonstrated 
with 64-slice CT that an adenosine stress CT protocol can identify stress-induced 
myocardial perfusion defects with a diagnostic accuracy comparable to SPECT.92 Ad-
ditionally, the average radiation required in this protocol was similar to the radiation 
dose of SPECT perfusion imaging. It is anticipated that with improved dose reduction 
protocols, the radiation dose will be reduced significantly. Recent studies have indi-
cated an improved diagnostic accuracy for CTP compared to coronary CTA alone for 
the detection of myocardial ischemia.87, 93 George et al. demonstrated in 53 patients 
with an intermediate to high pre-test likelihood of CAD that the diagnostic accuracy 
of CTP to predict reversible ischemia on SPECT was higher than coronary CTA.87
Evaluation of myocardial infarction
Over recent years, MRI has been successfully employed to image the presence of in-
farcted myocardium with delayed contrast enhancement imaging. However, several 
studies have demonstrated that the presence of infarction can be also identified on 
CT.88 Because of the pharmokinetics of the contrast material, a difference between 
the accumulation of contrast in infarcted and normal myocardium can be visualized. 
Accordingly, early hypo-enhancement can be observed on the CT images during 
the first pass of contrast medium at the area of infarcted myocardium. In addition, 
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delayed hyper-enhancement of infarcted tissue can be detected similarly to MRI. 
Good correlations between infarct imaging with CT and other imaging modalities 
such as MRI and SPECT imaging have been demonstrated.88-90 Moreover, a good 
correlation between enhancement patterns (both early hypo-enhancement and late 
hyper-enhancement) and recovery of myocardial function at a follow-up of 3 months 
post-infarction was reported, suggesting that CT may be useful to predict functional 
recovery after infarction.91 However, it is important to realize that in general, delayed 
enhancement imaging with CT requires additional imaging and thus involves ad-
ditional radiation exposure. Also, a larger amount of contrast agent is required for 
delayed enhancement imaging as compared to imaging the coronary arteries alone.
Fractional flow reserve (FFR)
It has been shown in the FAME (FFR vs. Angiography for multivessel evaluation) 
trial that revascularization guided by invasive assessment of FFR is superior in terms 
of outcome over revascularization driven by angiographic stenosis severity.94 This 
observation highlights that functional (ischemia) assessment may be preferred over 
anatomical assessment (stenosis severity) to guide the need for revascularization. 
Invasive assessment of FFR however, may not be the first choice in patients with 
stable chest pain, and a non-invasive approach may be preferred. With the applica-
tion of computational fluid dynamics and complex mathematical calculations, novel 
software tools allow for the non-invasive assessment of FFR from coronary CTA data-
sets (FFRct) without additional imaging, modification of CT acquisition protocols, or 
administration of medication.95 An example of this approach (as compared to ICA and 
Figure 11. Case example of FFRct with corresponding invasive coronary angiogram.
Multiplanar reformat of a coronary CT angiogram demonstrating obstructive stenosis of the proximal 
portion of the left anterior descending (LAD) coronary artery and a computed fractional flow reserve 
(FFRCT) value of 0.62, indicating ischemia. Invasive coronary angiography demonstrates obstructive 
stenosis of the proximal portion of the LAD and measured fractional flow reserve (FFR) values of 0.65, 
indicating ischemia.
From: Min et al., JAMA 2012
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invasive FFR) is shown in Figure 11. In the DISCOVER FLOW (diagnosis of ischemia-
causing stenoses obtained via noninvasive fractional flow reserve) trial, Koo et al. 
have demonstrated good agreement between FFRct and invasive FFR in 103 patients 
in whom 159 coronary arteries were evaluated.96 At present, FFRct is not suitable for 
implementation in the daily practice since FFRct calculations are time consuming 
(calculation of FFRct may require up to 5 hours) and requires sophisticated computa-
tion which is not available in routine clinical imaging departments.96
Transluminal attenuation gradient
Another method to improve assessment of the hemodynamic significance of a 
coronary stenosis with CTA could be the calculation of the transluminal attenuation 
gradient (TAG). 97 For this purpose a MPR is generated of each coronary. Along the 
center-line of this MPR the luminal intensity is measured at 1mm increments. TAG is 
then defined as the slope of the regression line of the decrease in luminal intensity 
from the proximal to the distal part of the coronary (Figure 12). A steep decrease in 
intensity (i.e. a more negative TAG) was associated with the presence of an obstruc-
tive lesion in that coronary.97 Recently Wong et al. have reported the incremental 
value of TAG measurements on 320-row CTA over CTA alone for the prediction of 
invasive FFR significant lesions.98 However, until present the exact clinical value of 
TAG is unknown and requires further trials and investigations.
Evaluation of myocardial function
Besides assessment of the coronary arteries, cardiac CT imaging also permits assess-
ment of left ventricular volumes and function. If data have been collected during the 
whole cardiac cycle, images can be retrospectively reconstructed in several phases 
to derive left ventricular ejection fraction from the left ventricular volumes. Indeed, 
numerous studies have shown that global left ventricular function assessed by CT 
correlates well with echocardiography and MRI, although CT appeared to minimally 
overestimate end-systolic volume and may thus slightly underestimate left ventricu-
lar ejection fraction.99, 100 In addition, regional wall motion abnormalities can be 
reliably evaluated as compared to MRI. 101 However, as images should be acquired 
throughout the cardiac cycle, left ventricular function protocols are associated with 
increased radiation exposure and CT may not be the first choice technique, but could 




Patients presenting with acute chest pain to the emergency room, suspect for an ACS 
but without the diagnostic ECG and troponin criteria. This poses an important dilemma 
in clinical cardiology: on the one hand, this population constitutes a large number of 
patients with a low prevalence of ACS, but on the other hand a substantial number 
of patients appear to develop an ACS once discharged. Coronary CT angiography 
is a feasible technique for non-invasive, fast, and accurate exclusion of obstructive 
CAD in patients presenting with acute chest pain. Moreover, a normal coronary CTA 
permits safe discharge with good short- to mid-term prognosis. This has increased in-
terest in using CT for non-invasive assessment of CAD in the emergency department, 
and in addition the technique can evaluate the presence/absence of other causes of 
acute chest pain such as aortic aneurysm, aortic dissection, or pulmonary embolism.
Figure 12. Patient example of transluminal attenuation gradient (TAG) calculation. 
Panel 1: Coronary CTA demonstrates calcified lesions in the proximal LAD coronary artery and moder-
ate stenosis in the mid LAD traject, confirmed by invasive coronary angiography. 
Panel 2: Luminal attenuation plot. Black dots represent 5-mm intervals at which intraluminal attenua-
tion (in Hounsfield units, HU) and luminal area (in mm2) were measured. TAG is shown by the yellow 
line and was -11.95 (HU/10mm).
Panel 3: Axial and representative cross-sectional views of coronary CTA. 
MLD: minimal lumen diameter, QCA: quantitative coronary angiography
From: Choi et al., JACC: cardiovascular imaging 2011 
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Four RCTs have been performed comparing a CT-based approach in the emergency 
room versus a standard of care approach. These trials confirmed the value of coro-
nary CTA to exclude CAD, with good outcome after discharge, and a reduction in 
hospital stay and costs. At the same time, an increase in ICA and revascularization 
rate was observed in patients with CAD on coronary CTA; this warrants further studies 
to determine the precise relation between the coronary CTA findings and referral 
for ICA. Finally, other applications such as the evaluation of coronary artery plaque 
composition, myocardial function and perfusion or fractional flow reserve are cur-
rently being developed and may also become valuable in the setting of acute chest 
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This editorial refers to: “Coronary Atheroma Volume and Cardiovascular Events Dur-
ing Maximally Intensive Statin Therapy” by Puri et al. pusblished in European Heart 
Journal in November 2013 
Hydroxymethylglutaryl (HMG) CoA-Reductase inhibitors or statins play an impor-
tant role in the primary and secondary prevention of coronary heart disease.  By in-
hibiting the enzyme HMG-CoA reductase, statins lower the production of cholesterol 
in the liver, resulting in lower LDL cholesterol levels. Besides lowering cholesterol 
levels, statin therapy slows down plaque progression and in some patients even cause 
plaque regression. 
In the beginning of the 90’s the first trials were initiated to assess the effect of 
statin therapy on plaque dynamics. Randomized trials, like MARS and REGRESS, 
used (quantitative) invasive coronary angiography (ICA) to assess luminal stenosis 
characteristics. Since ICA only allows assessment of the coronary lumen, differences 
in minimal lumen diameters (MLD) and mean segment diameters (MSD) between 
baseline and follow-up were assessed as a measurement of coronary plaque change.1,2 
These early studies demonstrated that moderate dose statin therapy on average re-
duces plaque progression. Importantly, this was associated with a reduction of major 
adverse cardiovascular events (MACE). Of note, it was shown that the beneficial effect 
of statin therapy is more pronounced in more severe lesions.1
A relative shortcoming of these studies was the inability of ICA to visualize true 
coronary atherosclerotic burden. Around the same time as the first angiographic 
studies with statin therapy were executed, a novel method for the assessment of 
coronary plaque burden was designed; intracoronary ultrasound (ICUS), nowadays 
known as intravascular ultrasound (IVUS). This invasive method uses ultrasound to 
create two dimensional tomographic images of the coronary lumen and vessel wall 
morphology.3 Since then IVUS is frequently used for coronary plaque assessment 
and has been widely validated for serial plaque imaging.4 IVUS is able to visualize 
true atherosclerotic burden with a high resolution and could be of value, not only 
for prognostic implications, but also to provide novel insights in the mechanisms of 
plaque dynamics in patients receiving statin therapy. In the future, non-invasive, serial 
assessment of coronary atherosclerosis could be feasible using quantitative computed 
tomography coronary angiography (QCT).5 Figure 1 demonstrates the difference in 
coronary plaque assessment between ICA, IVUS and QCT.
In this issue of the European Heart Journal Puri et al. present the results of a novel 
sub-study of the SATURN trial. In this study, 1039 patients underwent serial IVUS 
before and after 24 months of statin therapy. Patients were randomized to the highest 
dose of either rosuvastatin (40mg) or atorvastatin (80mg), which is currently the most 

















Figure 1. Difference in coronary plaque assessment between IVUS , invasive coronary angiography 
(ICA) and quantitative computed tomography coronary angiography (QCT).
Panel A demonstrates quantitative coronary angiography (Qangio XA version 7, Medis medical image 
systems B.V.). After delineation of the contrast-filled lumen the percentage stenosis can be calculated. 
The yellow area in Panel B represents the coronary plaque. However, since the vessel wall cannot be 
depicted on ICA this is a derived parameter. Panel C demonstrates a cross-sectional IVUS image of a 
coronary artery. This view allows assessment of coronary atherosclerosis. After segmentation of the EEM 
and lumen contours as demonstrated in Panel D, the plaque burden can be assessed. Panel E represent 
a cross-section of a QCT analysis of a coronary artery (Qangio CT research edition version 1.3.6., Medis 
medical image systems B.V.). In a similar fashion as IVUS, the lumen and vessel wall are segmented 
(Panel F). Thereafter, coronary plaque burden can be calculated. In addition, QCT allows for character-
ization of coronary atherosclerosis. 
Abbreviations: EEM: external elastic membrane, IVUS: Intravascular Ultrasound
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single coronary, without significant luminal stenosis or previous revascularization. 
The authors investigated the prognostic influence of baseline percentage atheroma 
volume (PAV) on: a) MACE b) lipid levels at baseline and follow-up and c) coronary 
plaque progression. It was demonstrated that PAV at baseline is associated with the 
occurrence of MACE during 2 years follow-up. The incidence of MACE in patients 
in the lowest quartile of PAV was 5.1% and was significantly increased stepwise 
per PAV quartile (5.1%, 5.7%, 7.9% and 12% respectively, p=0.001). This relation 
remained significant after correction for baseline risk factors. Of particular interest, 
neither LDL cholesterol levels at baseline or after high dose statin treatment could 
independently predict MACE. Thereafter, the correlation between PAV at baseline 
and plaque progression on IVUS was assessed. As expected, patients with PAV above 
median demonstrated a greater reduction in PAV at 12 months follow-up. Accord-
ingly, in these patients lumen volume was significantly more increased after therapy 
compared to patients with PAV below median. However, no significant differences in 
vessel wall volume were observed between the two groups. Thus, patients with heavy 
disease burden at baseline benefit relatively more from aggressive/high dose statin 
therapy with regard to plaque regression, compared to patients with a light disease 
burden, confirming the older ICA results with modest dose statin therapy 
One of the most striking results of this study is the fact that LDL levels at baseline or 
after statin treatment showed no predictive value for MACE. This could lead to doubt 
about the beneficial effect of LDL-lowering therapy. However, as also discussed by 
the authors, there is overwhelming evidence for the beneficial effects of statin therapy 
on plaque progression and MACE.6 As demonstrated by IVUS in the REVERSAL-trial, 
there is a significant association between the amount of LDL-cholesterol reduction 
due to statin therapy and slowed progression of atherosclerosis (as assessed by PAV). 
Currently, statin therapy is so fundamentally established in daily practice, its benefi-
cial effect is beyond doubt. Even though it has been demonstrated that in patients 
receiving statin therapy LDL cholesterol levels have no additional prognostic value, 
further lowering of LDL cholesterol levels with novel PCSK9 monoclonal antibodies 
could further reduce the residual risk in these patients.7, 8 These drugs are currently 
investigated in trial to assess the safety and efficacy.
Recently, evidence has become available suggesting that the effect of statin therapy 
on prognosis in not solely mediated through lowering of LDL-cholesterol but also 
so-called “pleiotropic effects” play an important role. These molecular mechanisms 
seem to be in part independent of LDL-lowering. Examples of these pleiotropic effects 
are:  improvement of endothelial function, stabilization of atherosclerotic plaques 
and decreasing oxidative stress and inflammation.9 Indeed, recent studies have dem-
onstrated that in addition to decrease in PAV, statin therapy leads to stabilization of 
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coronary atherosclerosis. Nozue et al performed IVUS Virtual Histology (IVUS-VH) 
in 39 patients during PCI and after 8 and 48 months of statin therapy. An increase in 
negative remodeling and calcified plaque was observed during follow-up suggesting 
stabilization of coronary plaque.10 This was further confirmed by Taguchi et al, in 120 
ACS patients receiving statin therapy who underwent serial IVUS. Both in patients 
showing plaque progression or regression, the amount of necrotic core, associated 
with plaque vulnerability, was significantly decreased after 8 to 10 months of statin 
therapy.11 In the SATURN sub-study, Puri et al. demonstrated that plaque regression 
was most pronounced in patients with PAV above the median. These patients pre-
sented with an unfavorable risk profile at baseline. It seems that the most diseased 
patients benefit the most from aggressive therapy. This was in line with a recent study 
that comparing plaque regression by statin therapy in patients with stable CAD and 
ACS demonstrated the most benefit of statin therapy in ACS patients.12 Unfortunately, 
the study by Puri et al. lacks further insight in the prognostic value of PAV changes by 
statin therapy. This would be an interesting topic, worth further investigation.
In conclusion, statin therapy lowers PAV and as a result improves prognosis. These 
beneficial effects are more pronounced in patients with a PAV above the median. 
Despite aggressive/high dose statin therapy, a high atherosclerotic plaque burden 
still remains a heavy burden and novel treatment modalities should be developed to 
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Purpose: Plaque constitution on CTA is associated with prognosis. At present only 
visual assessment of plaque constitution is possible. An accurate automatic, quantita-
tive approach for CTA plaque constitution assessment would improve reproducibility 
and allows higher accuracy. The present study assessed the feasibility of a fully au-
tomatic and quantitative analysis of atherosclerosis on CTA.  Clinically derived CTA 
and IVUS VH datasets were used to investigate the correlation between quantitatively 
automatically derived CTA parameters and IVUS VH.
Methods: A total of 57 patients underwent CTA prior to IVUS VH. First, quantitative 
CTA (QCT) was performed. Per lesion stenosis parameters and plaque volumes were 
assessed. Using predefined HU thresholds, CTA plaque volume was differentiated 
in 4 different plaque types necrotic core (NC), dense calcium (DC), fibrotic (FI) and 
fibro-fatty tissue (FF). At the identical level of the coronary, the same parameters 
were derived from IVUS VH. Bland-Altman analyses were performed to assess the 
agreement between QCT and IVUS VH.
Results: Assessment of plaque volume using QCT in 108 lesions showed excellent 
correlation with IVUS VH (r = 0.928, P <0.001) (Figure 1). The correlation of both FF 
and FI volume on IVUS VH and QCT was good(r = 0.714, P< 0.001 and r = 0.695, 
P <0.001 respectively) with corresponding bias and 95% limits of agreement of 24 
mm3 (-42 ; 90) and 7.7mm3 (-54 ; 70). Furthermore, NC and DC were well-correlated 
in both modalities(r = 0.523, P <0.001) and (r = 0.736, P <0.001). 
Conclusion: Automatic, quantitative CTA tissue characterization is feasible using a 
dedicated software tool.  
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Introduction 
Computed tomography coronary angiography (CTA) is a well established non-
invasive method for the assessment of coronary atherosclerosis. At present, there is a 
rich amount of data confirming the correlation between stenosis degree on CTA and 
invasive coronary angiography.1, 2 Moreover, several studies have demonstrated the 
prognostic value of stenosis degree as assessed by CTA in the occurrence of adverse 
cardiovascular events.3, 4 In addition to the assessment of stenosis degree, CTA allows 
in vivo characterization of coronary atherosclerotic plaque to differentiate non-
calcified, calcified and mixed plaque. These CTA plaque types have been associated 
with prognosis.5 Besides, several additional plaque characteristics on CTA have been 
associated with plaque vulnerability (e.g. positive remodeling, spotty calcification, 
low attenuation plaque).6 
Ultimately, CTA stenosis degree and plaque constitution can be derived by a fully 
automatic, quantitative approach, allowing high accuracy and good reproducibility. 
Previously, semi-automated methods to characterize plaque on CTA have been de-
scribed. 7, 8 However, a dedicated fully automatic quantitative CTA plaque character-
ization tool to assess plaque constitution is currently unavailable.
The present study assessed the feasibility of an automatic and quantitative analysis 
of CTA data. In this study, clinically derived CTA and intravascular ultrasound virtual 
histology (IVUS VH) datasets were used to investigate the correlation between quan-
titatively, automatically derived CTA parameters and IVUS VH. For this assessment, 
IVUS VH was defined as the golden standard since it is an approved method for the 
in-vivo assessment of coronary plaque characteristics and has been well validated 
against histopathology.9 IVUS VH allows for the assessment of plaque vulnerability 
and is associated with outcome.10 The correlation between CTA plaque character-
istics and intravascular ultrasound virtual histology (IVUS VH) has previously been 
described.11-13. 
In this investigation automatic, quantitative assessed stenosis degree and plaque 
constitution on CTA were compared to IVUS VH. For this purpose, a dedicated 3-di-
mensional registration algorithm was used, allowing a slice-by-slice comparison of 
both modalities. In short, the aim of the present study was 1) to perform an automatic 
quantitative CTA analysis of stenosis degree and plaque constitution and 2) to validate 





The patient population consisted of 57 patients who presented with chest pain at the 
outpatient clinic (Leiden, the Netherlands) and underwent CTA, followed by clinically 
referred invasive coronary angiography (ICA). In addition, IVUS VH was performed to 
further evaluate the severity and extent of coronary artery disease. 
CTA images were acquired using either a 64-slice CT scanner (Aquilion 64, Toshiba 
Medical System, Otawara, Japan) or a 320-row volumetric scanner (Aquilion ONE, 
Toshiba Medical System, Otawara, Japan). Non-ionic contrast material (Iomeron 400, 
Bracco, Milan Italy or Ultravist 370, Bayer Schering Pharma AG Berlin, Germany) was 
administered with an amount of 80-110 ml followed by a saline flush with a flow rate 
of 5 ml/s. Contra-indications for CTA were: 1) renal insufficiency (glomerular filtration 
rate < 30 ml/min); 2) known allergy to iodine contrast material; and 3) pregnancy. 
Only scans with adequate image quality were included for the current analysis.  The 
effective dose was calculated using a conversion factor of 0.014 mSv/(mGy x cm)
IVUS VH examinations were acquired during conventional ICA using a dedicated 
IVUS console (S5tm Imaging system Volcano Corporation, rancho, Cordova, CA, USA) 
in combination with a 20MHz, 2,9 F phased-array IVUS Catheter (Eagle Eye, Volcano 
Corporation, Rancho Cordova, CA, USA). Motorized pullback was performed at a 
constant speed of 0.5 mm/s until the IVUS catheter reached the guiding catheter. 
Exclusion criteria for IVUS VH were severe stenosis, (subtotal) vessel occlusion or 
vessel tortuosity. 
Clinical data were prospectively entered into the departmental Cardiology Infor-
mation System (EPD-Vision, Leiden University Medical Center) and retrospectively 
analyzed. In each patient, the presence of CAD risk factors was recorded.
The feasibility of quantitative CTA analysis software to assess stenosis severity has 
been reported previously.14 For the current analysis, the most recent update of this 
program was used, which allows fully automatic, quantitative assessment of both 
stenosis severity and plaque constitution (QAngioCT Research Edition version 1.3.6, 
Medis Medical Imaging Systems, Leiden, the Netherlands). In all patients quantitative 
computed tomography (QCT) was performed to determine lumen and vessel wall 
borders. Subsequently, using a dedicated 3-dimensional registration algorithm, CTA 
images were registered with the corresponding IVUS VH run as shown in Figure 1. 
Thereafter, automatic lesion quantification was performed in both modalities to 
assess stenosis parameters and plaque constitution. Finally, the correlations for all 
parameters (Table 1) between the both modalities were assessed. 
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Quantitative CTA analysis
Lumen and vessel wall detection.
First, an automatic tree extraction algorithm was used to obtain all the 3-dimensional 
centerlines of the coronary tree.15 Based on these centerlines, straightened multi-
planar reformatted (MPR) volumes were created of those vessels of which an IVUS 
VH examination was available. Next, the lumen border contours and vessel wall 
borders were assessed according to the previously reported method.14 This method 
uses spatial fi rst- and second-derivative gradient fi lters in longitudinal cross sections 
in combination with knowledge of the expected CTA intensity values in the arter-
ies. Thereafter lumen and vessel contour are detected in the individual transversal 
IVUS-VH 
= = = 
MDCT 
IVUS 
IV. III. II. Panel: I. 
Figure 1. Schematic illustration of the characterization of coronary plaque on CTA: cross-correlation 
with IVUS VH.
First, the 3-dimensional centerline was generated from the CTA data set using an automatic tree extrac-
tion algorithm (Panel I). Using a unique registration a complete pullback series of IVUS images was 
mapped on the CTA volume using true anatomical markers (Panel II). Fully automatic lumen and ves-
sel wall contour detection was performed for both imaging modalities (Panel III). Finally, fusion-based 
quantifi cation of atherosclerotic lesions was based on the lumen and vessel wall contours as well as the 
corresponding reference lines (estimate of normal tapering of the coronary artery), as shown in panel IV. 
At the level of the minimal lumen area (MLA) (yellow lines), stenosis parameters, could be calculated 
for both imaging techniques. Additionally, plaque volumes and plaque types were derived for the whole 
coronary artery lesion, ranging from the proximal to distal lesion marker (blue markers). Fibrotic tissue 
was labeled in dark green, Fibro-fatty tissue in light green, dense calcium in white and necrotic core 
was labeled in red.
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cross-sections perpendicular to the centerlines, whereby the locations from the lon-
gitudinal analyses are taken into account. This method is insensitive to differences in 
attenuation values between data sets and independent of window and level settings.
Plaque constitution.
Two approaches for tissue (plaque) classification were implemented. The first used 
predefined fixed intensity cut-off values on the Hounsfield Units (HU) to assess plaque 
constitution. Currently, different cut-off values are available in the literature, which 
are obtained by comparing CTA with IVUS VH or histological examination.6, 16 For 
the current analysis, the fixed HU cut-off values used for classifying were: -30 – 75, 
for necrotic core, 76 – 130 for fibro-fatty, 131 – 350 for fibrotic, and 351+ for dense 
calcium. These values were initially based on the paper by Brodoefel et al. and em-
pirically optimized using three representative training sets. 16
The second approach used an adaptive threshold based on the principle that plaque 
attenuation values are influenced by luminal contrast densities.17, 18 Therefore, in this 
approach, the HU thresholds are adapted according to lumen attenuation values. This 
method is based on two principles. 
The first principle is the decrease in lumen intensity from the proximal to the distal 
part of the coronary artery. The intensity cut-off values are adapted by the same linear, 
decreasing trend along the vessel. 
The second principle is that the lumen intensities are lower in the parts of a se-
vere stenosis and higher in the parts with severe calcified lesions due to blooming 
artifacts. Therefore, intensity cut-off values are locally compensated by subtracting 
a percentage of the difference to correct for the cut-off values in these locations. 
These dynamic thresholds were automatically derived and are user independent. The 
Table 1. QCT derived parameters and their corresponding definitions.
QCT parameter Definition
Lesion length (mm) The distance between the proximal and distal 
ends of the coronary lesion
Lumen volume (mm3) Total volume of the lumen between the 
proximal and distal ends of the coronary lesion
Vessel wall volume(mm3) Total volume of the vessel wall between the 
proximal and distal ends of the coronary lesion
Plaque volume(mm3) Total volume of plaque wall between the 
proximal and distal ends of the coronary lesion. 
Defined as vessel wall volume – lumen volume
Minimal Lumen Area (MLA) (mm2) The minimal lumen area at the point of 
maximal obstruction.
Percentage lumen area stenosis at the level of 
the MLA (%)
1 - (MLA/corresponding reference lumen area) 
x 100%
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inter- and intra observer variability for the lumen and vessel segmentation have been 
previously described.19, 20 The assessment of plaque constitution was performed fully 
automatically.
Cross-correlation with IVUS VH 
To validate the results of the QCT analysis, CTA images were compared to IVUS 
VH images of the corresponding artery. IVUS VH lumen and vessel wall contours 
were generated using QCU (QCU- CMS 4.59, Medis, Leiden, The Netherlands). A 
dedicated software tool was used to fuse the CTA and IVUS VH images as previ-
ously described.14 First using anatomical landmarks (side-branches, ostia, calcified 
plaques) the IVUS VH images were mapped on the longitudinal CTA centerline. 
Secondly, the IVUS VH cross-sectional images were translated and rotated to fit onto 
the corresponding CTA cross-section. This 3-dimensional registration method allows 
correction of deviations in IVUS VH caused by inconstant motorized pullback speed 
and enables a slice-by slice comparison of the coronary artery. 
In both modalities, CTA and IVUS VH, lesions are manually defined by placing 
reference locations at non-diseased, non-bifurcated proximal and distal parts of the 
segment of interest. A slope is automatically defined between these reference loca-
tions which represent an estimate of the normal proximal-to-distal tapering of the 
segment of interest. Consecutively, using the reference slope, the minimal lumen area 
(MLA) as well as the proximal and distal ends of a lesion were automatically assessed 
as shown in Figure 1.  Subsequently, a number of parameters were derived from QCT 
and IVUS VH in each analyzed coronary lesion as described in Table 1.
In addition to coronary arteries with atherosclerotic lesions, a vessel-based analysis 
of non-diseased coronary arteries was performed in the mid part of the coronary 
artery. In these non-diseased vessels, lumen and plaque volumes were assessed in 
both modalities. Since no plaque was present in these vessels, no comparison of 
plaque characteristics was performed. 
Statistical analysis
Continuous data are presented as mean ± SD if normally distributed or as median 
(interquartile range (IQR)) if non-normally distributed. Categorical data are presented 
as absolute numbers and percentages. A comparison was made between QCT and 
IVUS VH parameters on a lesion basis. Bland-Altman analyses were performed to 
assess the bias and the limits of agreement for the comparison between QCT and 
IVUS VH (GraphPad Prism software, version 5.01, GraphPad software Inc, San Diego, 
California, MA, USA). Bland-Altman analyses represent the difference of each pair 
plotted against the average value of each pair. Additionally, to correct for intra-patient 
correlation linear mixed models were used. The differences for each parameter be-
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tween QCT and IVUS VH was calculated and entered as a dependent value. For 
this analysis, the 95% confidence intervals (95% CI) were calculated. Furthermore, 
the feasibility of QCT to assess luminal parameters in non-diseased segments was 
assessed in all plaque free segments. 
Results
For this study, 61 patients with diagnostic quality of the CTA were selected. In 4 of 
these 61 patients (7%) image quality was still insufficient to perform tissue charac-
terization. The remaining 57 patients were included in this study. These 57 patients 
underwent CTA using either a 320-row volumetric (n = 41) or a 64-row helical scan-
ner (n = 16). Median time between CTA and IVUS VH was 2 (IQR 0 – 64) days.  The 
effective dose of the CTA acquired on 320-row CTA was 6.5 ± 4.0 mSv, The mean 
radiation dose for 64-slice CT performed in our centre has been previously described 
(18.1 ± 5.9 mSv) 21 . Baseline characteristics are described in Table 2; the mean age 
was 57.8 ± 11.5 years and 68% of patients were male. In these 57 patients an IVUS 
VH run was available of 138 vessels; 29 of these vessels were unsuitable for further 
analysis because of the presence of a stent (n = 11) or insufficient quality of either the 
IVUS VH run (n = 6), the CTA extraction (n = 7) or other technical limitations (n = 5). 
For the final analysis, 109 vessels were used of which 69 revealed atherosclerosis, 
whereas 40 vessels did not. In these 69 diseased vessels, 108 lesions were identified. 
These 108 lesions were used for the lesion based comparison.
Coronary plaque volume
The results of the comparison of coronary plaque volumes (per lesion) are depicted 
in Figure 2. There was an excellent correlation between vessel volume on QCT and 
vessel volume on IVUS VH (r = 0.957, P <0.001). Based on linear mixed models, ves-
sel volume was significantly overestimated on QCT as compared to IVUS VH, median 
vessel volume (242 mm3 (IQR 152 – 371) vs. 238 mm3 (IQR 141 – 331), respectively, 
95% CI of the mean difference ranging from 5.3 to 24.8 mm3, P = 0.003). Bland-
Altman analysis demonstrated a bias of 15 mm3 with 95% limits of agreement ranging 
from -84.9 to 115 mm3. The correlation between lumen volume on QCT and IVUS 
was excellent (r  =  0.917, P  <0.001). QCT significantly underestimated the lumen 
volume: the median volume was 92 mm3 (IQR 60 – 136) on QCT compared to 111 
mm3 (IQR 64 – 163) on IVUS VH (95 CI of the mean difference ranging from -28.3 
to -14.6 mm3, P <0.001). The bias of the Bland-Altman analysis of lumen volume 
was -21.5 mm3 with 95% limits of agreement from -92.3 to 39.4 mm3. Accordingly, 
the correlation between plaque volume measured with both modalities was similar 
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(r = 0.928, P <0.001). QCT overestimated plaque volume with a bias of 36.5 mm3 
(P <0.001) with limits of agreement of -48.8 to 121.9 mm3.
Coronary stenosis parameters
Good correlations were observed for the assessment of minimal lumen area (MLA) 
and lumen area stenosis, r = 0.836 and r = 0.701, respectively. However MLA was 
underestimated on CTA, as demonstrated by a bias of -1.62 mm2 with 95% limits of 
agreement ranging from -5.54 to 2.30 mm2. Median MLA on QCT was 4.3 mm2 (IQR 
3.12 - 5.83) compared to 5.20 mm2 (IQR 3.75 – 7.90) on IVUS VH (95% CI of mean 
difference ranging form -2 to -1.2 mm2, P  <0.001). In contrast, area stenosis was 
Table 2. Baseline characteristics of study population (n=57).
Men 39 (68)
Age (years) 57.8 ± 11.5
Calcium score 69 (0 – 287) 
(range 0 – 3247)
Known CAD 11 (19)
Risk Factors
 Diabetes 14 (25)
 Hypertension † 38 (67)
 Hypercholesterolemia ‡ 27 (47)
 Smoking 20 (35)
 Obesity (BMI ≥ 30 kg/m2) 14 (25)
 Positive family history* 25 (44)
Medication
 Beta-blockade 29 (51)
          ACE inhibitor / AT II blockade 30 (53)
 Diuretics 19 (33)
 Nitrate 11 (19)
 Calcium antagonist 10 (18)
 
Data are represented as mean ± SD, median (interquartile range) or as number and percentages of 
patients.
†Defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or the use of 
antihypertensive medication. ‡Serum total cholesterol ≥230 mg/dL or serum triglycerides ≥200 mg/dL 
or treatment with lipid lowering drugs. 
*Defined as the presence of coronary artery disease in first-degree family members at <55 years in men 
and <65 years in women.
Abbreviations: CAD, coronary artery disease; BMI, body mass index; ACE, angiotensin converting en-
zyme; AT II, angiotensin II 
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significantly overestimated on QCT (median 42.8% (IQR 32.22 – 55.12)) compared 
to IVUS VH (median 40.06% (IQR 28.66 – 50.49) (95% CI of mean difference ranging 
from 0.7 to 5.6 %, P = 0.01). Bland-Altman analysis demonstrated a bias of 3.17 % 
with limits of agreement ranging from -21.61 to 27.96 %
Coronary plaque constitution 
The results of both fixed and dynamic threshold CTA tissue classifier are demonstrated 
in Table 3. Bland-Altman analyses of the two different CTA tissue classifier methods 





























































































































































































































































Figure 2. Bland-Altman analyses of vessel volume, lumen volume and plaque volume,. 
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Fibrotic 39.7(19.9-67.3) 43.2 (23.1-76.1) 1.6 ; 13.8 0.013 0.695, <0.001 7.7 -54.8 70.2
Fibro-
fatty
9.3(4.9–19.4) 25.9 (16.0-41.6) 13.3 ; 19.0 <0.001 0.714, <0.001 24.4 -41.8 90.7
Necrotic 
core
11.8(6.0–22.3) 22.8 (14.7-38.9) 10.4 ; 19.1 <0.001 0.523, <0.001 14.8 -29.7 59.2
Dense 
calcium
5.4(1.7–11.6) 7.6 (2.1-24.9) 6.6 ; 15.9 <0.001 0.736, <0.001 11.3 -36.4 59.0
Dynamic threshold
Fibrotic As above 55.7(36.1-94.9) 15.0 ; 25.9 <0.001 0.787, <0.001 20.4 -35.7 76.6
Fibro-
fatty
“ 28.3(16.2-45.9) 16.7 ; 23.6 <0.001 0.704, <0.001 20.2 -15.2 55.6
Necrotic 
core
“ 11.0(5.6-24.7) -1.6 ; 3.6 0.458 0.479, <0.001 1.0 -25.9 27.9
Dense 
calcium
“ 6.95(0.9-18.9) 4,5 ; 12.5 <0.001 0.733, <0.001 8.5 -32.5 49.5
IVUS VH, Intravascular Ultrasound Virtual Histology, QCT, quantitative computed tomography,  LOA, 














































































































































































































































































































































Figure 4. Bland-Altman analyses of plaque constitution as assessed using fixed thresholds.
Comparison between QCT and IVUS VH for fibrotic tissue, fibro-fatty tissue, necrotic core and dense 
calcium volumes.
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Method 1: fixed thresholds.
On a lesion basis, good correlations were observed for volumes of fibrotic tissue 
(r = 0.695, p <0.001), fibro-fatty tissue (r = 0.714, p <0.001), necrotic core (r = 0.523, 
p <0.001) and dense calcium (r = 0.736, p <0.001). Bland-Altman analysis, as de-
picted in Figure 3 and described in Table 3, demonstrated a significant overestimation 
of the volumes of all four plaque types by QCT. For necrotic core, bias was 11.3 
mm3 with limits of agreement ranging from -29.7 to 59.2 mm3. The smallest bias was 
observed for fibrotic tissue (7.7 mm3) with limits of agreement ranging from -54.8 to 
70.2. mm3.
Method 2: dynamic thresholds.
The results of the dynamic CTA tissue classifier are described in Table 3. The volumes 
of dense calcium, fibrotic and fibro-fatty volumes were all significantly overestimated 
by QCT (P <0.001.) No significant differences were observed in necrotic core vol-
umes between both modalities (P = 0.481). In Figure 5, the Bland-Altman analysis 
of the dynamic tissue classifier is depicted. The narrowest limits of agreement were 
observed for necrotic core volume ranging from -25.9 to 27.9 mm3 with a bias of 1.0 
mm3. However, the correlation coefficient for necrotic core (r = 0.479, P <0.001) 
was smaller compared to the other three plaque types. In Figure 6 an example is 
demonstrated of CTA plaque constitution assessment of a coronary lesion using the 
two different methods. 
Non-diseased coronary arteries
In non-diseased coronary arteries (n  =  40), vessel, lumen and plaque volume on 
QCT were significantly correlated with IVUS VH (r = 0.947, r = 0.920 and r = 0.738, 
respectively (p <0.001). However median vessel volume was significantly overesti-
mated on QCT as compared to IVUS VH (410 mm3 (IQR 250 - 616) versus 408 mm3 
(IQR 236 – 550)) (95% CI of the mean difference ranging from 25.5 to 85.5 mm3, 
p = 0.001)). Lumen volumes were significantly smaller on QCT as compared to IVUS 
VH (median 190 mm3 (IQR 92 – 303) versus median 283 mm3 (IQR 147 - 422) (95% 
CI of the mean difference ranging from -90.3 to -40.5 mm3, p <0.001)). Accordingly, 
plaque volume on QCT was significantly higher (median 236 mm3 (IQR 157 – 324)) 
as compared to IVUS VH (median 112 mm3 (IQR 66 – 153)). 
Discussion
The present study has demonstrated the feasibility of a fully automatic, quantitative 












































































































































































































































Figure 5. Bland-Altman analyses of plaque constitution as assessed using dynamic thresholds.
Comparison between QCT and IVUS VH for fibrotic tissue, fibro-fatty tissue, necrotic core and dense 
calcium volumes.
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plaque constitution. Using a dedicated 3-dimensional registration algorithm a slice-
by-slice comparison was made between QCT and IVUS VH. Very good correlations 
were observed for lumen, vessel and plaque volume between QCT and IVUS VH. 
Still, lumen volume was slightly underestimated and vessel volume slightly overesti-
mated on QCT. The assessment of MLA and lumen area stenosis using QCT correlated 
well with IVUS VH( r = 0.836 and r = 0.701, respectively).
In addition, the performance of two different approaches for tissue characterization 
was evaluated. The differentiation of coronary plaque volume in fibrous, fibro-fatty, 
necrotic core and dense calcium on QCT correlated well with IVUS VH. The dynamic 
A B 
C 
Figure 6. An example of a coronary lesion, plaque constitution is assessed using two methods of tissue 
characterization. 
The x-axis represents the distance from the coronary ostium in mm. The y-axis represents the area of 
either the lumen (lower part of graph) or the vessel wall (upper part of graph) in mm2. The part be-
tween the two graphs shows the plaque constitution using a color code with fibrotic tissue labeled in 
dark green, fibro-fatty tissue in light green, dense calcium in white and necrotic core labeled in red. 
Plaque constitution is assessed using either method 1 (Panel A) or method 2 (Panel B). In Panel C the 




threshold approach performed better compared to the fixed threshold approach, as 
demonstrated by more narrow limits of agreement on the Bland-Altman analyses.
Coronary stenosis assessment
CTA is a suitable method for the non-invasive evaluation of coronary atherosclerosis. 
Beyond the assessment of luminal narrowing it allows for the visualization of coro-
nary plaque. The prognostic value of CTA has been extensively reported and CTA is 
commonly used in clinical practice to rule out atherosclerosis in patients with low-to-
intermediate pre-test likelihood of CAD.22 Currently, CTA datasets are mainly visually 
analyzed to assess luminal narrowing. This visual approach requires an experienced 
observer, is subjected to interobserver variability and has lesser reproducibility. In the 
literature a quantitative analysis of CTA datasets on luminal narrowing and plaque 
constitution has been proposed as an objective and accurate method for analyzing 
CTA images. Several previous studies have reported different quantitative assessments 
of CTA images 7, 8, 12, 23. These studies have shown wide variety in results, mainly caused 
by differences in CTA contour detection algorithms. In the present study, good corre-
lations were observed for the assessment of plaque volume (r = 0928), lumen volume 
(r = 0.917) and vessel volume (r = 0.957). Vessel volume was slightly overestimated, 
whereas lumen volume was underestimated resulting in overestimation of plaque 
volume. In line with the present findings, Bruining et al.24 have demonstrated an 
overestimation of coronary plaque volume. In 48 patients, the investigators compared 
a quantitative CTA analysis with limited manual interference to IVUS. In contrast to 
the present investigation, the authors report an underestimation of coronary vessel 
wall volume. This discrepancy is potentially caused by differences in the vessel wall 
detection algorithm. In the future, the assessment of coronary plaque volume on CTA 
could be applied as a non-invasive method for the investigation of plaque regression 
or progression in patients or to assess the effect of medical therapy. In addition to 
coronary volume parameters, the ability of QCT to assess stenosis severity was inves-
tigated. Despite an overestimation on QCT for lumen area stenosis, good correlations 
were observed compared to IVUS VH. The method applied in the present study is 
best comparable to the ATLANTA study. 12 In this prospective study 50 patients were 
enrolled. In 50 lesions, a quantitative analysis of CTA datasets was performed and 
compared with IVUS VH. Similar to the present findings an overestimation of MLA 
and an overestimation of plaque volume was observed. 
Coronary plaque constitution
Beyond establishing luminal narrowing, CTA allows for the assessment of coronary 
plaque constitution. Previous studies have indicated the correlation between CTA 
plaque characteristics and plaque vulnerability.6 Also, the prognostic value of CTA 
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plaque constitution has been reported.25 Potentially, an accurate, quantitative as-
sessment of coronary plaque constitution could provide more detail on the relation 
between plaque vulnerability and plaque constitution on CTA.  However, at present 
an automatic, quantitative assessment of plaque constitution is unavailable. Previous 
studies have assessed mean HU of coronary plaques on CTA in different plaque types 
as assessed with IVUS (e.g. hypo or hyperechogenic).26 In contrast, the present study 
has used predefined HU thresholds to compare the four different plaque volumes 
with both modalities. In previous investigations the feasibility of manual or semi-
automatic quantitative CTA plaque constitution analyses has been assessed using 
IVUS VH as a reference. 7, 12 However, data is lacking evaluating a direct a slice-by-
slice comparison between automatically, quantitatively assessed plaque constitution 
and IVUS VH. 
Two different methods were applied for the quantitative analysis of plaque constitu-
tion.
Method 1: fixed thresholds.
The first method used fixed, predefined HU thresholds to differentiate coronary 
plaque volume in four different plaque types. This method has been applied in previ-
ous investigations.7, 12 In the present study, significant correlations were observed for 
all four plaque components. Still, an overestimation of plaque volume was noted for 
all different components on QCT. However, corresponding bias on Bland-Altman 
analysis were small for all components. These results are in line with previous reports. 
Indeed, using an automated vessel segmentation algorithm in 50 patients, Voros et 
al.12 demonstrated small difference, but wide limits of agreement for the assessment of 
plaque constitution on CTA compared to IVUS VH.  In contrast, in a study by Brodoef-
fel et al.7 in 14 patients, a comparison was made between plaque constitution on CTA 
and IVUS VH. The authors reported a good correlation for overall plaque volume; 
however, no significant correlation could be demonstrated for different plaque types. 
Method 2: dynamic thresholds.
Recently, Dalager17 et al. have demonstrated that differences in luminal intensities 
have an effect on the attenuation values inside the plaque. A decrease in luminal 
intensity was associated with lower coronary plaque HU. Besides, Choi at al.27 have 
shown that coronary stenosis severity has an effect on luminal intensities. A signifi-
cant decrease in luminal HU was observed at the location of a severe obstruction. It 
can therefore be expected that at the location of a severe stenosis different thresholds 
apply for the assessment of plaque constitution. These two previously described 
mechanisms formed the basis of the second approach on tissue characterization. A 
dynamic threshold algorithm was applied which automatically adapt HU thresholds 
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based on the luminal intensity values at the level of the plaque. This was previously 
proposed in a review by Akram et al. 18 suggesting that it is quite important for the 
implementation of plaque segmentation algorithms to take local attenuation values 
into consideration. For this reason a dynamic tissue characterization algorithm was 
implemented. As demonstrated, the performance of the dynamic threshold approach 
was superior to a fixed threshold approach. For all four plaque types, limits of agree-
ment of Bland-Altman analyses were smaller for the dynamic threshold approach. 
This indicated that there is indeed an effect of luminal intensities on coronary plaque 
HU. An accurate characterization of coronary plaque requires a method which ac-
counts for these differences. Possibly, more sophisticated algorithms to account for 
local difference in plaque attenuation values could be established. This would require 
further studies into local differences in attenuation values.
Recently, the influence of 100kV scanning on plaque constitution assessment became 
a topic of interest. In the present study none of the patients were scanned using 
100kV In a recent publication by Horiguchi et al. 28 using in vitro models the authors 
demonstrated equal performance of 100 kV in 120 Kv in soft plaque densitometry. 
In contrast, the intracoronary CT values were approximately 50 HU higher in 100 
kV scans compared to 120kV scans. Potentially, applying the dynamic threshold 
algorithm used in the present study could correct for these intracoronary density 
differences and would allow for more accurate tissue characterization.
Clinical implications
At present the clinical value of quantitative CTA plaque constitution assessment has 
yet to be established. Although a reasonable correlation was observed for the as-
sessment of coronary plaque constitution between QCT and IVUS VH, there still is a 
large variability in different plaque volumes between both modalities. It is unlikely 
that full agreement of coronary plaque constitution between QCT and IVUS VH will 
be achieved. To appreciate the prognostic value of quantitatively assessed plaque 
constitution on CTA, future studies are needed.  
Limitations
Although the present study demonstrated that automatic quantification of coronary 
plaque is feasible, some limitations need to be considered. For the present study only 
scans with sufficient quality were included. Therefore, the value of QCT in scans with 
severe noise or motion artifacts is unknown. The present analysis was a single-center, 
single-vendor study. An analysis of CTA datasets acquired by different CT-scanners 
could provide additional valuable insight.  IVUS VH was used as the gold standard. 
However, two limitations of this technique need to be considered. First, the radial 
resolution of IVUS VH is limited to 100µm, allowing less accurate assessment of 
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coronary plaque. Secondly, coronary calcium creates an acoustic shadow on IVUS 
VH caused by the inability of the echo signal to penetrate calcium. Although, plaque 
located behind calcifications is labeled on IVUS VH, the accuracy of characterizing 
tissue surrounding dense calcium is unknown. Potentially this leads to an underes-
timation of calcium volume on IVUS VH. In addition, a direct comparison between 
QCT plaque characterization and histopathology could provide further insights into 
the pathophysiology of CTA plaque constitution.  
Conclusions
The present study has demonstrated the feasibility of automatic, quantitative analysis 
of CTA images. QCT demonstrated excellent correlations for the assessment of plaque 
volume and stenosis parameters as compared to IVUS VH. Furthermore, plaque 
constitution was well-correlated between both modalities. In a direct comparison 
between a fixed threshold approach and a dynamic threshold approach for the quan-
tification of plaque type volume, the dynamic threshold performed better as shown 
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Purpose: We enhance intravascular ultrasound virtual histology (VH) tissue charac-
terization by fully automatic quantification of the acoustic shadow behind calcified 
plaque. VH is unable to characterize atherosclerosis located behind calcifications. In 
this study, the quantified acoustic shadows are considered calcified to approximate 
the real dense calcium (DC) plaque volume.
Methods: In total, 57 patients with 108 coronary lesions were included. A novel 
post-processing step is applied on the VH images to quantify the acoustic shadow and 
enhance the VH results. The VH and enhanced VH results are compared to quantita-
tive computed tomography angiography (QTA) plaque characterization as reference 
standard.
Results: The correlation of the plaque types between enhanced VH and QTA dif-
fers significantly from the correlation with unenhanced VH. For DC, the correlation 
improved from 0.733 to 0.818. Instead of an underestimation of DC in VH with a 
bias of 8.5 mm3, there was a smaller overestimation of 1.1 mm3 in the enhanced VH.
Conclusion: Although tissue characterization within the acoustic shadow in VH is 
difficult, the novel algorithm improved the DC tissue characterization. This algorithm 
contributes to accurate assessment of calcium on VH and could be applied in clinical 
studies.
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Introduction
Intravascular ultrasound Virtual HistologyTM (IVUS VH) is considered to be the gold 
standard for in vivo assessment of coronary plaque characteristics.1,2 However, a 
limitation of this technique is the ability of the ultrasound signal to fully penetrate 
calcified tissue, resulting in an acoustic shadow behind calcified tissue.3 Therefore, 
IVUS only visualizes the leading edge of calcium, due to a nearly total reflection of 
the echo signal. Moreover, tissue located behind large calcifications with a clearly 
edged acoustic shadow cannot be classified accurately and determination of the 
extent of the calcifications and other plaque characteristics is not possible.4 Even 
though the accuracy is unknown, IVUS based tissue characterization methods such 
as VH® (Volcano) or iMapTM (Boston Scientific) provide classifications of the plaque 
in these acoustic shadow areas.5 However, coronary atherosclerosis in the acoustic 
shadow is rarely classified as dense calcium (DC). This may lead to underestimating 
the DC area and overestimating of other plaque components. We hypothesized that 
most of the tissue in the acoustic shadow is DC and aim to compensate for the 
underestimated calcified areas in VH.
Therefore, a novel masking algorithm was developed in which a fully automatic 
post-processing step is applied on the VH images to quantify the acoustic shadow 
behind calcified areas. The quantified regions are modified and added to the total DC 
volume. To validate this new post-processing step, the enhanced VH (eVH) results are 
compared to plaque characteristics obtained with computed tomography angiogra-
phy (CTA).
Methods
The study population consisted of a previously described patient cohort of 57 patients 
with chest pain.6 In brief, all patients underwent CTA followed by clinically referred 
invasive coronary angiography (ICA) and IVUS VH. The Institutional Review Board 
of the Leiden University Medical Center approved this retrospective evaluation of 
clinically collected data, and waived the need for written informed consent.
IVUS Virtual Histology
Acquisition and quantification.
The examinations were acquired during conventional ICA using a dedicated IVUS 
console (S5tm Imaging system Volcano Corporation, Rancho Cordova, CA, USA) in 
combination with a 20MHz, 2.9 F phased-array IVUS Catheter (Eagle Eye, Volcano 
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Corporation, Rancho Cordova, CA, USA).All IVUS lumen and vessel wall delinea-
tions were quantified with QCU-CMS-Research v4.69 (research version of QIvus, 
developed by the Leiden University Medical Center). Additionally, the tissue region 
between the lumen and vessel wall was characterized by the integrated Volcano 
VH software in the following plaque types: necrotic core (NC), dense calcium (DC), 
fibrotic tissue (FI) and fibro-fatty tissue (FF).
Post-processing of the acoustic shadow.
A novel automatic method was developed to combine VH tissue characterization with 
an acoustic shadow detection method in order to quantify calcified plaque behind 
the acoustic shadow. This is performed in five automatic steps as shown in Figure 1:
1) The potential acoustic shadow regions are determined for each transversal IVUS 
frame by dividing it into two-degree wide wedges, resulting in 180 wedges.
2) For every wedge, the mean and maximum grayscale intensities of the plaque area 
are compared to the corresponding mean and maximum grayscale intensities 
of four predefined layers located outside of the external elastic membrane (0-
0.2 mm, 0.2-0.5 mm, 0.5-1.0 mm and 1.0-2.0 mm). If the mean and maximum 
grayscale intensity of each layer is less than the corresponding mean and maxi-
mum grayscale intensities of the plaque area, the wedge is marked as potential 
acoustic shadow.
3) Every transversal frame is analysed per one degree along a virtual polar scan-line. 
If the sum of grayscale intensities from the lumen border up to and including 
the VH determined dense calcium region is larger than 20% of the sum of all 
grayscale intensity values of the scan-line, the angle is marked as an acoustic 
shadow angle.
4) A mask is constructed based on the marked acoustic shadow angles covering all 
pixels behind the dense calcified regions as shown in Figure 1D.
A B C D 
Figure 1: The automatic post-processing steps on the IVUS VH. 
A) The first step shows the 180 wedges. B) shows the second step with the four predefined layers in grey 
and white and in green the potential acoustic shadows. C) shows the third step with shadows in blue 
where the calcium regions are larger than 20%. D) shows the final masks with the calcified regions in 
white.
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5) The area and volume of the masked areas are quantified and added to the total DC 
area and DC volume.
Computed tomography coronary angiography
Acquisition.
Of the 57 patients, 16 CTA exams were acquired using a 64-row helical CT scanner 
(Aquilion 64, Toshiba Medical System, Otawara, Japan) and 41 from a 320-row volu-
metric scanner (Aquilion ONE, Toshiba Medical System, Otawara, Japan). The scan 
protocol was previously described.7,8 Scans with poor image quality were excluded 
for the current analysis.
Quantification of coronary atherosclerosis.
CAD on CTA was quantified using dedicated software (QAngio CT Research Edition 
v1.3.6, Medis medical imaging systems bv, Leiden, the Netherlands). The validity 
of this software tool for the segmentation of the coronary anatomy was previously 
established.9 For characterization of CAD, two different approaches are available in 
the software. One approach with predefined fixed intensity cut-off values on the 
Hounsfield Units (HU) and an adaptive approach where cut-off values are adapted 
according to lumen attenuation. In the present analysis the adaptive threshold for 
CTA plaque constitution was used as the reference standard.6 This adaptive threshold 
is based on the principle that plaque intensity is influenced by luminal contrast densi-
ties and decrease from the proximal to the distal part of the vessel. Therefore, in this 
automatic- and user-independent approach, the HU cut-off values of the different 
plaque types are adapted according to lumen intensity. First, a linear trend line is 
fitted through the mean lumen intensity. Next, the threshold for NC is defined as 200 
HU below this estimate with a maximum of 75 HU and the DC threshold is defined 
as 100 HU above this estimate with a maximum of 450 HU. The threshold between 
FI and FF is set on 20% of the difference between the NC and DC threshold. This way, 
the intensity cut-off values are adapted by the same linear, decreasing trend along the 
vessel (see Figure 2). Additionally, because the lumen intensity is lower in parts of a 
severe stenosis, the NC cut-off value is locally decreased with 125% of the difference 
between the estimate and the real lumen intensities. In contrast, lumen intensity is 
higher in calcified parts due to blooming artefacts. Therefore, the DC cut-off value is 




Comparison between VH and CTA
To compare the VH data with the CTA data a previously described comparison al-
gorithm was used.6 All transversal IVUS images were matched and fused with the 
corresponding transversal CTA images using anatomical landmarks (side-branches, 
ostia, and calcified plaques) as shown in Figure 3. The plaque volumes of all different 
plaque components in the lesions in each corresponding artery were assessed. Both 
the original VH images and the post-processed, eVH images were compared to QCT 
as shown in Figure 4.
Statistical analysis
Statistical analyses were performed with the use of SPSS software (version 20.0, SPSS 
Inc., Chicago, IL, USA). First, the absolute plaque volumes of each plaque type on 
VH and eVH were compared. Second, both the VH and eVH plaque parameters 
were compared to QCT. For this purpose, the Spearman correlations were calculated. 
Moreover, the absolute median differences between QCT and VH or eVH were es-
tablished. Thereafter, Bland–Altman plots were made to assess the bias and the limits 
of agreement for the comparison between VH and CTA (GraphPad Prism software, 
version 5.01, San Diego, California, USA). These plots show the difference of each 
pair plotted against the average value of each pair. Additionally, the Pitman-Morgan 
test of variances was used to demonstrate if the variances in the comparisons of 
QCT with VH with and without post-processing were significantly different.10 The 
Pitman-Morgan test takes the correlation between two variances into account. A P-
value ≤0.05 was considered statistically significant.
275 350 
75 








Figure 2: The adaptive threshold scheme.
The graphs shows the thresholds in HU (above the black line is DC, above the green line is FI, above 
the red line is FF and below the red line is NC) that are used for each measured mean lumen intensity 
on the x-axis for each crossectional CTA image. For example, if the mean lumen intensity is more than 
350 HU, everything below 75 HU is NC, between 76 and 150 is FF, between 151 and 450 is FI and 
above 451 is DC. 
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Results
Baseline patient characteristics were previously described.6 For this analysis, 109 
vessels were used of which 69 revealed atherosclerosis, whereas 40 vessels did not. 
In these 69 diseased vessels, 108 lesions were identifi ed. These 108 lesions were used 
for the present lesion based comparison.
Plaque classifi cation on VH compared to eVH
The quantifi cation results of both VH and eVH are depicted in Table 1. On VH median 
FI volume was 39.7(19.9-67.3) mm3, while applying the novel algorithm decreased 
the median FI volume to 37.6(16.8–61.5) mm3, (P<0.001). Similarly, the total volume 
of FF decreased from 9.3(4.9-19.4) mm3 to 7.9(4.1-16.9) mm3, (P<0.001). Also, NC 






IV. III. II. I. 
IVUS VH 
= = = 
Figure 3: Schematic illustration of the comparison of VH and eVH with QCT.
First, the centerline was generated from the CTA data set  (I). IVUS images are fused with the CTA vol-
ume using anatomical landmarks (II). Lumen and vessel wall contours were detected for both imaging 
modalities (III). Finally, lesions were quantifi ed on the segmented plaque as shown in panel IV. Plaque 
volumes and plaque types were derived for the whole lesion, ranging from the proximal to distal lesion 
marker (blue markers). Both VH and eVH were compared to QCT. 
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In the total population, the volume of DC in VH was 815.22 mm3. An acoustic 
shadow was detected in 106 of the 108(98%) lesions. The quantified acoustic shadow 
resulted in a total volume of 1033.93 mm3. These quantified areas were added to 
Table 1: Absolute differences between VH vs eVH plaque constitution compared to QCT plaque con-
stitution (n=108).






















Enhanced dense calcium 10.0(3.0-22.8) -3.6;1.5 0.401
eHV, Enhanced Virtual Histology; CI, confidence interval; IQR, interquartile range; VH, virtual histol-







Figure 4: Example of the registered images after fusion.
The yellow scale bars represent 5 mm. A) CTA image with IVUS overlay B) in green correctly translated 
and rotated on the CTA image. C) contains the corresponding VH overlay from D) and similarly E) con-
tains the eVH image from F). The QCT tissue overlay is shown in G) from the CTA image in H) Note that 
all overlays are mirrored in the top row for a correct fusion. The overlays in C-G have five color codes: 
red (NC), light-green (FF), dark-green (FI), white (DC), and blue for the masked areas. There is a nice 
correspondence between the masked areas in E) and the two calcified areas with high intensities in H) 
with in between a calcified area with lower intensity, more similar to the luminal contrast intensity in 
the bifurcating artery. This example shows that the DC area in VH is underestimated when compared 
to the DC area in the tissue overlay in G). Adding the blue quantified acoustic shadow to the total DC 
volume in eVH will approximate the DC volume in QCT.
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the DC volumes providing a total enhanced DC volume of 1949.15 mm3. Overall, 
the median DC volume increased from 5.4(1.7-11.6) mm3 to 10.0(3.0-22.8) mm3, 
(P<0.001).
Plaque classification on QCT
The QCT plaque quantification results were previously described.6 In brief, on 
QCT, the median FI volume was 55.7(36.1-94.9) mm3, the median FF volume was 
28.3(16.2-45.9) mm3, the median volume of NC was 11.0(5.6-24.7) mm3 and the DC 
volume was 6.95(0.9-18.9) mm3.
Comparison of VH and eVH to QCT plaque classification
To validate the novel algorithm, the VH and eVH data were compared to QCT. The 
results of this comparison are demonstrated in Table 1.
Absolute differences.
The median DC volume was significantly underestimated by VH compared to QCT 
(5.4(1.7-11.6) mm3, vs. 6.95(0.9-18.9) mm3 P<0.001). After applying the novel 
algorithm to the VH data, there was no significant difference between the DC volume 
on both modalities 10.0(3.0-22.8) mm3 for eVH vs. 6.95(0.9-18.9) mm3 for QCT, 
P=0.401). However, for NC a significant difference between QCT and eVH was ob-
served (11.0(5.6-24.7) mm3 on QCT vs 10.1(4.2-18.8) mm3 on eVH P=0.006). For FI 
and FF a significant difference was observed for both VH and eVH compared to QCT.
Correlation and agreement.
For all four plaque types there was difference in correlation between QCT and VH 
compared to QCT and eVH after applying the novel algorithm (Table 2). The largest 
change in correlation between VH and QCT was observed for DC. Adding the quanti-
fied area to the DC volume improved the correlation with QCT from 0.733 to 0.818. 
The correlations of the other plaque types changed less if the novel algorithm was 
applied to the VH data.
The results of the corresponding Bland-Altman plots for the DC volume of both VH 
and eVH compared to QCT are shown in Table 2 and depicted in Figure 5. Without 
masking, DC volume in VH was underestimated with a bias of 8.5 mm3 compared 
to the QCT. After applying the masking tool it was overestimated with a bias of -1.1 
mm3. The masking is especially useful on cases with large DC volumes as shown in 
Figure 5 where the systematic error in the large DC volumes is smaller for eVH. The 
last column in Table 2 depicts the statistical significance of the difference in variances 
between the two comparisons (i.e. QCT vs. VH and QCT vs. eVH). As demonstrated 
with the Pitman-Morgan test of variances, the agreement in DC volume between 
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VH and QCT was significantly improved by applying the masking tool (P<0.001). 
Similarly, there was a significant change in variance for the FF and FI between VH 
and eVH compared to QCT. However, for these plaque types the agreement of QCT 
was better with VH than with eVH. For NC, there was no significant difference in 
variances between QCT vs. VH and QCT vs. enhanced VH. An example of a coronary 
lesion and the resulting comparison between QCT and VH without and with the 
enhanced plaque quantification is shown in Figure 6.
Figure 5: Bland-Altman plots for both the DC volume of VH and DC volume of eVH compared with 
QCT.














Fibrotic 0.787,<0.001 20.4 -35.7 76.6
<0.01
Enhanced fibrotic 0.750,<0.001 24.3 -54.6 77.8
Fibro fatty 0.704,<0.001 20.2 -15.2 55.6
0.05
Enhanced fibro fatty 0.728,<0.001 22.6 -7.3 44.5
Necrotic core 0.479,<0.001 1.0 -25.9 27.9
0.76
Enhanced necrotic core 0.425,<0.001 3.7 -26.4 61.4
Dense calcium 0.733,<0.001 8.5 -32.5 49.5
<0.001Enhanced dense 
calcium
0.818 <0.001 -1.1 -28.3 31.7
VH, virtual histology; LOA, limits of agreement; QCT, quantitative computed tomography
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Discussion
This study presents the results of a novel post-processing step on VH data to com-
pensate for the limited ability of IVUS to penetrate dense calcified tissue. The novel 
algorithm detects, masks, and quantifies the acoustic shadow behind calcium. By 
adding the quantified acoustic shadows to the total DC volume, the correlation be-
tween DC volumes on VH and QCT improves significantly. Moreover, the agreement 




Figure 6: Quantification of plaque volumes along the vessel. 
A) An example of a coronary lesion in CTA. The x-axis represents the distance from the coronary ostium 
in mm. The y-axis represents the area of either the lumen (lower part of graph) or the vessel wall (upper 
part of graph) in mm2. The part between the two graphs shows the plaque constitution using a color 
code. In the corresponding VH data is shown in B) and in C) the results with the quantified shadows 
in blue. The enhanced quantification has better correspondence with the CTA analysis after adding the 
quantified shadow areas to the DC.
Chapter 5
100
small overestimation of DC volume in the enhanced VH. However, for FI and FF the 
agreement with QCT was reduced after applying the novel algorithm.
Acoustic shadow
The limited ability of the echo-signal to penetrate coronary calcium results in two 
problems.5 Firstly, the outer vessel boundaries located in the acoustic shadow are 
difficult to segment and need to be manually adjusted. This potentially leads to 
observer bias. However, an experienced observer can manually overcome this prob-
lem. Secondly and most important, the noise in the acoustic shadow is classified as 
coronary atherosclerosis by RF based methods as VH or iMapTM(Boston Scientific).11 
Ideally, an acoustic shadow should be completely dark in B-mode IVUS images due 
to the greatly limited ability of the ultrasound signal to penetrate the calcified plaque. 
Current software tools fail to identify these acoustic shadows and quantify the tissue 
within the acoustic shadow. These regions are characterized mainly as FI or FF by VH 
or characterized mainly as necrotic tissue by iMap. The validity of this quantifica-
tion is unknown. Recent echogenicity methods solve this problem by classifying the 
acoustic shadows behind calcifications as ‘unknown’.12 The acoustic shadow can be 
delineated manually, but is very time consuming. Moreover, a manual approach is 
susceptible to inter- and intra-observer variability for determining and masking the 
regions in the acoustic shadows. Bayturan et al. investigated a novel type of ‘attenu-
ated plaque’ which occurs in the absence of DC.13 Attenuated plaque was defined as 
hypoechoic plaque with deep ultrasonic attenuation (shadow) despite the absence of 
DC and is associated with high risk lesions. The acoustic shadow behind this attenu-
ated plaque can also be detected by this post-processing procedure by using step 4 to 
differentiate between attenuated shadow regions and shadow regions resulting from 
DC as classified by VH or for example by echogenicity if there is no VH available.14
Novel algorithm
For the present study a novel algorithm was developed to automatically detect and 
quantify the regions of acoustic shadow. Our hypothesis is that most of the tissue in 
the acoustic shadow is DC, or at least a larger volume than is detected with IVUS 
VH. To compensate for the suspected underestimation of DC within these regions, 
the quantified areas were added to the total DC volume. Although the corrected DC 
volumes in eVH show improved bias and correlation with QCT, the post-processing 
step does not detect any additional DC but selects regions without enough signal 
for reliable tissue characterization. Adding the quantified acoustic shadows to the 
overall DC volume, could result in overestimating DC in VH because not all plaque 
within the acoustic shadow is calcified. However, excluding the quantified shadows 
from the VH results will result in larger underestimation of the DC volume, because 
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all DC areas located in the acoustic shadow (i.e. calcifications located behind other 
calcified areas) will be excluded as well. Moreover, a thin or non-dense calcified 
plaque would allow for penetration of the acoustic signal and would likely not result 
in an acoustic shadow.
Coronary artery calcium on IVUS
Coronary calcium, as assessed with different imaging modalities, is a representation 
of overall atherosclerotic burden. The prognostic value of coronary artery calcifi-
cations has been widely established.15 Therefore, accurate assessment of coronary 
calcium on IVUS is of value in clinical practice. Calcifications on IVUS are strongly 
correlated with overall coronary plaque burden, but show limited correlation with 
stenosis severity.16
Besides sole DC, the relation between DC and necrotic core (considered a vulner-
able plaque type) is of clinical value. Previous studies addressed the prognostic value 
of the NC/DC ratio on IVUS VH. On IVUS VH the ratio between NC and DC was 
the only significant parameter associated with cardiovascular risk factors for sudden 
coronary death in men.17 Moreover, the NC/DC ratio was positively associated with 
a high-risk acute coronary syndrome presentation.18 Indeed, ruptured plaques have 
a smaller calcium arch, and relatively more deep calcium than superficial calcium 
compared to non-ruptured plaques.19
The influence of coronary calcium on atherosclerotic plaque characterization with 
VH is an ongoing topic of debate.20 Some studies suggest that coronary calcium on 
VH is surrounded by an area of artefact incorrectly quantified as NC.21 This was 
confirmed by Pu et al. in a study with 131 coronary lesions, combining VH with near-
infrared spectroscopy (NIRS).22 In all lesions with calcified plaque, NC was present 
on VH. However, in these calcified plaques no relation was observed between per-
centage NC of VH and lipid core burden index on NIRS, suggesting an overestimation 
of NC in VH due to the artefact caused by calcium. By masking the regions behind 
the DC in the acoustic shadow, the median NC volume decreases compared to VH 
which potentially could improve the relation with NIRS. Furthermore, Thim et al. 
found no correlation between NC size determined by IVUS VH and real histology.23 
Although they did not include histological examples with large calcifications and 
acoustic shadows on the corresponding VH images, they suggest that the NC tissue 
detection in VH and the presence of calcifications are linked. A similar assessment of 
DC by VH and real histology is needed to provide further insights in this approach of 
enhancing VH results.
In addition to the relation with clinical presentation, coronary calcium influences 
the local response to medical therapy for plaque regression. Bruining et al. performed 
IVUS in 118 patients randomized to treatment with perindopril or placebo.24 Patients 
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with little calcium showed plaque regression on perindopril treatment, whereas 
patients with moderate calcium showed no change in atherosclerosis. This led to the 
concept that coronary calcium content should be considered in quantitative analysis 
of therapy effect in atherosclerosis regression studies and need accurate assessment.
By quantifying the acoustic shadow, the presented algorithm can enhance the as-
sessment of DC in VH. By applying the algorithm, there is a small trade-off in the 
agreement of NC, but there is no significant difference in NC variance between VH 
and eVH as shown in the last column of Table 2. Potentially, this novel tool provides 
better applicability of VH for DC assessment.
Limitations
Although results of the presented study show that the VH results can be enhanced to 
improve correlation and bias of DC with QCT, there are some limitations. The post-
processing step was applied on VH data and analyses from a single-centre. The influ-
ence of the post-processing step on the output of different IVUS catheters/vendors is 
unknown, specifically if iMap would benefit in the same degree of this approach.11 
The agreement for FI and FF became less with the novel algorithm. However, for 
clinical purpose accurate assessment of DC and NC is of greater value. Both NC and 
DC on VH are associated with ACS presentation or plaque rupture, whereas FI and 
FF are not.1,25
For this comparison, the QCT was used as the gold standard. However, the segmen-
tation of plaque areas and the tissue classification in QCT is influenced by blooming 
artefacts. Also, bias between both modalities is always present because of the differ-
ence in segmented plaque volumes. QCT overestimates the plaque volume by an un-
derestimation of the lumen volume and a slight overestimation of vessel wall volume 
compared with IVUS.6 A direct comparison between the plaque characterization in 
VH and OCT or histopathology could provide further insights into the distribution of 
DC in areas within the acoustic shadows.26
Conclusion
Although tissue characterization within the acoustic shadow in VH is unreliable, an 
automatic post-processing step to quantify the acoustic shadow in order to add these 
regions to the calcified tissue enhances the agreement with QCT DC characterization.
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Purpose: Potentially, Agatston coronary artery calcium (CAC) score could be calcu-
lated on contrast CTA. This will make a separate non-contrast CT scan superfluous. 
This study aims to assess the performance of a novel fully automatic algorithm to 
detect and quantify the Agatston CAC score in contrast CTA images.
Methods: From a clinical registry, 20 patients were randomly selected for each 
CAC category (i.e. 0,1-99,100-399,400-999,≥1000). The Agatston CAC score on 
non-contrast CT was calculated manually, while the novel algorithm was used to 
automatically detect and quantify Agatston CAC score in contrast CTA images. The 
resulting Agatston CAC scores were validated against the non-contrast images.
Results: A total of 100 patients (60±11 years, 63 men) were included. The median CAC 
score on non-contrast CT was 145(IQR 5-760), whereas the contrast CTA CAC score 
was 170(IQR 23-594) (P=0.004). The automatically computed CAC score showed a 
high correlation (R=0.949; P<0.001) and intra-class correlation (R=0.863; P<0.001) 
with non-contrast CT CAC score. Moreover, agreement within CAC categories was 
good (Kappa 0.588).
Conclusion: Fully automatic detection of Agatston CAC score on contrast CTA is 
feasible and showed high correlation with non-contrast CT CAC score. This could 
imply a radiation dose reduction and time saving by omitting the non-contrast scan.
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Introduction
Coronary artery disease (CAD) is one of the leading causes of death worldwide.1 
Coronary artery calcium (CAC) is a representative marker of the overall coronary 
atherosclerosis burden.2 The amount of coronary artery calcium is routinely detected 
and quantified on a non-contrast computed tomography (CT) scan according to the 
Agatston scoring approach.3, 4 This Agatston CAC score has been demonstrated to 
have prognostic value for cardiovascular events, independent of age, ethnicity and 
sex.5-10 However, for the estimation of severity and extent of coronary stenosis a 
contrast computed tomography coronary angiography (CTA) has to be performed.11, 12 
This technique allows evaluation of coronary stenosis with good accuracy compared 
to invasive coronary angiography.13-16 Moreover, contrast CTA provides accurate 
visualization of the coronary vessel wall and allows assessment of coronary plaque 
constitution. 
In current clinical practice, a non-contrast CT scan is often performed to quantify 
the Agatston CAC score. Subsequently, depending on the clinical question, a contrast 
CTA scan is performed to assess coronary stenosis severity. While the non-contrast 
CT scan and contrast CTA are performed separately, they both contribute to radia-
tion exposure.17 Since calcified lesions can be distinguished on contrast CTA, it is 
conceivable that contrast CTA images could be used to detect coronary calcium and 
calculate the Agatston score. If Agatston CAC score calculation on contrast CTA im-
ages is accurately achievable, it could result in making a separate non-contrast CT 
scan superfluous, hence resulting in a decrease in cost, time and radiation exposure. 
Previous studies have addressed this topic, aiming to assess the potential of software 
tools to quantify CAC on CTA datasets, however, these algorithms required (partial) 
manual interference or provided moderate results.18-22 Recently, using a novel soft-
ware algorithm, fully automatic quantification of the Agatston CAC score on contrast 
CT has become feasible. However, the accuracy of this tool has yet to be determined. 
Therefore, the aim of this present study was to 1) assess the feasibility of a novel tool 
to fully automatically detect and quantify CAC in contrast CTA images, and calculate 
the Agatston CAC scores and 2) to compare the derived Agatston scores with Agatston 
CAC scores obtained from traditional non-contrast CT scans and assess the agreement 
per Agatston CAC score risk category. 3) The contribution of the non-contrast CT to 




Patients and study protocol 
The population consisted of 100 patients from an ongoing clinical registry. Per 
Agatston CAC score risk categories (i.e. 0, 1-99, 100-399, 400-999,  ≥1000), 20 
patients, with sufficient image quality of the non-contrast CT and the contrast CTA, 
were randomly selected to ensure an equal distribution. These patients had known 
or suspected CAD and were clinically referred for the evaluation of chest pain to the 
Leiden University Medical Center, between 2008 and 2012. All patients underwent a 
non-contrast CT scan followed by a contrast CTA.
Patients with previous, myocardial infarction, percutaneous coronary intervention 
(PCI) or coronary artery bypass graft surgery (CABG) were excluded. The clinical data 
were prospectively entered into the departmental Cardiology Information System 
(EPD-Vision©, Leiden University Medical Center, the Netherlands) and retrospec-
tively analyzed. The Institutional Review Board of the Leiden University Medical 
Center approved this retrospective evaluation of clinically collected data, and waived 
the need for written informed consent. 
Cardiac CT and CTA acquisition 
Patients were scanned with either a 64-slice CT scanner (Aquilion 64, Toshiba Medi-
cal System, Otowara, Japan) or a 320-row volumetric scanner (Aquilion ONE, Toshiba 
Medical System, Otowara, Japan). Contra-indications for CTA were, 1) impaired renal 
function (glomerular filtration rate< 60), 2) pregnancy, 3) (supra-) ventricular arrhyth-
mias, 4) known allergy to contrast agent, 5) severe claustrophobia. Prior to CT exami-
nation, beta-blocking medication was administered if the heart rate was ≥65 beats per 
minutes, unless contra-indicated. Patients received 0.4 mg of nitrates sublingual prior 
to the scan. Non-contrast CT and contrast CTA were performed according to standard 
clinical practice.23, 24  For assessment of the CAC-score on non-contrast CT, images 
with a 3mm slice-thickness were reconstructed. Scan parameters for 64-slice CTA 
were 400ms gantry rotation time, collimation of 64x0.5mm, tube voltage of 100-135 
kV and tube current of 250-350mA, depending on body mass index. Scan parameters 
for 320-row CTA were 350ms gantry rotation time, collimation of 320 x0.5mm, tube 
voltage of 100-135 kV and tube current of 400-580mA, depending on body mass 
index. Images were acquired prospectively and reconstructed at 75% and at the best 
phase of the R-R interval.25 Radiation dose was calculated with a dose-length product 
conversion factor of 0.014 mSv/(mGy x cm).26  
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Quantification of Agatston CAC score on non-contrast CT scan
The standard non-contrast CT scan was made to manually assess the total amount of 
CAC in the coronary arteries, defined according to the Agatston CAC-scoring method. 
To analyze the CAC score, the collected images were transferred to a workstation 
for evaluation using dedicated post-processing software (CalcSore v1.1.1 by Medis 
specials bv). Coronary calcified lesions were manually selected and quantified in 
non-contrast CT scans with a threshold of 130 Hounsfield Unit (HU). 
Quantification of Agatston CAC score on contrast CTA
Prior to coronary artery calcium quantification, image quality of both non-contrast 
CT and contrast CTA was assessed using the following ordinal scale: good image 
quality, moderate image quality or poor image quality. Image data sets without mo-
tion artefacts or increased image noise were evaluated as good quality datasets with 
motion artefacts or increased image noise were classified as moderate. Clinically 
non-diagnostic scans were classified as poor image quality and were excluded.
A novel algorithm for fully automatic detection and quantification of the calcium 
volume and Agatston CAC score on the contrast CTA datasets was developed. The 
Agatston CAC score was automatically derived in the following steps:
1. The coronary tree was automatically extracted from the CTA dataset using a 3D 
vessel-tracking algorithm.27 
2. Using an automatic tree labeling algorithm, the segments of the coronary tree 
were automatically labeled according the AHA 17-segment model.27-29 Subse-
quently, the four main coronaries, i.e., right coronary artery (RCA), left main (LM) 
artery, left anterior descending (LAD) artery and left circumflex (LCx) artery and 
corresponding side-branches were identified based on this labeling result. Multi-
planar reformations (MPRs) were created based on the centerlines of the detected 
coronaries. An experienced observer verified the extracted and labeled coronary 
tree.
3. To automatically detect and quantify CAC, a novel algorithm was used to identify 
the presence of calcium in the coronary arteries. A reference trend line on the 
lumen intensity values along the centerline was fitted for each individual vessel, 
ranging from the proximal to the distal part of the vessel. After this, only the pixels 
near the centerline with intensity values higher than the reference trend line are 
considered to be calcified and selected for further processing using and advanced 
region growing scheme (Figure 1.)
4. All detected calcified pixels in the MPRs are projected back into the original 
volume. Any emerging gaps within projected spots are filled if needed. Next, the 
volume is resampled to have a slice thickness of 3 mm. 
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5. Based on the detected CAC volumes for each of the four main coronaries and 
side-branches, the Agatston CAC score was automatically calculated using a 
predefined conversion factor of 2.74.19 
An example of the automatic CAC assessment on contrast CTA with corresponding 
non-contrast CT reference is depicted in Figure 2. 
First, the Agatston CAC scores derived from contrast CTA using the novel software 
tool were compared to the Agatston CAC score from non-contrast CT as a refer-
ence. Second, differences in performance of the software per coronary vessel were 
assessed. Third, the agreement between the two methods per Agatston CAC score risk 
category was assessed. Last, the contribution of the non-contrast CT to the overall 
radiation exposure was calculated. 
Statistical analysis
Continuous data are presented as mean ± SD if normally distributed or as median 
(interquartile range, IQR) if non-normally distributed. Categorical data are presented 
as absolute numbers and percentages. A comparison was made between the non-
contrast CT Agatston CAC score and the contrast CTA Agatston CAC score.  Non-
Figure 1. Method for automatic coronary calcium detection.
Example of the method for automatic coronary calcium detection. Panel A shows an MPR with two 
calcified coronary lesions (white arrows). Panel C demonstrates the luminal intensities plot. The x-axis 
represents the distance from the coronary ostium, the y-axis represents the peak intensity along the 
centerline (HU). The red line is the trendline of this plot. Large deviations from this trendline are con-
sidered coronary calcium (white arrows) Panel B demonstrates a cross-sectional view of the coronary 
artery with the detected coronary calcium marked in bleu. The yellow line indicates the coronary lu-
men border. 
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parametric tests were used to compare the absolute difference between the CAC score 
derived from non-contrast CT scan and contrast CTA. A non-parametric correlation 
(Spearman) and intra-class correlation (ICC) were used to calculate the correlation 
between the two methods. An ICC less than 0.4 indicated poor correlation, an ICC 
between 0.4 and 0.75 indicated fair to good  correlation, and an ICC greater than 
0.75 indicated excellent correlation.30 Thereafter,  the Bland-Altman method was 
used to assess the  limits of agreement for the Agatston CAC score between the two 
methods.31 The Bland-Altman was calculated for both absolute and percentage differ-
ences. For clarity, a magnified view of the Bland-Altman plot with an X-axis range up 
to 1000 was provided. The agreement within the Agatston CAC score risk categories, 
was evaluated using the weighted kappa (k) statistics. Poor, fair-to-good and excellent 
were defined by a k-value of <0.4, between 0.4 and 0.75, and > 0.75, respectively.32 






Figure 2. Patient example of coronary calcium detection with both methods.
A 66 year old male patient with calcified coronary plaque in the LAD. Panel A illustrates the coronary 
artery calcium (CAC) on the non-contrast CT scan (arrows). Panel B depicts the manual detection of 
the calcified lesions on the same non-contrast CT scan. Panel C shows CAC in the same patient on 
the contrast CTA scan. Panel D depicts the automatic detection and quantification of the calcium on 
the contrast CTA scan with a novel fully automatic algorithm. The Agatston CAC score was 63 on the 
non-contrast CT scan and 58 on the contrast CTA scan as assessed with the fully automatic algorithm.
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significant. All statistical analyses were performed with SPSS software (Version 20.0, 
SPSS Inc., Chicago, Illinois).
Results 
Patient population
The total patient population consisted of 100 patients with a mean age of 60 ± 11 
years and 63 patients (63%) were male. The clinical baseline characteristics of the 
patients are listed in Table 1. Hypercholesterolemia was observed in 33% of patients, 
and 21% of patients presented with obesity. Of the 100 scans, 54 were classified as 
good; the remaining 46 were classified as moderate quality. 
Table 1. Patient characteristics. 
Baseline characteristics Total (N = 100)
Age (yrs) 60 ± 11
Gender (% male) 63 (63%)
Cardiovascular risk factors 
 Hypertension† 38 (38%)
 Hypercholesteromia‡ 33 (33%)
 Diabetes mellitus 31 (31%)
 Family history of CAD* 33 (33%)
 Current Smoker 15 (15%)
 Obesity (BMI ≥ 30 kg/ m2) 21 (21%)
Agatston CAC score (non-contrast CT) images) 606 ± 997
=-
145 (IQR 5 – 760)
Data are represented as mean ± SD, median (interquartile range) or as number and percentages of 
patients.
†Defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90
mmHg or the use of antihypertensive medication.
‡Serum total cholesterol ≥230 mg/dL or serum triglycerides ≥200 mg/dL or treatment with lipid lower-
ing drugs. 
*Defined as the presence of coronary artery disease in first-degree family members at <55 years in men 
and <65 years in women.
Abbreviations:  BMI: body mass index, CAD: coronary artery disease, CAC: coronary artery calcium, 
CT: computed tomography, IQR: interquartile range.
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Agreement between non-contrast CT and contrast CTA Agatston CAC 
score
The median Agatston CAC score on non-contrast CT was lower compared to the Ag-
atston CAC score on contrast CTA (145(IQR 5-760) and 170(IQR 23-594), P=0.004, 
respectively) (Table 2). Overall, the median difference was 0 (-217-35). 
 The correlation between the non-contrast CT- and contrast CTA Agatston CAC 
score is displayed in Figure  3. The Agatston CAC score on non-contrast CT was 
highly correlated with the contrast CTA Agatston CAC score (R=0.949, P<0.001 and 
ICC=0.863, P<0.001). The correlation was similar between scans of good image qual-
ity (R=0.934) and moderate image quality (R=0.949). The correlation was similar for 
patients scanned with 100kV (n= 13), R=0.994, P<0.001, 120 kV (n=72), R=0.935, 














LM 0 (0-37) 0 (0-13) 0.160 0.513, (P<0.001) 0.757, 
(P<0.001)
LAD 83 (1-369) 86 (0-281) 0.371 0.894,(P<0.001) 0.854, 
(P<0.001)
RCA 16 (0-251) 33 (0-150) 0.001 0.827, (P<0.001) 0.793, 
(P<0.001)
LCX 4 (0-53) 11 (0-65) 0.703 0.754, (P<0.001) 0.851, 
(P<0.001)
Total 145 (5-760) 170 (23-594) 0.004 0.949, (P<0.001) 0.863, 
(P<0.001)
Abbreviations: CT: computed tomography, CTA: computed tomography coronary angiography, ICC: 
Intra-class correlation, IQR: Interquartile Range, CX: circumflex artery, LAD: Left anterior descending 
artery, LM: Left main, RCA: Right coronary artery.















































Figure 3. Correlation between non-contrast CT Agatston CAC score and contrast CTA Agatston CAC 
score. 
The left figure shows the full range scatter plot. The right figure shows a magnified view of the non-
contrast CT Agatston CAC score up to 1000.
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P<0.001, or 135 kV (n=15), R=0.960, P<0.001. For all three kV settings the ICC 
between the non-contrast CT and contrast CTA CAC score was 0.784. 
 The Bland-Altman analysis of the Agatston CAC score as assessed with both 
methods is shown in Figure 4. The non-contrast CT Agatston CAC score was lower 
compared to the contrast CTA Agatston CAC score as demonstrated by a bias of -176 
with 95%-limits of agreement ranging from -1248 to 896. The bias on a percentage 
basis was 3% with 95%-limits of agreement ranging from -174% to -168%. As dem-
onstrated in the Bland-Altman analysis the absolute error increases with increasing 
CAC-scores (lower panels). However, on a percentage basis this trend is not observed 
(upper panels).  
The per-vessel analysis, as described in Table 2, demonstrated similar results. Cor-
relations for LAD, RCA and LCX were 0.894, 0.827 and 0.754, respectively (P<0.001). 
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Figure 4. Bland-Altman of non-contrast CT Agatston CAC score and contrast CTA Agatston CAC score. 
The left panel shows the Bland-Altman plot.  De dotted vertical lines represent the bias with corre-
sponding 95% limits of agreement. The right panel shows a magnified view of the same Bland-Altman 
plot with an X-axis range of 1000. In the two upper panels the Y-axis represents the percentage differ-
ence of the Agatston CAC score between the two methods. In the lower two panels the Y-axis represents 
the absolute difference.
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However, the correlation for LM CAC score was lower (R=0.513, P<0.001) compared 
to the correlation for the overall CAC score. Except for RCA, there were no significant 
absolute differences between non-contrast CT Agatston CAC score and contrast CTA 
Agatston CAC score per vessel.  
Agreement within Agatston CAC score risk categories
The agreement between the two methods within the traditional Agatston CAC score 
risk categories was assessed and depicted in Table 3. The fully automatic algorithm 
used on contrast CTA classified 67/100 patients (67%) in the same cardiovascular risk 
category compared with the non-contrast CT Agatston CAC score. Of the remaining 
33 (33%) patients, 10 (10%) shifted to a higher category and 23 (23%) to a lower 
category. Importantly, of the 20 patients with a non-contrast CT Agatston CAC score 
of 0, 18 (90%) patients were accurately classified as CAC score of 0 on the contrast 
scan. Only two patients shifted to a higher category, these patient had a contrast CTA 
Agatston CAC score of 11 and 14.  Furthermore, in the CAC score category of 1-99, 
14 (70%) patients remained in the same category while 3 (15%) patients shifted to a 
lower category and 3 (15%) patients to a higher category. In the category 100-399, 
11 (55%) patients remained in the same category, while 5 (25%) patients shifted to a 
lower category of 1-99 and 4 (20%) patients shifted to a higher category of 400-999. 
Of the 20 patients in the category 400-999, 10 (50%) patients remained in the same 
category after calcium scoring on CTA images, while 9 (45%) patients shifted to a 
Table 3. Agreement within CAC score risk categories between the contrast CTA Agatston CAC score 
and the non-contrast CT Agatston score.
Non-contrast CT Agatston CAC score
Category 0 1-99 100-399 400-999 ≥1000 Total
Contrast CTA
Agatston CAC score
0 18 3 0 0 0 21
1-99 2 14 5 1 0 22
100-399 0 3 11 8 0 22
400-999 0 0 4 10 6 20
≥1000 0 0 0 1 14 15
Total 20 20 20 20 20 100
Same 18 14 11 10 14 67
Shift up 2 3 4 1 0 10
Shift down 0 3 5 9 6 23
The underlined numbers indicate agreement between both methods. 




lower category and 1 (5%) patient to a higher category of ≥1000. Lastly, 6 (30%) 
patient in the risk category of ≥1000, shifted to a lower category. Overall, the agree-
ment within the Agatston CAC score risk categories was good (k= 0.588). This was the 
same for scans with good (k= 0.578) and fair (k= 0.586) image quality. 
Radiation dose
In total, the mean radiation dose was 9.10 ± 5.78 mSv. For non-contrast CT the radia-
tion dose was 1.39 ± 0.39 mSv and for the contrast CTA 7.60 ± 5.78 mSv. On average, 
the radiation dose of the non-contrast CT was 20% of the total radiation exposure.  
Discussion 
The present study assessed the feasibility and accuracy of a novel software tool for 
fully automatic detection of CAC and subsequent quantification of the Agatston CAC 
score on contrast CTA images. The automatic algorithm was evaluated by using the 
non-contrast CT Agatston CAC score as a reference standard.  The Agatston CAC score 
derived from contrast CTA was well-correlated with non-contrast CT Agatston CAC 
score. Moreover, even though a third of the patients were reclassified in a different 
CAC-risk category, the overall agreement within the traditional Agatston CAC score 
risk categories was good, thus providing accurate assessment of cardiovascular risk 
in correspondence with the Agatston CAC score derived from non-contrast CT. Based 
on these results, the novel software tool allows for accurate quantification of CAC 
on contrast CTA and could thus provide an important prognostic and well validated 
marker of risk. Omitting the non-contrast CT from the scan protocol could have 
potentially reduced the radiation exposure in this study cohort by 20%. 
Contrast CTA conversion factor
Different voxel size, contrast attenuation and applied threshold for calcium scoring 
influences the Agatston CAC score between the non-contrast CT images and contrast 
CTA.20, 21, 25, 33, 34 To adapt for this difference, a conversion factor is required. This 
factor was previously established by Mylonas et al.19 For this purpose, 92 patients 
underwent both a non-contrast CT scan and contrast CTA scan to measure CAC. 
Using linear regression analysis, a conversion factor of 2.74 for the CAC score on 
contrast CTA was established. A subsequent validation study in 47 patients, revealed 
an excellent correlation between Agatston CAC score derived from non-contrast CT 
and contrast CTA after applying the predefined conversion factor. The same conver-
sion factor was used in the present study to calculate the Agatston CAC score on 
contrast CTA. 
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Different methods for quantification of CAC score on contrast CTA
Several previous studies have focused on the feasibility of assessing and computing 
the CAC scores from contrast CTA images.18-22, 35 The main challenge in all these stud-
ies was to establish an accurate method to differentiate between CAC and coronary 
artery luminal contrast. 
Manual delineation of CAC.
Manually segmentation of  CAC from the contrast filled lumen by delineating the 
calcified spots was performed by Bijl et al. in 100 patients, of which 50 presented 
without  CAC36. To derive the Agatston CAC score from contrast CTA images, calcifica-
tions were manually delineated and thereafter quantified with a HU threshold of 130 
for each voxel within the marked area. The CAC score, derived from the contrast CTA, 
was well correlated with non-contrast CT CAC score. Similar to the present study, 
in only a small number of patients with a non-contrast CAC score of zero, CAC was 
detected on contrast CTA. Even though manual input was needed, the inter-observer 
agreement was as excellent for the CTA-derived Agatston scores.
Fixed HU thresholds.
Another method to differentiate between CAC and contrast was sought in increasing 
the HU threshold for CAC detection hence avoiding the need for manually drawn 
contours.  Glodny et al. used a detection threshold of 600 HU to compute the Ag-
atston CAC on CTA images.20 Although the increased attenuation threshold revealed 
an excellent correlation for the Agatston CAC score between non-contrast CT and 
contrast CTA, an overall underestimation of the calcium scoring in CTA images was 
observed. The authors provide no detail on the CAC-risk categories. In contrast, Hong 
et al. selected 50 patients to derive a Agatston CAC score on contrast CTA images, 
with a detection threshold of 350 HU.21 In this study, the CAC score on contrast CTA 
was significantly overestimated.  The under- and overestimation of the Agatston CAC 
score in the previous studies can be the result of inadequate threshold definitions 
in some patients. Luminal contrast could have exceeded the HU threshold level, 
thereby being detected as coronary artery calcium, or vice-versa, CAC being mistak-
enly characterized as luminal contrast.
Patient specific HU thresholds.
Previous publications have indicated that HU threshold for coronary plaque quan-
tification are dependent on luminal contrast intensity and CT scan protocol.33, 37 To 
account for this, a scan (or patient) specific threshold could be preferable. Mylonas 
et al. determined the HU threshold for CAC scoring based on contrast attenuation.19 
For this purpose, the calcium detection threshold was set at aortic attenuation (HU) 
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+ 2 standard deviations (SD). In this study, an excellent correlation was observed 
between CAC score on contrast CTA and non-contrast CT. Moreover, 83% of patients 
were classified in the same CAC risk category. However, this method needed manual 
threshold determination and manual CAC selection.
Similarly, Bischoff et al. used 150% of the mean attenuation (HU) in the ascending 
aorta as a threshold.22 An excellent correlation was observed between CAC score 
based on contrast CTA compared to non-contrast CT and  >90% of patients were 
classified in the same CAC risk category. However, manual interference forms part of 
the method; the study used a manual threshold determination and semi-automated 
system for CAC scoring. 
Advanced algorithms.
In the present study, a novel HU adaptive algorithm was used. This trend-line based 
algorithm facilitates patient specific calcium detection that adapts itself to the contrast 
attenuation. Similar to the present study, Ebersbergen et al. described a tool to fully 
automatically derive coronary artery calcium scores from contrast CTA studies in a 
cohort of 127 patients.35 This study used an automated model-based image process-
ing algorithm, whereas the present study used an algorithm based on HU intensities. 
Ebersbergen et al. demonstrated no significant difference in Agatston CAC scores 
between non-contrast CT calcium scoring and contrast coronary CTA. Moreover, a 
significant relation was noted between both methods as well as good agreement 
within the CAC score risk categories. Similar to our study, the approach of Ebersber-
gen et al. underlined the superiority of advanced algorithms for CAC scoring on CTA. 
These algorithms are accurate, reproducible and provide a patient specific approach, 
adaptive to luminal contrast attenuation. 
Clinical implications
Risk classifications.
The prognostic value of CAC score has been extensively studied.10, 23, 38, 39 For this 
purpose the CAC score is usually stratified into risk categories.23, 39 An increase in 
mortality was observed per increment in CAC score risk category.10, 38, 39 For clinical 
purpose, accurate determination of the CAC score risk category is sufficient for risk 
classification of patients (i.e. the exact CAC score is less important). In this study, a 
good agreement within the Agatston CAC risk categories was observed. This indicates 
that quantifying the Agatston CAC score on contrast CTA is sufficiently accurate for 
clinical decision making. In addition to the clinical value of the CAC score, the prog-
nostic value of CAC progression has been established.40, 41 However, in the present 
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study, no serial CAC-score or CTA were available. Therefore, the accuracy of the 
assessment of CAC progression could not be established.   
Radiation exposure reduction.
The risk of cancer per 10.000 CAC scans in female patients of 50 years old is 
3/10,000.42 Even though this number seems relatively small, it is estimated that the 
incidence of cancer induced by non- contrast CT for CAC score in the United States is 
around 80-400 per year. In the present patient cohort there is potential for 20% radia-
tion dose reduction, if the non-contrast CT scans are excluded from the protocol. 
Recently, modifications to contrast CTA scan protocol have resulted in decreased 
radiation dose, thus reducing CTA radiation exposure.43 These radiation dose reduc-
tion advances could not contribute to less radiation exposure by the non-contrast 
CT scan because the Agatston CAC score requires a fixed scan protocol.  Therefore, 
with the current low-dose scan protocols the radiation dose of the non-contrast CT is 
relatively high and the gain of omitting the non-contrast CT from the scan protocol 
even greater.
Limitations
Some limitations of the present study need to be considered. For this analysis, patients 
with poor quality images were excluded for the detection and quantification of Ag-
atston CAC score on contrast CTA. It is unclear how the software tool would perform 
in datasets with high noise levels or severe motion artifacts. In this study the algorithm 
performed suboptimal in the RCA. This coronary artery is most affected by motion 
during the cardiac cycle and therefore more prone for motion artefacts.44 Moreover, 
the relative lower correlation for LM calcifications could be due to low number of 
patients (n=38) with a positive CAC score in the LM. The observer variability for 
the assessment of the CAC-score on non-contrast CT was not assessed in this study. 
However, this method is widely used and accepted as a robust measurement. The 
observer variability for the contrast CTA CAC-score could not be assessed since this 
was a fully automatic method. All cardiac CTA datasets were performed with either a 
64-slice CT scanner or a 320-row volumetric scanner from one vendor. Therefore, the 
applicability of this algorithm to datasets acquired on other vendor machines needs 
to be further studied.  Differences in the detection of the Agatston CAC score between 
non-contrast CT and contrast CTA could have been caused by the difference in image 
slice thickness.45 CAC in non-contrast CT is visually detected in the axial plane in 3.0 
mm reconstructed images, whereas CAC in the contrast CTA scan was detected on 
MPRs based on images with a 0.5 mm slice thickness. Due to this difference, calcified 
spots located in-between slices of the non-contrast CT are detected on the contrast 
CTA, resulting in an overestimation of CAC score on contrast CTA. In clinical prac-
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tice, observers could perform an additionally manual verification of the contrast CTA 
Agatston CAC scores, thereby reducing the number of false positive/negative results. 
For the present study a predefined conversion factor was applied based on a previous 
study.19 It is expected that a conversion factor specific for the present algorithm would 
have provided even higher correlations and better agreement. 
Conclusion
A fully automatic detection and quantification of Agatston CAC score on contrast CTA 
is feasible and shows an excellent correlation with the Agatston CAC score derived 
from non-contrast CT. Furthermore, a good agreement was obtained between the 
non-contrast CT and the contrast CTA within the Agatston CAC score risk categories. 
Importantly, the accuracy to rule-out CAC on contrast CTA compared to non-contrast 
CT was excellent. By virtue of the excellent correlation between both methods, this 
fully automatic system could be applied in future clinical practice, thereby saving 
time on manual interpretation and potentially reduce radiation exposure, by obviat-
ing the need for a separate non-contrast CT scan. 
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Purpose: Automated software tools have permitted more comprehensive, robust and 
reproducible quantification of coronary stenosis, plaque burden and plaque location 
of coronary computed tomography angiography (CTA) data. The independent asso-
ciation between these quantitative CTA parameters and the presence of myocardial 
ischemia has not been explored. The aim of the present investigation was to evaluate 
the association between quantitatively assessed parameters of coronary artery lesions 
(QCT) on CTA and the presence of myocardial ischemia on gated myocardial perfu-
sion single-photon emission computed tomography (SPECT).
Methods:Forty patients (mean age 58.2±10.9 years, 27 men) with known or suspected 
CAD who had undergone multi-detector row CTA and gated myocardial perfusion 
SPECT within 6 months were included. From CTA datasets, vessel and lesion-based 
visual analysis was performed. Consecutively, lesion-based QCT was performed to 
assess plaque length, plaque burden, percentage lumen area stenosis and remodeling 
index. Subsequently, the presence of myocardial ischemia was assessed using the 
summed difference score (SDS ≥2) on gated myocardial perfusion SPECT. 
Results:Twenty-five (62.5%) patients showed myocardial ischemia in 37 vascular ter-
ritories. Quantitative significant stenosis and quantitative assessment of lesion length 
were independently associated with myocardial ischemia (OR 7.72 [2.41 – 24.7], 
P <0.001 and OR 1.07 [1.00 – 1.45], P = 0.032, respectively) after correcting for clini-
cal variables and visually assessed significant stenosis. The addition of quantitative 
significant stenosis (χ2 = 20.7) and quantitative assessment of lesion length (χ2 = 26.0) 
to the clinical variables and the visual assessment (χ2 = 5.9) had incremental value in 
the association with myocardial ischemia.
Conclusion:Coronary lesion length and quantitative assessed significant stenosis 
were independently associated with myocardial ischemia. Both quantitative param-
eters have incremental value over baseline variables and visual significant stenosis. 
Potentially, QCT can refine assessment of CAD, which may be of potential use for 
identification of patients with myocardial ischemia. 
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Introduction
Computed tomography angiography (CTA) allows evaluation of coronary artery ste-
nosis with high image quality and diagnostic accuracy when compared to invasive 
coronary angiography.1-4 As CTA provides detailed information on coronary anatomy 
and stenosis, it has been proposed as a suitable rule-out test for the evaluation of low 
to intermediate risk patients with suspected coronary artery disease (CAD) 5. Although 
the degree of coronary luminal narrowing is of importance in patients with CAD, 
previous studies have shown that coronary stenosis is not an accurate predictor of 
myocardial ischemia.6 It has been previously reported that in 50% of patients with a 
significant stenosis, which was defined as ≥50% luminal narrowing on CTA, myocar-
dial ischemia was not detected on myocardial perfusion single photon emission com-
puted tomography (SPECT).6 Beyond coronary stenosis, additional coronary plaque 
parameters such as lesion extent, plaque composition as well as plaque location have 
shown to be significantly associated with myocardial ischemia.7, 8 However, these 
parameters are not systematically assessed in clinical practice and the assessment of 
CAD is mostly based on quantification of coronary artery calcium score and visual 
estimation of the luminal narrowing. Recent advances in post-processing MDCT 
data software have permitted automated quantification of coronary stenosis severity 
and plaque characteristics.9 This automated software provides good diagnostic ac-
curacy and reproducibility to assess significant coronary artery stenosis. Currently, 
the relation between quantitative CTA (QCT) derived parameters and the presence 
of myocardial ischemia on SPECT data is unknown. Accordingly, the present study 
aimed to assess the association between QCT parameters and presence of myocardial 
ischemia as assessed with myocardial perfusion SPECT.
Methods
Patient population
Forty patients from an ongoing clinical registry who were referred for multi-detector 
row CTA and stress-rest gated myocardial perfusion SPECT (performed within 6 
months) were included. Only patients with sufficient image quality of both modalities 
were selected. Cardiovascular risk factors and cardiac medication were derived from 
medical record data. Known CAD was defined as a history of myocardial infarc-
tion, or evidence of CAD on previously performed diagnostic tests. Patients who had 
undergone prior percutaneous coronary intervention or coronary artery bypass graft 
surgery were excluded. Patients with atrial fibrillation, renal insufficiency (glomerular 
filtration rate  <30 mL/min), known allergy to iodine-containing contrast agents or 
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pregnancy were also excluded. Also, patients with cardiac events or coronary revas-
cularization during the time elapsed between cardiac CTA and myocardial perfusion 
SPECT were excluded from further analysis.
The number of coronary plaques per vascular territory along with their location 
and characteristics were assessed visually from CTA. Subsequently, a novel auto-
mated post-processing imaging algorithm was applied which permits quantitative 
assessment of CTA datasets.  The most severe coronary lesion was identified in each 
coronary artery and QCT was performed to assess coronary stenosis parameters as 
described in Table 1. 
Stress-rest myocardial perfusion SPECT with 99mtechnetium tetrofosmin was per-
formed to assess the extent and location of myocardial ischemia. Myocardial ischemia 
was defined as a summed difference score (SDS) of ≥2.10 Clinical data were prospec-
tively entered into the departmental Cardiology Information System (EPD-Vision©, 
Leiden University Medical Center, the Netherlands) and retrospectively analyzed. 
The Institutional Review Board of the Leiden University Medical Center approved this 
retrospective evaluation of clinically collected data, and waived the need for written 
informed consent. 
Table 1: QCT derived parameters and their corresponding definitions.
QCT parameter Definition
Lesion length (mm) The distance between the proximal and distal 
ends of the coronary lesion
Mean plaque burden The sum of ((vessel wall area – lumen area) / 
vessel wall area) per slice / number of slices 
Minimal and maximal plaque thickness (mm) The minimal and maximal distance between the 
vessel wall and the lumen
Minimal Lumen Area (MLA) (mm2) The minimal lumen area at the point of maximal 
obstruction
Percentage lumen area stenosis at the level of 
the MLA (%)
1 - (MLA/corresponding reference lumen area)
Minimal lumen diameter (mm) The minimal lumen diameter (mm) at the point 
of maximal obstruction determined by the MLA
Diameter stenosis (%) The percentage diameter stenosis at the point 
of maximal obstruction determined by the MLA
Plaque burden at the MLA ((vessel wall area – lumen area) / vessel wall 
area) x 100% at the level of the MLA
Eccentricity index at the level of the MLA (maximum plaque thickness– minimum plaque 
thickness) / maximum plaque thickness 
Remodeling index at the level of the MLA Vessel wall area / corresponding reference 
vessel wall area at the level of the MLA), in 
which positive remodeling was defined as a 
remodeling index >1.0 32
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Cardiac CTA examination
Cardiac CTA imaging was performed using either a 64-detector row helical scanner 
(n=24) (Aquilion 64, Toshiba Medical Systems, Otawara, Japan) or a 320-detector 
row volumetric scanner (n=16) (Aquilion ONE, Toshiba Medical Systems, Otawara, 
Japan).
Patients with a heart rate above 65 beats/min received 50 or 100 mg metoprolol 
orally one hour before imaging, unless contraindicated. A non-contrast enhanced 
and contrast-enhanced scan was performed. Reconstructed images were transferred 
to a remote dedicated workstation with post-processing software (Vitrea FX 1.0, Vital 
Images, Minnetonka, MN, USA). The non-enhanced scans were used to assess the 
total amount of coronary artery calcium score according to the Agatston approach 11. 
CTA datasets were evaluated according during routine clinical practice independent 
of the quantitative CTA analysis. Image quality of the CTA scans was classified as: 
(1) good image quality (scans without motion artifacts), (2) moderate image quality 
(scans with motion artifacts or increased image noise) and (3) poor image quality 
(non-diagnostic scans); the last were excluded from the analysis. The number and lo-
cation of atherosclerotic plaques per vascular territory and plaque morphology were 
visually evaluated from CTA data sets. Significant coronary obstruction was defined 
as ≥50% luminal narrowing. Atherosclerotic plaques were morphologically classified 
as non-calcified (lesions with lower density compared to contrast-enhanced lumen), 
calcified (lesions with high density) or mixed (lesions having elements of both non-
calcified and calcified lesions).
Quantitative computed tomography coronary angiography 
Dedicated software (QAngioCT Research Edition, Medis Medical Imaging Systems, 
Leiden, the Netherlands) was used for automated quantification of all coronary le-
sions.9 The software automatically displays the centerline along the vessel and detects 
the contours of the lumen and vessel wall while allowing the observer to manually 
correct them if needed. First, a fast vessel-tracking algorithm was used to obtain the 
3-dimensional centerline (ranging from the proximal to distal marker) of the coronary 
artery. Based on this centerline, a straightened multi-planar reformatted (MPR) vol-
ume of the segment of interest was created. Consecutively, the lumen border contours 
and vessel wall borders were detected according to methods described previously.9 
The approach uses spatial first- and second-derivative gradient filters in combination 
with knowledge of the expected CT intensity values in the arteries; therefore, this 
method is insensitive to differences in attenuation values between data sets. Auto-
mated quantitative processing steps were independent from viewing settings. Next, 
automated quantification of each coronary lesion was performed. For each coronary 
lesion, reference lines for both lumen and vessel wall were generated using proximal 
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and distal non-diseased, non-bifurcated reference regions. The mean lumen or vessel 
wall area of these regions was used to define the reference slope for lumen and vessel 
wall contours, respectively. The reference lines for lumen and vessel wall represent an 
estimate of the normal proximal-to-distal tapering of the coronary artery. The minimal 
lumen area (MLA), the proximal start of the coronary lesion and the distal end of 
coronary lesion were automatically defined using the detected lumen contours and 
the difference with the normal tapering of the artery. A number of QCT parameters, 
listed in Table 1, were derived for each coronary lesion. In addition to coronary ves-
sels with atherosclerotic lesions, automated quantification of non-diseased coronary 
vessels was performed in the mid part of the coronary vessel, which was used as the 
best estimate of coronary luminal narrowing per non-diseased coronary artery. Le-
sions in diagonal branches were allocated to LAD, lesion in intermediate (IM) branch 
or marginal (OM) branch were allocated to CX. The reproducibility of QCT has been 
reported previously,9 showing good reproducibility of QCT for assessment of minimal 
lumen area and lumen area stenosis. 
Stress-rest gated SPECT
Gated myocardial perfusion SPECT with 99mtechnetium tetrofosmin (500 MBq, 
MYOVIEW, General Electric Healthcare, United Kingdom) was performed according 
to a 2-day stress-rest protocol. In patients who were able to exercise, a symptom-
limited bicycle test was performed. In patients unable to exercise, a pharmacologic 
stress test was performed with either adenosine or dobutamine infusion. Injection of 
the radiopharmaceutical was done at peak exercise; in the third minute of pharmaco-
logical stress induction for adenosine or at the maximum calculated target heart rate 
for dobutamine. Data-acquisition was performed with a triple-head SPECT camera 
system (GCA 9300/HG; Toshiba Corporation, Tokyo, Japan), equipped with low-ener-
gy high-resolution collimators, 45 minutes after injection of the radiopharmaceutical. 
A 20% window was used around the 140-keV energy peak of technetium-99m, after 
which the SPECT data were stored in a 64x64 matrix. 
Post-processing of stress- and rest-SPECT datasets was performed using previously 
validated automated software.12 Data-reconstruction was performed in vertical and 
horizontal long- and short-axis views perpendicular to the heart axis. The myocar-
dial segments were assigned to the different perfusion territories using a 20-segment 
model.13 Each segment was visually scored by an experienced observer (AJS) accord-
ing to the standard scoring scale of 0 to 4 (normal, mild, moderate, severe reduction 
or absence of tracer uptake).13, 14 To calculate the summed stress score (SSS) and the 
summed rest score (SRS), the total segmental perfusion scores during stress and rest 
were added, respectively. The summed difference score (SDS) was calculated as the 
133
QCT correlates of myocardial ischaemia
difference between the summed stress score and the summed rest score. Myocardial 
ischemia was defined as an SDS ≥ 2.10 
On a vessel basis, the presence of myocardial ischemia was assessed and allo-
cated to the corresponding vascular territory as previously described.15 Accordingly, 
myocardial ischemia of the anterior and septal wall was allocated to lesions in the 
left anterior descending coronary artery (LAD), whereas ischemia in the lateral wall 
was allocated to lesions in the left circumflex coronary artery (LCX). Furthermore, 
myocardial ischemia in the (postero) inferior wall was assigned to lesions in the right 
coronary artery (RCA). 
Statistical analysis
For reasons of uniformity, summary statistics for all continuous variables were pre-
sented as mean ± standard deviation (SD), whereas categorical variables were pre-
sented as frequencies and percentages. Vessel-based analysis was performed based 
on the most severe lesion per vessel according to the quantitatively assessed percent-
age lumen area stenosis. Independent-samples T tests were used to compare QCT 
parameters between patients with and without myocardial ischemia on SPECT. The 
agreement between both visual and quantitative assessment of significant coronary 
stenosis and SPECT was evaluated using the weighted kappa (k) statistics. Excellent, 
fair-to-good and poor agreement were defined by a k-value of > 0.75, between 0.4 
and 0.75, and < 0.4, respectively.16 To evaluate the association between baseline char-
acteristics, visual CTA parameters, QCT parameters and the presence of myocardial 
ischemia, multivariate regression analyses were performed. Myocardial ischemia was 
introduced as dependent variable. Relevant baseline clinical variables were entered 
into the first model. Variable selection was performed using a backward conditional 
method (entry, 0.05; removal, 0.10). Three nested models were subsequently created 
by introducing separately the following variables: visual significant stenosis (model 
2), quantitative significant stenosis (model 3) and quantitative assessed lesion length 
(model 4). For each variable in the model, an odds ratio (OR) with 95% confidence 
interval (CI) was calculated. The incremental value of the QCT parameters over 
clinical risk variables and visual assessed stenosis degree was assessed by compar-
ing the global χ2 values. The likelihood-ratio chi-square test was used to assess the 
significance of the incremental χ2 values.  All statistical tests were two-sided and a 
P-value <0.05 was considered to be statistically significant. All statistical analyses 





A total of 40 patients (58.2 ± 10.9 years, 27 men) with known (n=16) or suspected 
(n=24) CAD were included. Of these patients, 16 (40%) presented with atypical chest 
pain, 12 (30%) with typical chest pain, the remaining 12 (30%) patients had diabetes 
and were evaluated because of an increased cardiac risk profile. The mean duration 
between cardiac CTA and gated myocardial perfusion SPECT examinations was 39.9 
± 42.2 days (median 33 days, interquartile range 10-52 days). Patients remained clini-
cally stable and no acute coronary events were recorded between evaluations. The 
clinical characteristics of the patients are listed in Table 2. 
Computed tomography coronary angiography
Visual CTA.
The mean coronary artery calcium score was 451±1490. In the overall patient 
population (n=40), 83 coronary arteries showed atherosclerosis and a total of 162 
Table 2. Patient characteristics.
Baseline characteristics n = 40
Age (years) 58.2 ± 10.9
Male 27 (67.5%)
Known CAD 16 (40.0%)
Cardiovascular risk factors
      Hypertension† 20 (50.0%)
      Hypercholesterolemia‡ 15 (37.5%)
      Diabetes mellitus 21 (52.5%)
      Family history of CAD* 17 (42.5%)
      Smoking 15 (37.5%)
      Body Mass index ≥30 kg/m2. 6 (15.0%)
Calcium score 450 ± 1490
28 (0-8730)
Left ventricular ejection fraction 61 ± 13
Data are represented as mean ± SD, median(range) or as number and percentages of patients.
†Defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90
mm Hg or the use of antihypertensive medication.
‡Serum total cholesterol ≥230 mg/dL or serum triglycerides ≥200 mg/dL or treatment with lipid lower-
ing drugs. 
*Defined as the presence of coronary artery disease in first-degree family members at <55 years in men 
and <65 years in women.
Abbreviations: CAD, coronary artery disease
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coronary lesions were identified. Visual CTA analysis showed 57 (35%) non-calcified 
lesions, 71 (44%) mixed lesions and 34 (21%) calcified lesions. In total, 25 coronary 
arteries contained a visually assessed significant stenosis of ≥50% luminal narrowing. 
Quantitative CTA.
QCT was performed in all 162 lesions to assess quantitative stenosis parameters as 
described in Table 1. Subsequently, in the 83 coronary arteries with atherosclerosis, 
the most severe lesion per main vascular territory (using the quantitatively assessed 
percentage lumen area stenosis) was determined. In Table 3 the results of the quanti-
tative analyses of all coronary lesions and the most severe lesion per artery is demon-
strated. In addition, in the remaining 37 non-diseased coronary arteries, QCT analysis 
was performed in the mid part of the vessel, which was used as a representative of 
the coronary artery. In total, 45 coronary arteries contained a quantitative assessed 
significant stenosis of ≥50% luminal narrowing (defined according the percentage 
area stenosis).
Stress-rest gated myocardial perfusion SPECT
Gated myocardial perfusion SPECT showed a mean SRS of 2.8 ± 3.9, a mean summed 
stress score of 5.7 ± 6.3, and a mean SDS of 3.8 ± 4.9. Myocardial ischemia (SDS 
of ≥2) was observed in 25 (62.5%) patients. Using a 20-segment model, myocardial 
ischemia was present in 31% (n=37) of the 120 vascular territories. The remaining 
69% (n=83) vascular territories showed no ischemia. A comparison was made be-
tween vascular territories with ischemia versus vascular territories without ischemia. 
In vascular territories showing myocardial ischemia, lesion length, percentage lumen 
area stenosis, percentage lumen diameter stenosis, mean plaque burden and maxi-
Table 3. Quantitative analysis of coronary lesions. 
QCT parameter All coronary lesions 
(n = 162)
Most severe lesion 
per artery (n=83)
Lesion length (mm) 12.10 ± 8.99 12.48 ± 9.14
Mean plaque burden (%) 76.12 ± 7.78 76.90 ± 7.92
Maximal plaque thickness (mm) 2.33 ± 0.71 2.39 ± 0.77
MLA (mm2) 2.97 ± 2.19 2.70 ± 1.81
Percentage lumen area stenosis (%) 47.80 ± 18.65 52.76 ± 19.67
Minimal lumen diameter (mm) 1.84 ± 0.64 1.76 ± 0.60
Percentage diameter stenosis (%) 29.10 ± 13.79 32.90 ± 14.96
Plaque burden at the MLA (%) 82.30 ± 8.39 83.29 ± 8.59
Eccentricity index at the level of the MLA 0.60 ± 0.15 0.60 ±0.16
Remodeling index at the level of the MLA 1.05 ± 0.21 1.07 ± 0.23
Abbreviations: MLA, minimal lumen area
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mal plaque thickness were significantly higher when compared to vascular territories 
without myocardial ischemia (Table 4).
Agreement between visual significant stenosis and quantitative assessed 
stenosis versus myocardial ischemia
On a vessel-based analysis, the number of significant culprit coronary lesions (≥50% 
luminal narrowing) was significantly higher using QCT as compared to visual CT 
analysis (45 (37.5%) vs. 25 (20.8%), P<0.001). Importantly, myocardial ischemia 
was present in 22 (48.9%) of those significant lesions assessed with QCT (k = 0.30, 
P=0.001), whereas ischemia was only present in 9 (36.0%) of the significant lesions 
visually assessed (k = 0.06, P=0.53). Figure 2 represents an example of  a female pa-
tient with an obstructive lesion in the LAD coronary artery and myocardial ischemia 
on gated myocardial perfusion SPECT.
Independent association between quantitative coronary CTA parameters 
and myocardial ischemia on gated myocardial SPECT
To evaluate the independent association between visual CTA, quantitative parameters 
and myocardial ischemia, 4 nested multivariate models were created. In model 1, 
Table 4. Vessel based comparison of visual and quantitative CTA parameters between coronary arter-






Visual CTA (per vessel (n=120))
No. of lesionsº 1.76 ± 1.57 1.17 ± 1.19 0.026
No. of bifurcation lesionsº 0.46 ± 0.61 0.22 ± 0.44 0.015
No. of non-calcified lesionsº 0.59 ± 0.72 0.42 ± 0.65 0.195
No. of mixed lesionsº 0.84 ± 1.32 0.45 ± 0.78 0.045
No. of calcified lesionsº 0.32 ± 0.71 0.30 ± 0.66 0.863
QCT parameters (per vessel (n=120))
Lesion length (mm)‡ 13.41 ± 12.09 6.68 ± 7.32 <0.001
Mean plaque burden (%)‡ 75.27 ± 11.59 70.98 ± 9.85 0.039
Max. plaque thickness (mm)‡ 2.31 ± 1.08 1.75 ± 0.83 0.003
Lumen area stenosis (%)‡ 48.40 ± 27.81 35.04 ± 25.35 0.011
Lumen diameter stenosis (%)‡ 30.94 ± 20.00 21.17 ± 16.87 0.007
Eccentricity index‡ 0.54 ± 0.14 0.54 ± 0.18 0.846
Remodeling index‡ 1.10 ± 0.22 1.03 ± 0.20 0.406
Data are represented as mean ± SD. ºTotal number of lesions, bifurcation lesions, non-calcified, mixed 
and calcified lesions per vascular territory. ‡Results of the selected most severe lesion per vascular ter-
ritory.
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Figure 1. Bar graph of the multivariable models.
The bar graph shows the incremental value of quantitative CT parameters over visual CT in the associa-
tion with myocardial ischemia on gated myocardial perfusion SPECT on a vessel-basis (n=120). The 
presence of quantitative signifi cant stenosis (≥50% percentage area stenosis) showed a signifi cant in-
cremental value over conventional clinical risk variables and visual assessed signifi cant stenosis (≥50% 
stenosis). Furthermore, lesion length provided a signifi cant incremental value over both clinical risk 
variables and the presence of a quantitative signifi cant stenosis (≥50% percentage area stenosis.
Figure 2. An example of a 53 year-old female patient with an obstructive lesion in the left anterior 
descending (LAD) coronary artery.
The quantitative computed tomography (QCT) processing steps of the culprit lesion are illustrated be-
low. At fi rst, automated QCT was used to detect both lumen (yellow) and vessel wall (orange) contours. 
Longitudinal lumen and vessel wall contours are shown in panel A, whereas transversal lumen and 
vessel wall contours at the level of the minimal lumen area (MLA) are shown in panel B. Quantifi cation 
of the culprit lesion was performed using proximal (green) and distal (red) reference markers as well 
as lumen (yellow) and vessel wall (orange) reference lines, as illustrated in panel C. Stress-rest gated 
myocardial perfusion SPECT is shown in panel D. The patient had corresponding myocardial ischemia 
in the LAD vascular territory on gated myocardial perfusion SPECT. For this patient, summed rest score 
was 0 and summed stress score was 2, resulting in a summed difference score of 2. QCT showed a le-
sion length of 23.7 mm, percentage lumen area stenosis of 69.6% and a mean plaque burden of 81.5%.
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clinical baseline variables were entered using backward selection. Subsequently, the 
presence of significant coronary stenosis as assessed with visual CTA was introduced 
in model 2 and the presence of significant coronary stenosis and lesion length as-
sessed with QCT were included in models 3 and 4, respectively. The results of the 
4 nested multivariate models are described in Table  5. Visual CTA assessment of 
luminal narrowing was not independently associated with the presence of ischemia 
(OR=1.84, P=0.246). In contrast, the presence of a quantitative assessed significant 
stenosis and lesion length were independently associated with the presence of 
myocardial ischemia on gated myocardial SPECT when added to relevant clinical 
variables (OR=7.36, P<0.01 and OR=1.07, P=0.028). 
Furthermore the incremental contribution of all parameters was assessed as shown 
in Figure  1. Visual significant stenosis provided no significant contribution to the 
model over relevant baseline risk factors (χ2 change from 4.6 in model 1 to 5.9 in 
model 2, P=0.248). The introduction of quantitative significant stenosis in model 3 
provided a significant increase in χ2 over model 1 (from 15.9 to 20.8, P<0.01). Ad-
ditionally, introducing lesion length into model 4 provided significant increment over 
quantitative stenosis (increase in model χ2 = 4.2, P=0.022).
Discussion
The present study demonstrated that quantitative derived CTA parameters are associ-
ated with the presence of myocardial ischemia on gated myocardial perfusion SPECT. 
The QCT derived parameters, coronary lesion length, mean plaque burden, maxi-
mal plaque thickness, percentage lumen area stenosis, and presence of significant 
coronary stenosis (≥50% percentage lumen area stenosis) were significantly higher 
in coronary artery lesions of vascular territories presenting with myocardial ischemia 
(Table 4). Furthermore, both coronary lesion length and the presence of quantitative 
significant coronary stenosis showed a significant incremental value in the associa-
tion with myocardial ischemia independent of conventional clinical risk variables 
and the presence of a visual assessed significant stenosis (≥50% percentage lumen 
area stenosis). 
CTA has a high diagnostic accuracy for the non-invasive detection of coronary 
atherosclerosis, but a large percentage of lesions are not associated with ischemia on 
SPECT, since it is considered that non-obstructive coronary stenoses do not induce 
ischemia.17 However, various studies have shown that myocardial ischemia is not 
only dependent on the presence of obstructive CAD, pointing to other potentially 
important plaque characteristics.18-20 It has also been reported that diffuse atheroscle-
rosis contributes to myocardial ischemia,21, 22 in which plaque extent as well as the 
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number of diseased segments have been identified as important parameters for the 
prediction of myocardial ischemia.8
In this perspective, cardiac CTA represents a useful non-invasive imaging technique 
as it provides information beyond coronary obstruction, including plaque composi-
tion, plaque burden, lesion length as well as plaque remodeling. These plaque char-
acteristics have shown to be independently associated with the extent, severity and 
reversibility of myocardial ischemia,23 even showing an incremental predictive value 
for myocardial ischemia over the presence of obstructive CAD.8 
Quantification of plaque parameters including lesion length, degree of luminal ob-
struction, plaque burden and remodeling could be more accurate than visual assess-
ment to evaluate the coronary atherosclerosis burden and the risk of ischemic events. 
In addition, quantitative assessment may provide a more reliable and reproducible 
approach than visual estimation to evaluate and follow-up patients with coronary 
atherosclerosis.
Previous attempts in quantifying coronary stenosis using either manual24 or semi-
automated25,26 approaches have been suboptimal due to the large variability intro-
duced by manual interference as well as difficulties in quantifying heavily calcified 
lesions.
Thus far, the feasibility of a novel dedicated algorithm for automated quantification 
of stenosis severity on CTA has been demonstrated in comparison with quantita-
tive coronary angiography showing improved diagnostic accuracy for assessment of 
significant coronary lesions compared to visual CTA analysis 27. Furthermore, QCT 
showed good correlations with quantitative intravascular ultrasound (IVUS) for as-
sessment of coronary stenosis.9 Although the feasibility of automated QCT analyses 
has been demonstrated, no study has currently been performed evaluating the value 
of QCT in the association with the presence of myocardial ischemia on myocardial 
perfusion SPECT. The current study is the first study that has evaluated the correlates 
of QCT parameters, derived by a novel algorithm for automated quantification of 
coronary lesions, with myocardial ischemia. Vessel-based analysis showed that 
vascular territories with ischemia had a significantly higher number of coronary le-
sions, bifurcation lesions as well as mixed lesions. QCT plaque parameters including, 
lesion length, mean plaque burden, maximal plaque thickness, percentage lumen 
area stenosis and percentage lumen diameter stenosis were significantly higher in 
vascular territories showing ischemia as compared to vascular territories without 
ischemia. These results indicate the presence of a significant association between 
quantitatively derived plaque parameters, representing the extent and severity of 
atherosclerotic lesions, and the presence of myocardial ischemia. Furthermore, in 
the present study these quantitatively derived plaque parameters were significantly 
associated with the presence of myocardial ischemia. Once corrected for clinical 
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risk variables and visually assessed stenosis degree, both lesion length and the pres-
ence of a quantitatively assessed significant stenosis were independently associated 
with myocardial ischemia. These results are in line with previous studies showing a 
significant association angiographically assessed lesion length and stenosis severity 
with myocardial infarction.28 Additionally, the presence of quantitative significant 
coronary stenosis (with a cutoff percentage area stenosis of ≥50% luminal narrowing) 
showed incremental value in a nested multivariate model using myocardial ischemia 
as the endpoint, whereas, the visual assessment of significant lesions (≥50% luminal 
narrowing) did not. This underlines the hypothesis that QCT provides a more accurate 
lesion analysis as compared to a visual assessment of the CTA images. 
Furthermore, lesion length as a representative of diffuse atherosclerosis provided 
a significant incremental value over the clinical risk variables, visually assessed sig-
nificant stenosis and quantitative significant stenosis. These results are supported by 
earlier findings that the additive effect of multiple mild stenoses in series eventually 
causes perfusion defect.21 The increase in lesion length represents a more extensive 
atherosclerotic involvement of the coronary artery, which may lead to considerable 
more myocardial ischemic damage than might be the case with a short localized 
obstructive lesion.
In addition, the number of quantitatively assessed significant coronary stenosis 
was significantly higher compared to the number of visually assessed significant 
coronary stenosis. Even though the correlation between the presence of myocardial 
ischemia and stenosis degree assessed using either a visual approach or QCT was 
poor, there was a significantly improved association between QCT and myocardial 
ischemia when compared to visual CTA and myocardial ischemia. This discrepancy 
between visual and QCT for assessment of significant coronary lesions may indicate 
the importance of using a more accurate quantitative approach for CTA. Accordingly, 
QCT allows an improved and comprehensive evaluation of coronary plaques which 
may cause myocardial ischemia.
Limitations
Some limitations need to be considered. In the current study, the prevalence of myo-
cardial ischemia was relatively low on a vessel basis. It would have been preferred 
to evaluate the performance of QCT in a larger population with higher prevalence 
of ischemia. However, since CTA is generally performed in low to intermediate risk 
patients, the present cohort is representative for a general CT population. In addi-
tion, QCT was only used in CTA data sets with good or moderate image quality. 
Furthermore, the present study was subject to selection bias caused by the exclusion 
criteria for CTA and SPECT. Finally, patients underwent 64- or 320-slice CTA, and 
currently the diagnostic accuracy of these two techniques has not been evaluated 
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in a head-to-head comparison; on the other hand, individual 64- and 320-slice CTA 
studies reported similar diagnostic accuracy for detection of CAD5.
Clinical implications
Recent observations have emphasized the discrepancy between coronary artery ste-
nosis (severity) and the presence of ischemia. As recently demonstrated in the FAME 
trials,29, 30 fractional flow reserve (FFR) guided coronary revascularization is superior 
to angiographic stenosis assessment. Also, the DEFACTO trial31 demonstrated that 
assessment of FFR from the CTA images provides incremental value over stenosis 
degree assessment. At present, it is unknown if either stenosis severity or ischemia 
has the largest influence on prognosis. Possibly, additional characteristics of coronary 
lesions other than stenosis degree are more related to the presence of myocardial 
ischemia. As QCT provides an accurate and comprehensive assessment of coronary 
plaques together with an improved association with myocardial ischemia when com-
pared to visual CT, QCT can be used to improve the diagnostic value of cardiac CTA. 
Accordingly, it may result in improved risk stratification and less subsequent testing. 
It has been shown that non-invasive coronary angiography with cardiac CTA allows 
detection of CAD (i.e. the detection of hemodynamically non-significant CAD) at a 
much earlier stage than gated myocardial perfusion SPECT. Besides, a normal myo-
cardial perfusion scan does not exclude CAD.17 Potentially, QCT can facilitate early 
detection of CAD and accurate identification of patients who may have myocardial 
ischemia. 
Conclusion
Coronary lesion length and the presence of a quantitatively assessed significant 
stenosis as derived from QCT are significantly correlated with myocardial ischemia 
on gated myocardial perfusion SPECT. Furthermore, QCT provides incremental value 
over CTA and baseline clinical risk factors in the association with ischemia on SPECT. 
Potentially, QCT can refine assessment of CAD, which may be of potential use for 
identification of patients with myocardial ischemia.
143
QCT correlates of myocardial ischaemia
References
 (1)  Hamon M, Biondi-Zoccai GG, Malagutti P et al. Diagnostic performance of multislice spiral 
computed tomography of coronary arteries as compared with conventional invasive coronary 
angiography: a meta-analysis. J Am Coll Cardiol 2006 November 7;48(9):1896-910.
 (2)  Hoffmann MH, Shi H, Schmitz BL et al. Noninvasive coronary angiography with multislice 
computed tomography. JAMA 2005 May 25;293(20):2471-8.
 (3)  Meijboom WB, Meijs MF, Schuijf JD et al. Diagnostic accuracy of 64-slice computed tomog-
raphy coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol 
2008 December 16;52(25):2135-44.
 (4)  Miller JM, Rochitte CE, Dewey M et al. Diagnostic performance of coronary angiography by 
64-row CT. N Engl J Med 2008 November 27;359(22):2324-36.
 (5)  von Ballmoos MW, Haring B, Juillerat P, Alkadhi H. Meta-analysis: diagnostic performance 
of low-radiation-dose coronary computed tomography angiography. Ann Intern Med 2011 
March 15;154(6):413-20.
 (6)  Hacker M, Jakobs T, Hack N et al. Sixty-four slice spiral CT angiography does not predict the 
functional relevance of coronary artery stenoses in patients with stable angina. Eur J Nucl Med 
Mol Imaging 2007 January;34(1):4-10.
 (7)  Naya M, Murthy VL, Blankstein R et al. Quantitative relationship between the extent and 
morphology of coronary atherosclerotic plaque and downstream myocardial perfusion. J Am 
Coll Cardiol 2011 October 18;58(17):1807-16.
 (8)  van Velzen JE, Schuijf JD, van Werkhoven JM et al. Predictive value of multislice computed 
tomography variables of atherosclerosis for ischemia on stress-rest single-photon emission 
computed tomography. Circ Cardiovasc Imaging 2010 November 1;3(6):718-26.
 (9)  Boogers MJ, Broersen A, van Velzen JE et al. Automated quantification of coronary plaque with 
computed tomography: comparison with intravascular ultrasound using a dedicated registra-
tion algorithm for fusion-based quantification. Eur Heart J 2012 April;33(8):1007-16.
 (10)  Sharir T, Germano G, Kang X et al. Prediction of myocardial infarction versus cardiac death by 
gated myocardial perfusion SPECT: risk stratification by the amount of stress-induced ischemia 
and the poststress ejection fraction. J Nucl Med 2001 June;42(6):831-7.
 (11)  Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. Quantification 
of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990 
March 15;15(4):827-32.
 (12)  Germano G, Kavanagh PB, Waechter P et al. A new algorithm for the quantitation of 
myocardial perfusion SPECT. I: technical principles and reproducibility. J Nucl Med 2000 
April;41(4):712-9.
 (13)  Hachamovitch R, Berman DS, Kiat H et al. Incremental prognostic value of adenosine stress 
myocardial perfusion single-photon emission computed tomography and impact on subse-
quent management in patients with or suspected of having myocardial ischemia. Am J Cardiol 
1997 August 15;80(4):426-33.
 (14)  Berman DS, Kang X, Van Train KF et al. Comparative prognostic value of automatic quantita-
tive analysis versus semiquantitative visual analysis of exercise myocardial perfusion single-
photon emission computed tomography. J Am Coll Cardiol 1998 December;32(7):1987-95.
 (15)  Cerqueira MD, Weissman NJ, Dilsizian V et al. Standardized myocardial segmentation and 
nomenclature for tomographic imaging of the heart: a statement for healthcare professionals 
Chapter 7
144
from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American 
Heart Association. Circulation 2002 January 29;105(4):539-42.
 (16)  Fleiss JL. Statistical methods for rates and proportions, 2nd edn. 2nd ed. New York: 1981.
 (17)  Schuijf JD, Wijns W, Jukema JW et al. Relationship between noninvasive coronary angiography 
with multi-slice computed tomography and myocardial perfusion imaging. J Am Coll Cardiol 
2006 December 19;48(12):2508-14.
 (18)  Azzarelli S, Galassi AR, Foti R et al. Accuracy of 99mTc-tetrofosmin myocardial tomography 
in the evaluation of coronary artery disease. J Nucl Cardiol 1999 March;6(2):183-9.
 (19)  Benoit T, Vivegnis D, Lahiri A, Itti R, Braat S, Rigo P. Tomographic myocardial imaging with 
technetium-99m tetrofosmin. Comparison with tetrofosmin and thallium planar imaging and 
with angiography. Eur Heart J 1996 April;17(4):635-42.
 (20)  Sacchetti G, Inglese E, Bongo AS et al. Detection of moderate and severe coronary artery 
stenosis with technetium-99m tetrofosmin myocardial single-photon emission tomography. 
Eur J Nucl Med 1997 October;24(10):1230-6.
 (21)  De Bruyne B, Hersbach F, Pijls NH et al. Abnormal epicardial coronary resistance in patients 
with diffuse atherosclerosis but “Normal” coronary angiography. Circulation 2001 November 
13;104(20):2401-6.
 (22)  Marcus ML, Harrison DG, White CW, McPherson DD, Wilson RF, Kerber RE. Assessing the 
physiologic significance of coronary obstructions in patients: importance of diffuse undetected 
atherosclerosis. Prog Cardiovasc Dis 1988 July;31(1):39-56.
 (23)  Lin F, Shaw LJ, Berman DS et al. Multidetector computed tomography coronary artery 
plaque predictors of stress-induced myocardial ischemia by SPECT. Atherosclerosis 2008 
April;197(2):700-9.
 (24)  Leber AW, Knez A, von ZF et al. Quantification of obstructive and nonobstructive coronary 
lesions by 64-slice computed tomography: a comparative study with quantitative coronary 
angiography and intravascular ultrasound. J Am Coll Cardiol 2005 July 5;46(1):147-54.
 (25)  Cheng V, Gutstein A, Wolak A et al. Moving beyond binary grading of coronary arterial ste-
noses on coronary computed tomographic angiography: insights for the imager and referring 
clinician. JACC Cardiovasc Imaging 2008 July;1(4):460-71.
 (26)  Raff GL, Gallagher MJ, O’Neill WW, Goldstein JA. Diagnostic accuracy of noninvasive coro-
nary angiography using 64-slice spiral computed tomography. J Am Coll Cardiol 2005 August 
2;46(3):552-7.
 (27)  Boogers MJ, Schuijf JD, Kitslaar PH et al. Automated quantification of stenosis severity on 
64-slice CT: a comparison with quantitative coronary angiography. JACC Cardiovasc Imaging 
2010 July;3(7):699-709.
 (28)  Meimoun P, Sayah S, Luycx-Bore A et al. Comparison between non-invasive coronary flow re-
serve and fractional flow reserve to assess the functional significance of left anterior descend-
ing artery stenosis of intermediate severity. J Am Soc Echocardiogr 2011 April;24(4):374-81.
 (29)  Tonino PA, De BB, Pijls NH et al. Fractional flow reserve versus angiography for guiding 
percutaneous coronary intervention. N Engl J Med 2009 January 15;360(3):213-24.
 (30)  De BB, Pijls NH, Kalesan B et al. Fractional Flow Reserve-Guided PCI versus Medical Therapy 
in Stable Coronary Disease. N Engl J Med 2012 August 27.
 (31)  Min JK, Leipsic J, Pencina MJ et al. Diagnostic Accuracy of Fractional Flow Reserve From 
Anatomic CT Angiography. JAMA 2012 August 26;1-9.
 (32)  Mintz GS, Nissen SE, Anderson WD et al. American College of Cardiology Clinical Expert 
Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravas-
145
QCT correlates of myocardial ischaemia
cular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force 
on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001 April;37(5):1478-92.

Chapter 8
Feasibility of an automated quantitative 
computed tomography angiography-derived 
risk score for risk stratification of patients with 
suspected coronary artery disease
de Graaf MA, Broersen A, Ahmed W, Kitslaar PH, Dijkstra J, Kroft LJ, Delgado V, Bax JJ, Reiber 
JH, Scholte AJ.




Purpose: Computed tomography coronary angiography (CTA) has important prognos-
tic value. Additionally, quantitative CTA (QCT) provides a more detailed, accurate 
assessment of coronary artery disease (CAD) on CTA. Potentially, a risk score incor-
porating all quantitative stenosis parameters allows for accurate risk stratification. 
Therefore, the purpose of this study was to determine if an automatic, quantitative 
assessment of CAD using QCT combined into a CTA risk score allows risk stratifica-
tion of patients.
Methods: In 300 patients QCT was performed to automatically detect and quantify 
all lesions in the coronary tree. Using QCT, a novel CTA risk score was calculated 
based on plaque extent, severity, composition and location on a segment basis. Dur-
ing follow-up the composite endpoint of all-cause mortality, revascularization and 
non-fatal infarction was recorded. 
Results: In total, 10% of patients experienced an event during a median follow-up 
of 2.14 years. The CTA risk score was significantly higher in patients with an event 
(12.5(IQR8.6–16.4) versus 1.7(IQR0–8.4), P<0.001). Among 127 patients with ob-
structive CAD (≥50% stenosis), 27 events were recorded, all in patients with a high 
CTA risk score. 
Conclusion: The present study demonstrated that a fully automatic QCT analysis of 
CAD is feasible and can be applied for risk stratification of patients with suspected 
CAD. Furthermore, a novel CTA risk score incorporating location, severity and com-
position of coronary lesion was developed. This score may improve risk stratification 
but needs to be confirmed in larger studies. 
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Introduction
The aim of the present study was to evaluate patients with suspected CAD undergoing 
CTA and: 1) perform a fully automatic quantitative assessment of coronary CTA da-
tasets to assess the location, severity and composition of CAD, and 2) to incorporate 
all these variables into one risk score. Further aims were: 3) to assess the value of 
this integrated score for risk stratification and 4) to compare the risk classification 
according to this new score as compared to existing risk scores.
Methods
Patients
The population consisted of 300 patients, referred for the evaluation of (a)typical 
chest pain or dyspnea. Patients with previous percutaneous coronary intervention 
(PCI) or coronary artery bypass graft (CABG) were excluded. Clinical  data were 
prospectively entered into the departmental Cardiology Information System (EPD-
Vision©, Leiden University Medical Center, the Netherlands) and retrospectively 
analyzed. The Institutional Review Board of the Leiden University Medical Center 
approved this retrospective evaluation of clinically collected data, and waived the 
need for written informed consent. 
CTA acquisition 
Patients were scanned either with a 64-slice CT scanner (Aquilion 64, Toshiba 
Medical System, Otowara, Japan) or a 320-row volumetric scanner (Aquilion ONE, 
Toshiba Medical System, Otowara, Japan). Coronary CTA was performed according 
to standard clinical practice as previously described.1  Only patients with clinical 
diagnostic image quality of the coronary CTA were included. 
Quantitative computed tomography 
QCT was performed in five automatic steps, as depicted in Figure 1. 
1) The coronary tree was automatically extracted from the coronary CTA dataset.2 
Using a tree labeling algorithm, the segments of the coronary tree were automatically 
labeled according the American Heart Association (AHA) 17-segements model.3;4 2) 
Curved multi-planar reformations (CMPR) of each coronary vessel and side-branch 
were created.2 3) The lumen and vessel wall were automatically segmented using a 
previously validated software tool (QAngio CT Research Edition version 1.3.6, Medis 
Medical Imaging Systems, Leiden, the Netherlands).5 4) Coronary plaque constitu-
tion was assessed using a dedicated tissue characterization algorithm as previously 
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described.6 This tissue characterization algorithm allows for the differentiation into 
four different plaque types. Currently, it is unclear how this should be translated 
to the commonly used classification of non-calcified, partially calcified and calci-
fied plaque. For this analysis, the percentage ratio between dense calcium (DC) and 
necrotic core (NC) (DC/(NC + DC)*100) was used to differentiate between partially 
calcified, non-calcified and calcified plaques. Lesions with a ratio <10% were con-
sidered non-calcified plaque as well as lesion without NC or DC, lesions with a 
ratio >75% were classified as calcified plaque. Coronary plaques with ratios ≥10% 
and ≤75% were classified as partially calcified plaque. 5) Coronary lesions were au-
tomatically detected. Within each segment, a regression analysis is performed on the 
lumen area graph to define a lumen reference line. A lesion is defined on the region 
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Figure 1. Schematic overview of the automatic quantitative CT algorithm.
The 3-dimensional coronary tree was extracted from the coronary CTA data set (Panel A). Using an automatic 
labeling algorithm the coronary tree was labeled according to the AHA 17-segment model (Panel B). Of each 
coronary artery a curved multiplaner reformation (CMPR) was constructed (Panel C). Next, a fully automatic 
detection of the lumen and vessel wall was performed (Panel D). Finally, each atherosclerotic lesion was auto-
matically detected based on the lumen and vessel wall contours as well as the corresponding reference lines 
(estimate of normal tapering of the coronary artery), as shown in panel E.  Stenosis parameters were calculated 
at the level of the minimal lumen area (MLA, vertical yellow marker). Additionally, plaque volumes and plaque 
types were derived for the whole coronary artery lesion, ranging from the proximal to the distal lesion marker 
(blue vertical markers). Fibrotic tissue was labeled in dark green, fibro-fatty tissue in light green, dense calcium 
in white and necrotic core in red. Finally, the CTA risk score per patient is automatically generated (Panel F).
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reference. If needed, this lesion is enlarged to include calcified spots located near the 
MLA (within 50 mm and >1 mm3). Lesions with negative stenosis degree and steep 
reference slopes (<-0.35 mm2/mm) were removed as well as short lesions (<1.5 mm), 
lesions in segments with small vessel and lumen areas (<8 mm2 and <1.5 mm2 re-
spectively), and distally located lesions (>150 mm from ostium).
The automatic lesion detection was confirmed by an experienced observer. The 
software allows the observer to override the automatic lesion detection. If needed, 
small adjustments were made.
CTA risk score
A novel comprehensive risk score was created to combine the information on location, 
extent, severity and composition of each coronary lesion. As described in Figure 2, 
the score consists of three components for each segment; a segment location weight 
factor, a stenosis severity weight factor and a plaque weight factor. 1) The location of 
each lesion is represented by a segment weight factor based on the Leaman score.4;7 
A different set of weight factors is applied to left or right dominant coronary artery 
systems. 2) Stenosis severity was described by the stenosis severity weight factor. A 
previous meta-analysis reported a hazard ratio (HR) of 1.35 (1.09 – 1.67)  for each 
significant stenosis in each segment of the coronary tree.8 Therefore 1.4 was chosen 
as the weight factor for a significant stenosis (≥50% area stenosis). 3) In a study 
performed by Gaemperli et al., stratifying the diseased segments according to plaque 
composition, the authors reported a HR of 1.21 (1.11 – 1.32) for segments with calci-
fied plaques, 1.57 (1.38-1.79) for segments with partially calcified plaques and 1.71 
(1.14-2.56) for segments with non-calcified plaques.9 This was translated in the score 
by a weight factor of 1.2 for calcified plaque, 1.6 for partially calcified plaque and 
1.7 for non-calcified plaque.
The CTA risk score is automatically calculated using QCT. When coronary plaque 
is absent (<30% area stenosis) the score is 0. When a stenosis is present, a score is 
given according to the location of the lesion in the coronary artery tree, this score is 
multiplied by the stenosis weight factor and multiplied by the plaque weight factor. 
The final score  is calculated by summation of the individual segment scores (range 
0-55) (Figure 2).
Modified Duke prognostic CAD index 
In addition, the modified Duke prognostic CAD index was applied to the QCT re-
sults.10;11  The score consist of 6 categories;1: <50% stenosis, 2: ≥2 stenoses 30% to 
49% (including 1 artery with proximal disease or 1 vessel with 50% to 69% stenosis, 
3: 2 stenoses 50% to 69% or 1 vessel with ≥70% stenosis, 4: 3 stenoses 50% to 69% 
or 2 vessels with ≥70% stenosis or proximal left anterior descending stenosis ≥70%, 
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5: 3 vessels  ≥70% stenoses or 2 vessels  ≥70% stenosis with proximal left anterior 
descending, 6: Left main stenosis ≥50%.Subsequently, the distribution of the novel 
CTA risk score within the Duke CAD categories was assessed. 
Follow-up and event definition
Patient follow-up data were gathered using clinical visits or standardized telephone 
interviews. A composite endpoint was constructed using all-cause mortality, revascu-
larization after 30-days and non-fatal myocardial infarction. This 30-day interval was 
Segment Weight Factor 
Segment           Right Dominant              Left Dominant 
LM  5  6 
Prox LAD  3.5  3.5 
Mid LAD  2.5  2.5 
Dist LAD  1  1 
D1  1  1 
D2  0.5  0.5 
Prox LCx  1.5  2.5 
Dist LCx  1  1.5 
AL/IM  1  1 
OM  1  1 
L-PL  0.5  0.5 
L-PDA  0  1 
Prox RCA  1  0 
Mid RCA  1  0 
Dist RCA  1  0 
R-PL  0.5  0 
R-PDA  1  0 
Plaque Weight Factor 
 
Calcified  1.2 
Mixed  1.6 
Non-Calcified   1.7 
Stenosis Weight Factor 
 
<50%  1 
≥50%  1.4 
Segment(n) Score = 
 
Plaque Weight Factor 
X 
Stenosis Weight Factor 
X 
Segment (n) Weigt Factor  
 
CTA risk Score = Σ Segment (1-17) Score 
Figure 2. Schematic overview of the CTA risk score.
The CTA risk score is calculated by the summation of the individual segment scores, which are obtained by 
multiplying the segment weight factor, the stenosis weight factor and the plaque weight factor. 
 AL: anterolateral segment; D1: diagonal 1; D2: diagonal 2; IM: intermediate segment; LAD: left anterior de-
scending coronary artery; LCA: left coronary artery; LCx: left circumflex coronary artery; LM: left main segment; 
L-PDA: left posterior descending artery; L-PL: left posterolateral segment; OM: obtuse marginal segment; RCA: 
right coronary artery; R-PDA: right posterior descending artery; R-PL: right posterolateral segment.
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used to exclude coronary CTA-driven events (referral for angiography mainly based 
on coronary CTA findings).12  Non-fatal myocardial infarction was defined based 
on criteria of typical chest pain, elevated cardiac enzyme levels, and typical ECG 
changes.13
Statistical analysis 
Continuous data are presented as mean ± SD if normally distributed or as median 
(interquartile range, IQR) if non-normally distributed. Categorical data are presented 
as absolute numbers and percentages. First, the QCT parameters were compared 
between both patients groups (with versus without events). Second, both the novel 
CTA risk score and the modified Duke prognostic CAD index were compared be-
tween both groups. Third, the ability of the CTA risk score for risk stratification of 
patients was assessed. For this purpose, the CTA risk score was stratified into a low 
and high risk category based on receiver operating characteristic (ROC) curve analy-
sis, ensuring the highest negative predictive value. First, the distribution of the risk 
score in patients with and without obstructive CAD (≥50% area stenosis in QCT) 
was assessed; and correlated to the occurrence of an event. In a similar fashion, 
the distribution within the Duke CAD categories was assessed. For this purpose, the 
Duke CAD categories were divided in three groups: Mild CAD, defined as Duke CAD 
category 1; Moderate CAD, defined as Duke CAD category 2-3; Severe CAD, defined 
by the three most severe categories. Fourth, to evaluate the independent predictive 
value of the CTA risk score, univariate and multivariate Cox-regression analyses were 
performed. All baseline or univariate significant clinical variables were entered into 
the multivariate model. All statistical tests were two-sided and a P-value <0.05 was 
considered statistically significant. All statistical analyses were performed with SPSS 
software (Version 20.0, SPSS Inc., Chicago, Illinois).
Results
The patient population consisted of 300 patients referred for the evaluation of chest 
pain during the period January 2008 - May 2010. Baseline characteristics are sum-
marized in Table 1.The median follow-up duration was 2.14 years (IQR1.07-3.48); 
28(9%) patients were lost to follow-up. During the follow-up period the composite 
endpoint occurred in 29 patients (event rate 10%) ; 25 (8%) patients underwent re-
vascularization (23 PCI and 2 CABG) after 30-day of CTA acquisition. Death occurred 
in 4 patients (1%). In patients with an event, mean age was higher and diabetes and 




The results of the QCT lesion analysis on a patient basis are depicted in Table 2. In 
patients with an event, significant obstructive lesions were more frequently observed. 
Furthermore, in patients with an event the mean number of partially calcified or 
calcified lesions was higher compared to patients without events. 









Age (years) 55±11.5 54±11.6 60±8.5 <0.001
Men 180(60%) 161(59%) 19(66%) 0.526
Diabetes Mellitus 90(30%) 76(28%) 14(48%) 0.024
Hypertension† 111(37%) 95(35%) 16(55%) 0.034
Hypercholesterolemia‡ 100(33%) 88(32%) 12(41%) 0.334
Smoker 52(17%) 47(17%) 5(17%) 0.988








Data are represented as mean ± SD, median (interquartile range) or as number and percentages of 
patients.
†Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90
mmHg or the use of antihypertensive medication.
‡Defined as serum total cholesterol ≥230 mg/dL or serum triglycerides ≥200 mg/dL or treatment with 
lipid lowering medication. 
* Defined as a body mass index of ≥ 30 Kg/m2
Table 2. Comparison of quantitative computed tomography coronary angiography results between 








No of plaques ≥30% 1.54±2.14 3.83±2.04 <0.001
No of plaques 30-50% 0.82±1.17 1.45±1.12 <0.001
No of obstructive lesions ≥50% 0.51±0.87 1.83±0.97 <0.001
No of severe lesions ≥70% 0.17±0.92 0.69±1.07 <0.001
No of calcified lesions 0.95±1.67 2.66±2.10 <0.001
No of partially calcified lesions 0.31±0.73 0.76±0.87 <0.001
No of non-calcified lesions 0.29±0.60 0.41±0.63 0.189
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CTA risk score
 In the overall population, the median CTA risk score was 3.0(IQR0.0-9.8). The me-
dian CTA risk score was significantly higher in patients with an event as compared to 
event-free patients (12.5(IQR8.6–16.4) versus 1.7(IQR0–8.4), P<0.001). Accordingly, 
in patients with a CTA risk score of 0, the event rate was <1% (1 of 130). Based on 
ROC curve analysis, a CTA risk score of 7 was defined as a cut-off value between 
low and high CTA risk score to ensure the highest negative predictive value. Figure 3 
provides a patient example of the QCT analysis. The distribution of patients with a 
high and low CTA risk score between patients with and without obstructive CAD is 
depicted in Figure 4.  Of interest, in the 112 patients with obstructive CAD, all events 
occurred in patients with a high CTA risk score.
Reclassification according to the presence of obstructive CAD and 
modified Duke prognostic CAD index
The results of the modified Duke prognostic CAD index calculation based on the QCT 
results are summarized in Figure 5. The majority of the patients were categorized in 
Duke CAD category 1. Indeed, all events in patients within Duke CAD category 2 
or 3 occurred in patients with a high CTA risk score. Only one event occurred in a 
patient with a low CTA risk score, this patient was classified in Duke CAD category 1. 
Cox-regression analysis
In the univariate Cox-regression analysis (Table  3), age and CTA risk score were 
significantly associated with the occurrence of an event. In the multivariate analysis, 
adjusted for significant baseline characteristics, the CTA risk score was independently 









No of narrowed coronary arteries 0.51±0.87 1.83±0.97 <0.001
Left main lesion 6(2%) 4(13%) 0.001
Right coronary artery lesion 45(16%) 11(37%) 0.005
Left anterior descending artery lesion 63(23%) 24(82%) <0.001
Left circumflex artery lesion 25(9%) 13(44%) <0.001
Lesions in proximal segments 0.34±0.68 1.07±1.0 <0.001
Lesions only in distal segments 0.38±0.89 1.31±1.17 <0.001




The present study assessed the feasibility of a novel, fully automatic QCT algorithm to 
quantify the location, severity and composition of coronary artery atherosclerosis on 
a patient basis. Particularly, differences in QCT derived CAD parameters were shown 
between patients with and without subsequent events. Second, a novel CTA risk score 
was developed, enabling to express the location, extent, severity and composition 
of CAD in a number for each individual patient. This score was significantly higher 
in patients who experienced an adverse event. Finally, the distribution of the CTA 
risk according to the presence of obstructive CAD and within the Duke CAD score 
categories was established.
A B C D 
E 
Figure 3. Patient example of the QCT analysis.
An example of a 54-year old man with a CTA risk score of 8.3. Panel A shows the MPR of the LAD of 
this patient in which a significant non-calcified plaque was present. In panel C, the cross-section at the 
minimal lumen area with corresponding proximal and distal reference regions is shown (Panels B and 
D).  The lesion was automatically detected and quantified (panel E) by the algorithm as depicted in 
Figure 1. The stenosis degree was 61% and the lesion was characterized as non-calcified plaque. Three 
months after the coronary CTA, the patient underwent invasive coronary angiography for progressive 
chest pain, followed by PCI of the LAD.
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Quantitative computed tomography coronary angiography (QCT)
The assessment of CAD on CTA images is mainly performed visually. However, the 
accuracy and reproducibility of visually analysed CTA images is limited.14 This may 
result in misclassification of obstructive or non-obstructive CAD; for example, in 
the multi-centre ACCURACY study a visually assessed obstructive CAD on CTA was 
confirmed in only 64% of patients using quantitative coronary angiography (QCA).15
These observations underscore the need for a robust, reproducible method for 
quantification of CAD on CTA.  Novel software tools have been designed allowing 
quantitative assessment of CTA datasets similarly to QCA.5;6;16;17 Leber et al. performed 
a quantitative analysis of CAD on CTA and compared the results to ICA and IVUS.17 In 
total, 798 segments were analyzed, illustrating a clear relation between plaque bur-
den as quantified on CTA and IVUS. However, for quantification of stenosis severity 
only modest correlations between CTA and ICA were shown. Voros et al. included 50 
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    
     
     
  
     
     
Figure 4. Distribution of the CTA risk score according to the presence of a significant stenosis.
Upper panel: Bar graph representing the distribution of patients with a low or high CTA risks score.
Lower panel: Bar graph representing the event rates in patients with a low or high CTA risk score in 
patients with and without obstructive CAD. In the patients with obstructive CAD, all events occurred in 
patients with a high CTA risk score. 
Chapter 8
158
patients who underwent cardiac CTA, ICA and IVUS.16  In this study, stenosis sever-
ity as derived from QCT correlated well with stenosis severity on QCA. Moreover, 
QCT and IVUS correlated significantly in the assessment of lumen and vessel area. 
These different findings between the study by Leber et al.18 and Voros et al.16, can be 
explained by the fact that Voros et al. used an automated method for assessment of 
the coronary artery lumen and vessel wall. The reproducibility of QCT has also been 
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   
      
      
Figure 5. Distribution of the CTA risk score according to the grouped Duke CAD category. 
Upper panel: Bar graph representing the distribution of patients with a low or high CTA risk score in 
the three groups. In the patients with mild CAD, a large proportion of patients (73%) were reclassified 
by a high CTA risk score. 
Lower panel: Bar graph representing the event rates in patients with a low or high CTA risk score in the 
three Duke CAD groups. In the patients with Duke CAD category 2- 3, all events occurred in patients 
with a high CTA risk score. 
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addressed by Papadopoulou et al. illustrating high inter- and intra-observer agreement 
for assessment of geometrical measurements of coronary atherosclerosis 19  
Quantitative assessment of coronary artery atherosclerosis and plaque constitu-
tion is clinically relevant.  Versteylen et al. performed a semi-quantitative analysis of 
CTA data and demonstrated that the 21 patients who developed an ACS more often 
presented with larger (non-calcified) plaque volumes and higher plaque burden as 
compared to  control patients.20  Importantly, the authors demonstrated incremental 
predictive value of semi-quantitative coronary CTA analysis over visual CTA interpre-
tation and Framingham risk score. 
For complete analysis of coronary artery atherosclerosis, not only quantitative 
analysis of stenosis severity and plaque burden is needed but also assessment and 
quantification of plaque constitution. Earlier studies have shown the agreement be-
tween plaque constitution on QCT as compared with IVUS Virtual Histology (IVUS 
VH). Brodoefel et al. compared QCT and IVUS VH in 22 coronary lesions, showing 
good correlations for assessment of overall plaque volume and non-calcified plaque 
volume, but the agreement between the 2 techniques for assessment of plaque con-
stitution was limited.21 The more sophisticated software for quantification of plaque 
constitution that was used in the current study has been shown to correlate well 
with IVUS VH in 57 patients (108 coronary lesions).6 Particularly, distinction and 
quantification of coronary plaque volume and plaque constitution is feasible with 
this software.
Novel CTA risk score
In the present study, a novel CTA risk score was developed. This score consists of three 
components per coronary lesion (i.e. plaque location, severity and composition). 






Age 1.05(1.01;1.09) 0.008 1.02(0.98;1.07) 0.238
Gender 1.30(0.61;2.80) 0.499
Diabetes Mellitus 1.86(0.90;3.86) 0.095 2.02(0.95;4.29) 0.067
Hypertension 2.13(1.02;4.42) 0.044 1.07(0.48;2.38) 0.866
Hypercholesterolemia 1.19(0.57;2.50) 0.640
Family history of CAD 1.41(0.68;2.92) 0.354
Smoking 0.95(0.36;2.48) 0.910
Obesity 1.41(0.60;3.29) 0.432
CTA risk score 1.12(1.07;1.16) <0.001 1.10(1.01;1.15) <0.001




Each component has been demonstrated to provide important prognostic information 
for risk stratification of patients with CAD. 
Stenosis location. The location of a coronary atherosclerotic lesion has important 
prognostic value. Patients with lesions located proximally in the coronary arteries 
have a worse prognosis as compared to patients with  distally located lesions.10 In 
the early 1980s, the Leaman score was developed to provide weight factors for each 
segment in the coronary artery tree based on the amount of myocardium at risk 
per coronary segment.7 This score was thereafter implemented in the angiographic 
SYNTAX-score, designed to quantify the complexity of CAD and its value has been 
established in clinical studies.22-24 The same Leaman weight factors were directly 
incorporated in the novel score used in the present study.
Stenosis severity. Currently, the assessment of CAD on coronary CTA is mainly 
targeting the detection or exclusion of obstructive CAD. However, the presence of 
non-obstructive CAD on coronary CTA is also associated with worse prognosis. In the 
CONFIRM registry, Chow et al. demonstrated a 3-fold increase in annual mortality rate 
for patients with non-obstructive CAD as compared to patients without atherosclero-
sis.25 To account for the clinical value of atherosclerotic burden and non-obstructive 
CAD, previously proposed scores have focused on the number of lesions and the 
extent of CAD. Min et al. for example applied the Duke modified CAD index to CTA 
images.16 In this score, patients were categorized according to the extent of CAD. The 
prognostic value of these scoring systems has recently been reported.10;26 However, in 
these scores only rough estimates are implemented, whereas in the present CTA risk 
score established values from literature were applied per coronary segment.8 
More recently, a novel score was designed based on the CONFIRM data.27 This score 
combines both clinical and CTA data. Similar to the CTA risk score, more weight is 
assigned to proximal lesions. In contrast, in the CONFIRM score non-calcified plaque 
was not incorporated, whereas in the CTA risk score this score was weighted a higher 
risk than calcified plaque.
Plaque constitution. Next to assessment of stenosis severity, CTA permits assess-
ment of plaque constitution, which provides additional prognostic value; Hou et al. 
showed in 4,425 patients that the presence of partially calcified and non-calcified 
plaques was associated with worse prognosis as compared to calcified plaques.28 
These results may suggest that non-calcified and partially calcified plaques represent 
a more vulnerable stadium of CAD, whereas calcified plaques may reflect more stable 
CAD. To account for this difference in prognosis, in the present score, different weight 
factors were applied for the different plaque constitutions.
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Limitations
Some limitations need to be considered. The current evaluation should be considered 
a feasibility study, to demonstrate the potential use of QCT, and to introduce the 
concept of a novel CTA risk score. Further studies in larger populations are needed 
to confirm the current observations. In addition, although QCT was automatically 
performed, still limited user input was needed to confirm the automatic lesion detec-
tion, which may potentially have introduced observer bias. Moreover, only scans with 
clinical diagnostic image quality were included. 
Conclusion
The CTA risk score only includes CTA derived information and no details on patients 
risk factors or symptoms. For clinical decision making the risk score should be con-
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Purpose: The aim of this study was to evaluate the feasibility of quantitative com-
puted tomography angiography (QCT) for the assessment of coronary atherosclerosis 
changes over time on serial coronary computed tomography angiography (CTA) in 
patients with stable chest pain.
Methods: The patient population consists of 53 patients clinically referred for the 
evaluation of chest pain who underwent a coronary CTA. After a minimum of 2 years 
CTA was repeated to evaluate changes in coronary atherosclerosis over time. For 
accurate and reproducible assessment of coronary artery disease (CAD) changes, all 
CTAs were quantitatively analysed using QAngioCT. All parameters of dimension and 
composition of CAD were compared between patients to assess possible regression 
and progression of CAD. 
Results: Of the 53 patients, 32(60%) showed regression of coronary total atheroma 
volume (TAV) whereas 21(40%) showed progression of coronary atheroma. In patients 
with progression of coronary atheroma, median TAVindexed increase was 117.73(56.76; 
236.01)mm3 compared to -82.49(-114.17; -42.58)mm3 for patients with regression. 
Patients with progression of coronary atheroma had progression of all four plaque 
types. However, patients with regression demonstrated a regression of all plaque 
components except for dense calcium, for which progression was observed. 
Conclusion: The assessment of changes in CAD with QCT is feasible. In patients with 
stable chest pain syndrome both regression and progression of coronary atheroma is 
observed. Potentially QCT could be applied to assess the efficacy of anti-atheroscle-
rotic therapy. 
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Introduction
Progression of coronary atherosclerosis is of clinical importance. Serial intravascular 
ultrasound (IVUS) or invasive coronary angiography (ICA) studies have been used to 
assess progression of atherosclerosis over time, mostly as part of an evaluation on the 
efficacy of anti-atherosclerotic therapy.1 However, these methods are invasive, time 
consuming and expensive. Computed tomography coronary angiography (CTA) is a 
suitable method for non-invasive assessment of coronary atherosclerosis. Its value in 
clinical practice has been extensively established.2, 3 For accurate and robust assess-
ment of coronary atherosclerosis, novel quantitative computed tomography (QCT) 
algorithms are available which allow quantification of coronary atherosclerosis 
dimensions and composition.4, 5 The accuracy and reproducibility of these tools have 
been previously validated.6 Potentially, these algorithms can be applied to quantify 
coronary atherosclerosis in serial CTA studies. Therefore, the aim of this study was to 
evaluate the feasibility of QCT for the assessment of coronary atherosclerosis changes 
over time on serial coronary CTA in patients with stable chest pain.
Methods
Patients
This prospective study included 137 patients clinically referred for the evaluation of 
chest pain to the Rijnland Hospital between July 2009 and June 2011. Patients un-
derwent a non-contrast computed tomography (CT) scan for coronary artery calcium 
(CAC) score and coronary CTA. By protocol, after a minimum of 2 years CAC-score 
and CTA were repeated to evaluate changes in coronary atherosclerosis over time. 
Patients who had undergone prior, myocardial infarction, percutaneous coronary 
intervention (PCI) or coronary artery bypass graft surgery (CABG) were excluded. The 
clinical data were prospectively entered into the hospital’s electronic patient file and 
retrospectively analysed. The Institutional Review Board approved this clinical study. 
Informed consent was obtained in all patients.  
CTA acquisition
All patients underwent a non-contrast and contrast coronary CTA. Contra-indica-
tions for CTA were, 1) impaired renal function (glomerular filtration rate  <30 ml/
min/1.73m2), 2) pregnancy, 3) (supra-) ventricular arrhythmias, 4) known allergy to 
contrast agent, 5) severe claustrophobia. CTA was performed according to standard 
clinical practice using a Philips Brilliance 64-slice CT scanner. Prior to CTA exami-
nation, beta-blocking medication was administered if the heart rate was ≥65 beats 
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per minute, unless contra-indicated. Scan parameters were as follows: tube voltage 
120kV, automated tube current modulation 250–400mA, pitch 0.2–0.3, collimation 
64 × 0.625mm, and gantry rotation time 420ms. Images were acquired prospectively 
and reconstructed at 75% and at the best phase of the R-R interval. All data were 
stored for offline analysis. The CAC-score was calculated by the Agatston approach. 
Contrast CTA image quality was classified as: (1) good image quality (scans with-
out motion artefacts), (2) moderate image quality (scans with motion artefacts or 
increased image noise) and (3) poor image quality (non-diagnostic scans); the last 
were excluded from the analysis.
Quantitative CTA
For accurate and reproducible assessment of CAD changes, all CTAs were quanti-
tatively analysed using QAngioCT Research Edition version 1.3.6 (Medis medical 
imaging systems, Leiden, The Netherlands). This software allows for quantitative 
assessment of both dimension and composition of coronary atherosclerosis. QCT 
was performed as previously described.4 In brief, the following automatic processing 
steps were performed. The 3-dimensional coronary tree was automatically extracted 
from the coronary CTA dataset. Using an automatic tree labelling algorithm, the seg-
ments of the coronary tree were automatically labelled according to the American 
Heart Association (AHA) 17-segment model. The extracted and labelled coronary 
tree was verified by an experienced observer. Next, of each coronary, multiplanar 
reformations (MPRs) were constructed based on the centrelines of the detected coro-
naries. Thereafter, the lumen and vessel wall were automatically segmented using 
a previously validated software tool and coronary artery atherosclerosis dimension 
quantified.5 If necessary, limited manual input was used to improve the automatic 
processing steps. With the help of a dedicated tissue characterization algorithm, 
coronary plaque composition was determined. This algorithm allows differentiating 
the detected coronary plaque into four different plaque types: fibrotic (FI) plaque, 
fibro-fatty (FF) plaque, necrotic core (NC) and dense calcium (DC). For the present 
study, a previously validated method using adaptive HU thresholds was used.5 
The four major coronaries were studied (i.e. right coronary artery (RCA), left main 
(LM) artery, left anterior descending (LAD) artery and left circumflex (LCx) artery). 
Moreover, segments with cross-sectional lumen areas (<1.5mm2 ) were excluded as 
well as segments shorter than 10 mm. The reproducibility of this algorithm has been 
previously addressed.6 The reported inter-observer concordance correlation coef-
ficient was 0.96 for plaque burden and plaque area. 
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Quantitative CTA atherosclerosis parameters 
Figure 1 depicts the definitions of the quantitative derived CTA parameters of athero-
sclerosis dimensions and composition used in this study. For all four plaque types 
(i.e. FI, FF, NC, DC0 volumes and percentages were derived from the software. All 
parameters were indexed to the mean segment length of the total population to ac-
count for different segment lengths per patient and per scan providing the possibility 
to compare these parameters over time.1 This was performed by calculating: 
Total volumeindexed(i) =
total volume
× mean segment length population
total segment length
To compare patients with regression and progression of coronary atheroma, ΔTAVi 
was calculated by subtracting TAVi baseline from TAVi follow-up. There is limited data in the 
literature to serve as a cut-off to define progression or regression of coronary atheroma 
volume on coronary CTA. To be as sensitive and accurate as possible, we prospec-
tively determined that any change in ΔTAVi  was considered as a change in coronary 
atheroma volume. Thus, ΔTAVi<0 mm3 was classified as regression and ΔTAVi>0 mm3 
as progression of coronary atheroma volume. Subsequently, the change over time in 
volume of the different coronary plaque types in relation to ΔTAVi was established.  
Statistical analysis
For reasons of clarity, all continuous parameters are reported as mean ± SD and me-
dian (interquartile range (IQR)). Categorical data are presented as absolute numbers 
and percentages. All analyses were performed on a patient-basis. First, both baseline 
and follow-up plaque characteristics were described. Moreover, the changes over 
time in these parameters were assessed. Second, a comparison was made between 
patients with progression or regression of coronary atheroma volume. The change 





Segment length (mm) Total distance between the proximal and distal point of the extracted segment.  
Lumen volume (mm3) Total volume of the vessel lumen of the extracted segment  
Vessel wall volume (mm3) Total volume of the vessel wall of the extracted segment 
Total atheroma volume (TAVi) (mm3) Total vessel volume – total lumen volume. 
Percentage atheroma volume (PAV) (%) [(Total vessel volume – total lumen volume) / total vessel volume] x 100%.  
Total (FI/FF/NC/DC)volume(mm3)  Total volume per plaque type 
Percentage (FI/FF/NC/DC) (%)  [(Volume of plaque type – plaque volume) / total plaque volume] x 100% 
Figure 1. Definitions of QCT plaque parameters.
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was compared between patients with regression or progression of coronary atheroma 
volume. The baseline patient characteristics were compared between patients with 
regression or progression of coronary atheroma volume. Lastly, the difference in 
baseline plaque characteristics was compared between patients with regression or 
progression of coronary atheroma volume.  All statistical tests were two-sided and 
a P-value <0.05 was considered statistically significant. All statistical analyses were 
performed with SPSS software (Version 20.0, SPSS Inc., Chicago, Illinois).
Results
Patient population
For this study, 137 consecutive patients were included with diagnostic qualitative 
CTA images. The flow diagram in Figure 2 illustrates the selection of patients eligible 
for inclusion as well as the reasons for exclusion. Of these patients, 65 did not have 
a follow-up appointment scheduled for logistic reasons or were lost to follow-up. 
Moreover, 7 patients only had a CAC-score at baseline. The remaining 65 patients 
completed the study with a CTA scan at baseline and follow-up. In 10 of the 65 
patients, the CTA image quality was insufficient. Furthermore, 2 of the remaining 
55 patients underwent revascularization between the two studies and were also 
excluded. In total, 53 patients with 377 segments were analysed. The median time 
between baseline and follow-up CTA was 25 (IQR 24-26) months. The patient char-
acteristics at baseline and follow-up are listed in Table 1. Mean age was 54 ± 8.7 
years and 28 (52.8%) of the patients were male. At baseline, 30% of patients received 
Initial study population 
(N=137) 
No follow-up scan (N=65) 
Baseline CA-score only (N=7) 
Baseline and follow-up 
scan available 
(N=65) 
Insufficient quality (N=10) 
Complete dataset 
(N=53) 
Revascularization between two 
studies (N= 2) 
Figure 2. Flowchart of the study population.
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Table 1. Patient characteristics.
Patient characteristics (n=53) Baseline Follow-up
Age (yrs.) 54 ± 8.7 N/A
Gender (% male) 28 (52%) N/A
Non AP complaints 8 (15%) 9 (17%)
AP Complaints 45 (85%) 44 (83%)
 Atypical AP complaints 32 (60%) 29 (55%)
 Typical AP complaints 12 (22%) 14 (26%)
 Typical and Atypical AP complaints 1 (2%) 1 (2%)
Cardiovascular risk factors
 Hypertension† 18 (34%) 17 (32%)
 Hypercholesterolemia ‡ 6 (11%) 6 (11%)
 Diabetes Mellitus 4 (8%) 5 (9%)
 Family history of CAD* 37 (70%) N/A
 Current Smoking 12 (23%) 12 (23%)
 Ex-Smoker 9 (17%) 9 (17%)
 Obesity (BMI ≥ 30 kg/m2) 2 (4%) 2 (4%)
Medication
 ACE/ATII 8 (15%) 8 (15%)
 Calcium channel blockers 4 (8%) 7(13%)
 NTG 7 (13%) 9 (17%)
 Bèta blockers 20 (38%) 16 (30%)
 Diuretics 7 (13%) 7 (13%)
 Asprin 19 (36%) 20 (38%)
 Statines 16 (30%) 22 (42%)
Triglycerides 1.31 ± 0.59 1.20 ± 0.50 
Cholesterol 5.53 ± 0.84 5.02 ± 1.38
 HDL Cholesterol 1.61 ± 0.57 1.54 ± 0.61
 LDL Cholesterol 3.44 ± 0.80 2.90 ± 1.04 
 VLDL Cholesterol 0.44 ± 0.50 0.42 ± 0.50
Creatinine 82.54 ± 13.03 79.58 ± 16.72 




Increase in Agatston CAC score 15 ± 25
5 (0 – 20)
Data are represented as mean ± SD, median (interquartile range) or as number and percentages of patients.
†Defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or treatment for 
hypertension
‡Serum total cholesterol ≥230 mg/dL or serum triglycerides ≥200 mg/dL or treatment with lipid lowering drugs. 
*Defined as the presence of coronary artery disease in first-degree family members at <55 years in men 
and <65 years in women.
Abbreviations: ACE: Angiotensin Converting Enzyme, AP: Angina pectoris, BMI: body mass index, CAC: coro-
nary artery calcium, IQR: Interquartile Range, NTG: Nitro-glycerine
Chapter 9
174
statins, compared to 42% at follow-up. The mean Agatston CAC-score at baseline was 
35 ± 60 compared to 51 ± 77 at follow-up. 
Comparison of QCT parameters between baseline and follow-up
Both baseline and follow-up coronary artery plaque characteristics were reported on a 
patient-basis (Table 2). The percentage atheroma volume (PAV) was 34.6(32.6-39.3)% 
at baseline and 36.1(32.5-41.2)% at follow-up, (P=0.241). The TAVi significantly 
increased from 737.6(629.1-901.5)mm3 at baseline, to 812.7(687.9-951.6)mm3 at 
follow-up (P=0.043). Overall, the median increase in TAVi was 5.10(-6.32-16.71)%. 
Overall both NCi and DCi were significantly increased at follow-up. NCi had in-
creased from 20.33(6.45-41.30)mm3 to 29.66(11.45-49.09)mm3, DCi had increased 
from 5.36(2.07-12.75)mm3 to 9.63(2.79-24.00)mm3. Figure 3 presents a case example 
with progression of atherosclerosis. 
Table 2. QCT plaque characteristics.
Baseline and follow-up plaque 
quantitative parameters
Baseline Follow-Up Change P-Value
Percent atheroma volume (PAV) (%)










Total atheroma volume (TAVi) (mm3)










% Change in total atheroma volume 





Total fibrotic tissue volume (FIi) (mm3)












Total fibro-fatty tissue volume (FFi) 
(mm3)










Total necrotic core volume (NCi) (mm3)
 Mean ± SD 24.75 ± 19.38 36.18 ± 35.43 11.42 ± 36.15
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Patients with regression vs. progression of coronary atheroma volume
Of the 53 patients, 32(60%) showed regression of coronary atheroma volume 
(ΔTAVi <0 mm3) whereas 21(40%) showed progression of coronary atheroma volume 
(ΔTAVi >0 mm3). In 29 (55%) patients an increase in PAV was observed, whereas 
24 (45%) patients showed a   decrease in PAV. Moreover, 26 (49%) patients had 
an increase in PAV  >1%, which is considered a relevant threshold for significant 
change under intensive lipid-lowering therapy in clinical studies.7, 8 A decrease in 
PAV >1% was observed in 22 (42%) patients. As depicted in Table 3, in patients with 
progression of coronary atheroma volume, median TAVi increase was 117.73(56.76; 
236.01)mm3. Patients with regression of coronary atheroma volume presented with 
a median decrease in TAVi of -82.49(-114.17; -42.58) mm3. Of particular interest, in 
patients with regression of coronary atheroma volume an increase in total DCi vol-
ume was observed 0.42(-0.96; 5.50) mm3 The other plaque types showed regression 
in these patients. In contrast, patients with progression of coronary atheroma volume, 
Table 2. (Continued)
Baseline and follow-up plaque 
quantitative parameters










Total dense calcium volume (DCi) 
(mm3)










% fibrotic tissue 










% fibro-fatty tissue 





















% dense calcium 


















Figure 3. Case example of a case with progression of coronary atherosclerosis.
Example of a the left anterior descending (LAD) artery of 48 years old female with stable angina. Panel 
A show the multiplanar reformation (MPR) of the LAD at baseline. Panel B demonstrated the corre-
sponding quantitative computed tomography data; the lower part of the graphs represents the lumen 
cross-sectional area, the upper part the vessel wall cores sectional area. The part between the graphs 
represents the plaque area. Dark-green represent fibrotic plaque, the light-green represent fibro-fatty 
plaque, red marks necrotic core and white marks dense calcium. Panel C shows a 3D-representation of 
the coronary vessel with the same color coding. Panel D-F represent the same vessel but after two year 
follow-up. Overall, progression of atherosclerosis is observed, specifically of calcified plaque. 
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showed an increase in in volume of all four plaque types. The differences in base-
line characteristics between patients with regression and patients with progression 
of coronary atheroma volume were assessed. Besides hypercholesterolemia, there 
were no significant differences between the two patients groups. Worth mentioning, 
there was no difference in increase in CAC-score between patients with regression 
or progression of coronary atheroma volume. Table 4 demonstrates the difference in 
baseline coronary atherosclerosis dimensions and composition between patients with 
regression or progression of coronary atheroma volume. Patients with regression of 
coronary atheroma had significantly higher baseline PAV compared to patients with 
progression of disease (36.64% (33.72; 40.62) vs 33.44% (31.50; 37.58), P=0.040). 
Both groups had comparable baseline composition of coronary atherosclerosis. 
Table 3. Comparison of change in coronary plaque dimension and composition over timebetween 
patients with regression vs. progression of coronary atheroma volume.
Change in plaque quantitative 
parameters






Change in PAV 
 Mean ± SD -2.63 ± 1.88 4.19 ± 3.63
 Median (IQR) -2.18 (-3.60; -1.10) 3.08 (1.08; 7.81) NA
Change TAVi
 Mean ± SD -104.81 ± 101.12 176.07 ± 184.82
 Median (IQR) -82.49 (-114.17; -42.58) 117.73 (56.76; 236.01) NA
Change in total fibrotic tissue volume 
(FIi) (mm3)
 Mean ± SD -46.00 ± 49.07 68.40 ± H73.38
 Median (IQR) -49.09 (-64.74; -10.48) 59.11 (24.60; 107.86) NA
Change in total fibro-fatty tissue 
volume (FFi) (mm3)
 Mean ± SD -20.35 ± 33.06 31.86 ± 48.68
 Median (IQR) -15.68 (-28.43; 2.20) 14.13 (2.08; 47.13) NA
Change in total necrotic core volume 
(NCi) (mm3)
 Mean ± SD -4.92 ± 17.69 22.15 ± 41.11
 Median (IQR) 0.53 (-8.12; 6.50) 10.55 (3.68; 26.55) NA
Change in dense calcium volume (DCi) 
(mm3)
 Mean ± SD 3.29 ± 14.27 9.00 ± 13.10




The present study addressed the feasibility of a novel CTA quantification tool to assess 
changes of coronary atherosclerosis in a CTA population evaluated for stable chest 
pain. In addition to the assessment of progression of coronary atheroma volume, the 
change in specific coronary plaque components was assessed. In 40% of the patients 
progression of coronary atheroma volume was observed, whereas 60% showed 
regression of atheroma volume. Patients with progression of coronary atheroma had 
progression of all four plaque types. However, patients with regression of atheroma 
demonstrated a regression of all plaque components except for dense calcium, for 
which progression was observed. 
Table 4. Comparison of baseline coronary plaque dimensions and composition between patients with 
regression vs. progression of coronary atheroma volume.
Baseline plaque 
quantitative parameters
Regression of coronary 
atheroma volume (n=21)
Progression of coronary 
atheroma volume (n=32) 
P-Value
Baseline PAV (N)
 Mean ± SD 37.80 ± 5.88 34.76 ± 4.60
 Median (IQR) 36.64 (33.72; 40.62) 33.44 (31.50; 37.68) 0.040
Baseline TAVi (N)
 Mean ± SD 801.09 ± 132.59 746.38 ± 208.59
 Median (IQR) 810.78 (697.84; 905.59) 695.04 (570.18; 856.84) 0.102
Baseline % fibrotic tissue 
(FI)
 Mean ± SD 69.88 ± 8.38 72.13 ± 9.80
 Median (IQR) 69.69 (64.00; 76.20) 73.82 (63.28; 78.11) 0.536
Baseline % fibro-fatty 
tissue (FF)
 Mean ± SD 21.83 ± 5.16 20.02 ± 7.07
 Median (IQR) 21.70 (17.51; 25.81) 18.77 (15.46; 25.54) 0.335
Baseline % necrotic core 
(NC)
 Mean ± SD 5.96 ± 3.34 5.10 ± 3.55
 Median (IQR) 5.97 (2.92; 8.06) 3.75 (2.08; 8.49) 0.383
Baseline % dense 
calcium (DC)
 Mean ± SD 2.32 ± 2.71 2.75 ± 2.52
 Median (IQR) 1.21 (0.38; 2.83) 2.16 (0.85; 4.04) 0.317
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Assessments of coronary atherosclerosis progression
Currently, the standard for evaluating coronary atherosclerosis changes is IVUS. This 
method allows evaluation of lumen and vessel wall dimensions as well as assessment 
of coronary atheroma volume. By applying radiofrequency backscatter analysis, IVUS 
Virtual Histology (VH) allows for assessment of coronary plaque components. IVUS 
VH has been validated against histopathology.9 Both IVUS and IVUS VH are often 
used in studies assessing coronary atherosclerosis progression or regression.1, 10-13 
However, since IVUS is an invasive and costly method, new research has focused 
on the value of CTA for the assessment of coronary atherosclerosis progression. By 
applying novel imaging quantification tools, coronary atherosclerosis dimension can 
be quantified on CTA and used to follow-up changes of atherosclerosis in patients.4, 6 
The validity of these tools has been established and QCT has become accepted as a 
research tool. More recently, using a Hounsfield Unit (HU) threshold, different plaque 
components can be individually assessed and quantified using QCT.5 This allows 
for a more advanced assessment of coronary atherosclerosis, similar to IVUS VH. 
Especially with decreasing radiation exposures for CTA, QCT techniques become 
more available for serial evaluation of coronary atherosclerosis. Another advantage of 
CTA over IVUS is that CTA allows for visualization of the entire coronary artery tree, 
whereas IVUS only allows assessment of large coronaries in which a catheter can 
be introduced. However, a major advantage of IVUS is the higher spatial resolution 
as compared to CTA. This allows for assessment of more subtle changes in coronary 
atherosclerosis.14
Quantification of CAD progression on CTA
Previous studies have focussed on the validity of quantifying CAD progression with 
CTA and quantification software. Papadopoulou et al. studied the natural history of 
coronary atherosclerosis in 32 patients with acute coronary syndrome.8 Patients were 
serially scanned with a mean interval of 39 months. Overall, the mean change in 
TAV was 6.7% and 34% of the patients demonstrated regression of coronary athero-
sclerosis, whereas 44% showed progression of disease. More recent investigations 
have addressed the feasibility of CTA to study plaque progression or regression as 
influenced by statin therapy. Hoffman et al. performed a second CTA in 63 patients 
who had 18-36 month earlier been clinically referred to CTA.15 Using commercially 
available software coronary atherosclerosis was quantified in a volumetric approach. 
It was demonstrated that statin therapy induced a decrease in the growth rate of 
non-calcified plaque but not of plaques containing calcium (i.e. mixed or calcified 
plaque). Similarly, Zeb et al. included 100 patients who underwent serial CTA with 
a mean interval of 13 months.16 In statin users, total plaque progression was signifi-
cantly reduced compared to non-statin users (33.3 mm3 ±90.5 vs. 31.0 mm3 ± 84.5). 
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Moreover, a significantly larger reduction in non-calcified plaque was observed in 
statin users compared to non-statin users. However, in both groups an increase in 
calcium was noted on the CTA. It seems that anti-atherosclerotic therapy leads to 
a reduction of non-calcified plaque without affecting the growth-rate of calcified 
plaque. Similarly, in the present study, in patients with regression of coronary ath-
eroma volume over time, an increase in calcium volume was observed. This has 
previously been shown in several IVUS VH studies that investigated the change in 
coronary plaque composition over time influenced by statin therapy.10-13 In the major-
ity of these studies, the volume and relative percentage of NC, FI or FF changed over 
time in patients receiving statin therapy. However, in none of the studies a significant 
change in DC was noted neither in patients receiving statin therapy, nor in the control 
cases.
Limitations
The study is hampered by some limitations. First, the study included a limited number 
of patients. Therefore the lack of significant differences in baseline characteristics 
between patient groups should be considered with care. Second, the patients were 
relatively disease free (mean CAC-score 35) and the results cannot be extrapolated 
to a population with a higher disease burden. Moreover, in current literature there 
is limited evidence for standard procedures for serial plaque imaging on coronary 
CTA. We have used a very sensitive parameter to define regression or progression of 
coronary atherosclerosis, namely any change in TAV. However, establishing standard 
procedures for assessing changes on CTA is needed. Additionally there was no refer-
ence data to compare the quantification results with (i.e. no IVUS or ICA); therefore 
the present study should be seen as a feasibility study. 
Conclusion
The assessment of changes in CAD with QCT is feasible. In patients with stable chest 
pain both regression and progression of coronary atheroma is observed. Potentially 
QCT could be applied to assess the efficacy of anti-atherosclerotic therapy. 
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Clinical aspects coronary CTA in high risk 
diabetic patients without chest pain syndrome

Chapter 10
Changes in ischaemia as assessed 
with single-photon emission computed 
tomography myocardial perfusion imaging 
in high-risk patients with diabetes without 
cardiac symptoms: relation with coronary 
atherosclerosis on computed tomography 
coronary angiography
de Graaf MA, Roos CJ, Mansveld JM, Kharagjitsingh AV, Dibbets-Schneider P, Kroft LJ, Jukema 
JW, Ficaro EP, Bax JJ, Scholte AJ.




Purpose: The study aims 1) to evaluate changes in myocardial ischemia on single 
photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) 
after 2 years in a cohort of high risk patients with diabetes without cardiac symp-
toms or known coronary artery disease (CAD) and 2) to assess the value of baseline 
computed tomography coronary angiography (CTA) derived coronary atherosclerosis 
parameters to predict changes in myocardial ischemia.
Methods: The population consisted of 100 high risk patients with diabetes without 
cardiac symptoms referred for cardiovascular risk stratification. All patients underwent 
coronary artery calcium (CAC) scoring, CTA and SPECT MPI. After 2 years follow-up, 
SPECT MPI was repeated to evaluate potential progression of ischemia.
Results: In total, 20% of patients presented with ischemia at baseline. Of these 20 pa-
tients, 7 (35%) still had ischemia at follow-up, whereas 13 (65%) showed resolution 
and 4(20%) showed progression of ischemia at follow-up. Of the 80 patients without 
ischemia at baseline, 65 (81%) had a normal MPI at follow-up and 15 patients (19%) 
presented with new ischemia. There were no significant differences in the CAC score 
or the extent, severity and composition of CAD on CTA between patients with and 
without ischemia at baseline. Similarly, no differences could be demonstrated be-
tween patients with and without ischemia at follow-up or between patients with and 
without progression of ischemia. 
Conclusion: The rate of progression of ischemia in high risk patients with diabetes 
without cardiac symptoms is limited. Few patients presented with new ischemia, 
whereas some patients show resolution of ischemia. Atherosclerosis parameters on 
CTA were not predictive of new onset ischemia or progression of ischemia. 
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Introduction
Cardiovascular death is the main cause of death in patients with diabetes mellitus 
(DM).1 Moreover, patients with DM often have silent myocardial ischemia on single 
photon emission tomography (SPECT) myocardial perfusion imaging (MPI) and coro-
nary artery disease (CAD) in an advanced stage on coronary computed tomography 
angiography (CTA).2-8 After 2-3 years of follow-up, a limited number of patients pres-
ent with new ischemia.9 However, no clinical variables predictive of new ischemia 
have yet been established. Potentially, atherosclerotic plaque characteristics on CTA 
could be associated with the onset of new ischemia. Therefore, the aim of this study 
was to: 1) evaluate changes in myocardial ischemia after 2 years in a cohort of high 
risk patients with diabetes without cardiac symptoms and 2) to assess the value of 
baseline CTA derived coronary atherosclerosis parameters to predict changes in 
myocardial ischemia on SPECT MPI in these patients.
Methods
Patients 
The patient population consisted of 159 high risk patients with diabetes without 
cardiac symptoms referred from a diabetic out-patient clinic for cardiovascular risk 
stratification as previously described.10, 11 Inclusion criteria for the study were: con-
firmed diagnosis of type 2 DM, normal resting electrocardiogram (ECG), absence of 
cardiac symptoms. Patients with known CAD or treated with anti-anginal medication 
were excluded, as well as patients with a previous stress test or coronary angiography. 
All patients underwent clinical evaluation, including laboratory testing, coronary 
artery calcium (CAC) scoring, coronary CTA and SPECT MPI between May 2005 and 
January 2006. After 2 years follow-up, SPECT MPI was repeated as prospectively 
scheduled to evaluate myocardial ischemia as indicated in the guidelines that were 
applicable at that time.12 Patients were treated according standard clinical care and 
based on test results.
The patient’s medical records were evaluated to assess if the patient underwent 
coronary revascularization between the 2 SPECT MPI studies. Clinical  data were 
prospectively entered into the departmental Cardiology Information System (EPD-
Vision©, Leiden University Medical Center, the Netherlands) and retrospectively 
analysed. The Institutional Review Board of the Leiden University Medical Center 
approved this retrospective evaluation of clinically collected data, and waived the 
need for written informed consent.
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SPECT myocardial perfusion imaging
Image acquisition.
ECG-gated technetium-99m sestamibi (99mTc-sestamibi;1000MBq) SPECT MPI was 
performed using a 2-day stress and rest protocol. Patients had to refrain from caffeine-
containing products 24-hours before testing. Vasodilator stress was performed using 
adenosine (140µg/kg/minute, intravenous for 6 minutes) with simultaneous handgrip 
exercise. Blood pressure and 12-lead ECG were recorded during adenosine stress. 
SPECT imaging was performed, 120 minutes after injection of the radiopharmaceuti-
cal, using a triple-head SPECT gamma camera (GCA 9300/HG, Toshiba Corporation, 
Tokyo, Japan). Images were acquired using a circular 360 degrees orbit in 64 projec-
tions and 20 second per projection.13 Attenuation correction was not performed.
Quantification of myocardial ischemia.
The  SPECT MPI datasets  were sent to an independent, dedicated core-lab (INVIA, 
Ann Arbor, Michigan, USA), blinded of patients’ history or scan order. By using Cor-
ridor4DM (INVIA, Ann Arbor, Michigan, USA), myocardial perfusion and reversibility 
(ischemia) was quantified as follows. 14, 15 First, the stress dataset was normalized to 
the maximum pixel intensity within the myocardium; all values were multiplied by 
100/value of the maximum pixel. Second, the rest dataset was normalized in the 
same manner using the peak in the location of the peak intensity in the stress map. 
The extent of hypoperfusion in the stress study was expressed as a percentage of the 
entire left ventricle. Comparing the rest and the stress study, allowed for assessment 
of reversibility by comparing the areas of hypoperfusion on the stress study to the 
same areas in the rest study; a ≥10% increase in tracer uptake was used to define 
reversibility. Reversibility was expressed as percentage of the entire left ventricle. 
Change in ischemia was calculated as the differences in reversibility between the 
baseline and follow-up study. To facilitate the analysis, patients were stratified into 
two groups based on differences in reversibility between the baseline and follow-up 
study. Any increase in ischemia was defined as progression, whereas a decrease in 
ischemia was defined as regression.
Coronary computed tomography angiography
Image acquisition.
Patients were scanned with either a 64-slice CT scanner (Aquilion 64, Toshiba Medi-
cal System, Otowara, Japan) or a 320-row volumetric scanner (Aquilion ONE, Toshiba 
Medical System, Otowara, Japan). Contra-indications for CTA were, 1) impaired renal 
function (glomerular filtration rate  <60 ml/min/1.73m2), 2) pregnancy, 3) (supra-) 
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ventricular arrhythmias, 4) known allergy to contrast agent, 5) severe claustrophobia. 
Non-contrast CT and contrast CTA were performed according to standard clinical 
practice. Prior to CT examination, beta-blocking medication was administered if the 
heart rate was ≥65 beats per minutes, unless contra-indicated. Datasets were sent to 
a remote workstation for analysis.
Image analysis.
Evaluation of the CTA was performed on a dedicated workstation (Vitrea FX, Vital Im-
ages, Minnetonka, MN, USA). For each patient the Agatston CAC score was measured. 
Thereafter, the CTA datasets were evaluated for the presence, severity and composition 
of coronary atherosclerosis as previously described.16  In brief, each segment of the 
coronary tree was scored as normal (<30%), non-obstructive (30-50%) or obstructive 
(≥50%) CAD. Coronary plaque composition was assessed as non-calcified, calcified 
or mixed-plaque.  Per patient, the number of segments with atherosclerosis and the 
number of each type of plaque were assessed. Significant coronary artery disease was 
defined by the presence of a coronary lesion with ≥50% stenosis.
Statistical analysis
For reasons of uniformity summary statistics for all continuous data are presented as 
mean ± SD. Normality of the data was confirmed by comparing the histogram with 
a normal probability curve. Categorical data are presented as absolute numbers and 
percentages. First, clinical patient characteristics were compared between patients 
with and without ischemia at baseline. Second, in a similar fashion, patients with 
and without ischemia at follow-up were compared. Third, patients with and without 
progression of ischemia were compared likewise. Thereafter, the CTA parameters 
of the extent, severity and composition of coronary atherosclerosis were compared 
between all patient groups. Statistical significance was assessed using non-parametric 
tests for continuous data with a non-normal distribution and t-test for data with a 
normal distribution. Chi-square tests were applied to categorical data. All statistical 
tests were two-sided and a P-value  <0.05 was considered statistically significant. 




The population consisted of 159 patients. In 36 patients, one of the two SPECT MPI 
studies was not performed (for logistical reasons). The datasets of the remaining 
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123 patients were sent to an independent core-lab for quantification of myocardial 
ischemia. In 16 patients quantitative analysis could not be performed due to protocol 
violations or insufficient image quality. The results of 107 patients were available for 
analysis, 7 patients underwent planned revascularization between the two studies and 
were therefore excluded.  The final patient cohort consisted of 100 patients.  Table 1 
demonstrates the baseline characteristics of the population. In total, 62 patients were 
male, half of the patients presented with hypertension or hypercholesterolemia. 
Mean diabetes duration was 113 ± 87 months. In Table 1, the medical therapy at 
baseline is described. In total, 52 patients received statin therapy, 17 aspirin and 31 
ACE-inhibitors. At follow-up, in 23 patients statin therapy was added and 8 patients 
received additional ACE-inhibitors. Aspirin was added in 22 patients. At follow-up, 
19 patients received anti-angina medication (i.e. beta-blockers, calcium-antagonists 
or nitrates). 
SPECT MPI results 
Median time between the 2 SPECT MPI studies was 30 (IQR 27-33) months. As shown 
in Figure 1, 20% of patients presented with ischemia at baseline, without need of re-
vascularization. Of these 20 patients, 7 (35%) patients still had ischemia at follow-up, 
whereas 13 (65%) patients showed resolution of ischemia and 4 showed progression 
of ischemia at follow-up. Of the 80 of patients without ischemia at baseline, 65 (81%) 
had a normal study at follow-up and 15 patients (19%) presented with new ischemia. 
Figure 2 demonstrates the rate of progression of ischemia. In patients with a normal 
baseline SPECT MPI, 19% of the patients presented with progression of ischemia. In 
Table 1, the baseline results stratified according to the presence of baseline ischemia 
are demonstrated.  Except for family history and low-density lipoprotein (LDL)-
cholesterol, there were no significant differences between patients with or without 
myocardial ischemia at baseline. In Table 2, the difference in characteristics between 
patients with and without ischemia at follow-up is shown. Remarkably, there were no 
significant differences between both patients groups. Table 3 summarizes the differ-
ences between baseline characteristics between patients with and without progres-
sion of ischemia. DM duration was significantly longer among patients who showed 
progression of ischemia (180 ± 97 vs. 135 ± 83 months, P=0.049). The remaining 
baseline characteristics were comparable between patients with and without progres-
sion of ischemia.  At follow-up, 5 patients presented with onset of chest-pain, of 
which 1 had progression of ischemia and 4 presented without new ischemia. Of the 
19 patients in whom anti-anginal medication was added, 2 presented with progres-
sion of ischemia (P=0.295). There was no relation between the onset of symptoms 
and new ischemia or progression of ischemia. 
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Age(years) 53 ± 10 54 ± 11 53 ± 10 0.791
Gender(% male) 62 (62%) 15 (75%) 47 (59%) 0.181
Hypertension† n(%) 52 (52%) 7 (35%) 45 (56%) 0.089
Hypercholesterolemia‡ n(%) 51 (51%) 11 (55%) 40 (50%) 0.689
Family history of CAD* n(%) 56 (65%) 5 (25%) 51 (64%) 0.002
Smoking n(%) 19 (19%) 6 (30%) 13 (13%) 0.161
Diabetes-related factors
 Age at time of 
diagnosis(years)
43 ± 12 45 ± 15 43 ± 11
0.443
 Diabetes duration(months) 113 ± 87 99 ± 95 117 ± 85 0.409
 HbA1C(%) 7.5 ± 1.6 7.7 ± 1.5 7.5 ± 1.7 0.633
Diabetes-related complications 0.857
 PVD n(%) 9 (9%) 2 (10%) 7 (9%)
 PNP n(%) 23 (23%) 6 (30%) 17 (21%)
 PVD and PNP n(%) 10 (10%) 2 (10%) 8 (10%)
Diabetes-related treatment 0.617
 Oral 61 (61%) 14 (70%) 47 (59%)
 Insulin 19 (19%) 2 (10%) 17 (21%)
 Oral and insulin 17 (17%) 3 (15%) 14 (17%)
Medication at baseline
 Aspirin n(%) 17 (17%) 6 (30%) 11 (14%) 0.084
 ACE-inhibitors n(%) 31 (31%) 7 (35%) 24 (30%) 0.665
 ARB 26 (26%) 5 (25%) 21 (26%) 0.909
 Statins n(%) 52 (52%) 14 (70%) 38 (48%) 0.072
Serum markers at baseline
 Total cholesterol(mmol/l) 4.8 ± 1.1 4.4 ± 1.0 3.9 ± 1.3 0.074
 LDL(mmol/l) 3.1 ± 1.1 2.7 ± 0.9 3.3 ± 1.1 0.049
 HDL(mmol/l) 1.4 ± 0.6 1.3 ± 0.4 1.4 ± 0.6 0.401
 Cholesterol/HDL ratio 3.9 ± 1.4 3.9 ± 1.5 3.9 ± 1.3 0.971
 Triglycerides(mmol/l) 2.0 ± 1.3 1.9 ± 0.8 2.1 ± 1.3 0.602
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CAD, coronary 
artery disease; DM, diabetes mellitus;  HDL, high density lipoprotein;  LDL, low density lipoprotein; 
PNP, polyneuropathy;  PVP, peripheral vessel disease
†Blood pressure ≥140/90 mmHg or treatment with antihypertensive medication; ‡ total cholesterol 
level >5.0mmol/L or use of cholesterol lowering medication; *defined as the presence of coronary 





93 of the 100 patients underwent coronary CTA and 98 patients CAC scoring. The 
median time between the first SPECT MPI and CTA was 22 (IQR 4 - 46) days. In 
Table  4 the CTA results are demonstrated, stratified according to the presence of 
baseline and follow-up ischemia. A comparison was made for the presence, extent 
and composition of coronary atherosclerosis on CTA.  For all parameters, there were 








Figure 1. Distribution of myocardial ischemia on SPECT MPI at baseline and after 2 years follow-up. 
Pie charts of the distribution of myocardial ischemia on SPECT MPI stratified according to baseline 








Figure 2. Distribution of progression of myocardial ischemia on SPECT MPI at baseline and after 2 
years follow-up. 
Pie charts of the distribution of progression myocardial ischemia on SPECT MPI stratified according to 
baseline ischemia. At baseline black marks ischemia, white represents a normal SPECT MPI. For follow-
up, black marks progression of ischemia.
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Similarly, no differences could be demonstrated between patients with and without 
ischemia at follow-up or between patients with and without progression of ischemia. 
Overall, 24 (26%) patients presented with obstructive CAD on CTA (of note: pa-
tients who underwent revascularization between the two SPECT MPI studies were 






Age(years) 54 ± 12 53 ± 9 0.641
Gender(% male) 13 (59%) 49 (62%) 0.750
Hypertension† n(%) 11 (50%) 41 (53%) 0.832
Hypercholesterolemia‡ n(%) 11 (50%) 40 (51%) 0.915
Family history of CAD* n(%) 10 (46%) 46 (59%) 0.259
Smoking n(%) 4 (18%) 15 (19%) 0.912
Diabetes-related  factors at FU
 Age at time of diagnosis(years) 43 ± 15 43 ± 10 0.912
 Diabetes duration(months) 136 ± 99 113 ± 85 0.300
 HbA1C(%) 7.7 ± 1.8 7.7 ± 1.5 0.876
Diabetes-related complications at FU 0.571
 PVD n(%) 2 (9%) 7 (9%)
 PNP n(%) 6 (27%) 18 (23%)
 PVD and PNP n(%) 7(32%) 4 (5%)
Diabetes-related treatment at FU 0.224
 Oral 9 (41%) 42 (54%)
 Insulin 3 (14%) 18 (23%)
 Oral and insulin 9 (41%) 16 (21%)
Medication at FU 
 Aspirin n(%) 12 (55%) 25 (32%) 0.054
 ACE-inhibitors n(%) 10 (45%) 28 (36%) 0.415
 ARB  n(%) 6 (27%) 22 (28%) 0.931
 Statins n(%) 17 (77%) 57 (73%) 0.692
 Beta-blockers  n(%) 2 (9%) 6 (8%) 0.831
 Calcium-antagonists  n(%) 1 (5%) 12 (15%) 0.182
 Nitrates  n(%) 0 (0%) 1 (1%) 0.594
Serum markers at FU
 Total cholesterol(mmol/l) 4.2 ± 1.1 4.5 ± 1.0 0.382
 LDL(mmol/l) 2.6 ± 0.9 2.7 ± 0.9 0.548
 HDL(mmol/l) 1.2 ± 0.3 1.3 ± 0.4 0.432
 Cholesterol/HDL ratio 3.6 ± 1.0 3.7 ± 1.2 0.645
 Triglycerides(mmol/l) 2.0 ± 1.7 1.9 ± 1.0 0.751
 Abbreviations and definitions as in Table 1.
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excluded). In patients with ischemia at baseline, more had obstructive CAD (33% 
vs. 24%, P=0.476) but these differences were not significant. These patients also 
had a higher mean CAC score (19 (IQR 0-115) vs. 4 (IQR 0-101), P=0.390), but the 







Age(years) 53 ± 12 53 ± 10 0.794
Gender(% male) 10 (53%) 52 (64%) 0.350
Hypertension† n(%) 9 (47%) 43 (53%) 0.653
Hypercholesterolemia‡ n(%) 9 (47%) 42 (52%) 0.725
Family history of CAD* n(%) 10 (53%) 46 (57%) 0.742
Smoking n(%) 4 (21%) 15 (19%) 0.800
Diabetes-related risk factors at FU
 Age at time of diagnosis(years) 41 ± 13 44 ± 11 0.320
 Diabetes duration(months) 180 ± 97 135 ± 83 0.049
 HbA1C(%) 8.1 ± 1.5 7.7 ± 1.6
Diabetes-related complications at FU 0.455
 PVD n(%) 2 (11%) 7 (9%)
 PNP n(%) 4 (21%) 20 (25%)
 PVD and PNP n(%) 4 (21%) 7 (9%)
Diabetes-related treatment at FU 0.249
 Oral 8 (42%) 43 (53%)
 Insulin 3 (16%) 18 (22%)
 Oral and insulin 8 (42%) 17 (21%)
Medication at FU 
 Aspirin n(%) 10 (53%( 27 (33%) 0.117
 ACE-inhibitors n(%) 9 (47%) 29 (36%) 0.350
 ARB  n(%) 5 (26%) 23  (29%) 0.856
 Statins n(%) 16 (84%) 58 (73%) 0.260
 Beta-blockers  n(%) 2 (11%) 6 (32%) 0.652
 Calcium-antagonists  n(%) 0 (0%) 13 (16%) 0.061
 Nitrates  n(%) 0 (0%) 1 (1%) 0.626
Serum markers at FU
 Total cholesterol(mmol/l) 4.3 ± 1.0 4.5 ± 1.0 0.469
 LDL(mmol/l) 2.6 ± 0.9 2.7 ± 0.9 0.653
 HDL(mmol/l) 1.2 ± 0.25 1.3 ± 1.2 0.435
 Cholesterol/HDL ratio 3.7 ± 1.2 3.7 ± 1.2 0.154
 Triglycerides(mmol/l) 1.9 ± 1.7 1.9 ± 1.0 0.435
 Abbreviations and definitions as in Table 1.
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difference was not statistically different.  In patients presenting with progression of 
ischemia, obstructive CAD occurred more often (35% vs. 24%, P=0.546) and CAC 
scores were slightly higher (16 (IQR 0-81) vs. 4 (IQR 0-112), P=0.408), but these 
differences were also not significant.
Discussion
The present study demonstrated a low rate of progression of ischemia after 2 years 
in high risk patients with diabetes without cardiac symptoms. Moreover, no relation 
between atherosclerosis parameters on CTA and changes of ischemia was observed.  
Previous studies have investigated the role of screening with SPECT MPI for silent 
ischemia in asymptomatic diabetic patients.17 Most importantly, in the Detection of 
Ischemia in Asymptomatic Diabetics (DIAD) study, 1123 diabetic patients without 
any suspicion of CAD were randomized between screening with SPECT MPI and no 
screening.18 Of the 522 patients who underwent SPECT MPI, 133 (22%) presented 
with an abnormal study, the majority (73%) of which were regional perfusion abnor-
malities.9 Except for gender, diabetes duration and heart rate response to Valsalva 
(performed as part of cardiac autonomic function testing), no clinical characteristics 
or laboratory markers could accurately predict the presence of silent ischemia in these 
patients.  Second, Lorenzo et al. included 180 asymptomatic diabetic patients who 
underwent SPECT MPI and were followed for a mean period of 36 months.19 In total, 
46 patients (26%) of the patients presented with an abnormal MPI. No differences in 
characteristics were observed between patients with and without myocardial isch-
emia. However, at present only one study has focused on progression of ischemia in 
these patients. In DIAD-2, 358 of the initial 522 patients underwent a second SPECT 
MPI study to evaluate the change in myocardial perfusion after a 3 year interval.9 
Similar to the present study, of the 71 (20%) patients who presented with an abnormal 
SPECT MPI study at baseline, 56 (79%) showed resolution of ischemia after 3 years, 
whereas only a limited number of patients (10%) with a normal baseline examination 
presented with new ischemia. Likely this resolution of ischemia was caused by inten-
sified medical therapy after recommendations in the American Diabetes Association 
(ADA) guidelines.20 Similarly, in the present report medical therapy was intensified at 
follow-up. However, no relation between added anti-anginal medication and isch-
emia progression could be established. Comparable to the present report, in DIAD-2 
the value of clinical characteristics to predict the risk of new ischemia was limited. 
Only peripheral vessel disease (PVD) and elevated LDL-cholesterol levels where as-
sociated with new onset of ischemia. 
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Presumably, the relative low rate of progression of ischemia is caused by accurate 
medical therapy. If these diabetic patients are treated according guidelines based on 
the outcomes of testing, the clinical follow-up is prosperous. It seems that medical 
treatment outweighs the potential negative effect of other clinical characteristics. It 
would however have been unethical to refrain patients from appropriate medical 
therapy. 
In the present report, there was no significant difference between the median 
CAC score in patients with and without baseline ischemia. In contrast, Anand et al. 
showed a significant association between the CAC score and myocardial ischemia in 
510 asymptomatic diabetic patients.21  MPI was performed in all patients with a CAC 
score >100 and in a random sample of patients with a CAC score ≤100. The CAC 
score was significantly associated with the presence of myocardial ischemia. Of 
particular interest, all patients with a CAC score ≤10 presented with a normal SPECT 
MPI. Furthermore, in the current report, no correlation was demonstrated between 
coronary atherosclerosis parameters of the extent, severity or composition of coronary 
atherosclerosis on CTA and baseline ischemia on SPECT MPI. Indeed, several studies 
have previously demonstrated the limited correlation between the coronary stenosis 
severity on CTA and ischemia on SPECT MPI, both in patients with stable angina and 
asymptomatic diabetic patients.11, 22  However, for the present study, it was hypoth-
esized that CTA could be able to identify different coronary atherosclerotic plaque 
characteristics which could predict changes in myocardial ischemia on SPECT MPI. 
The relation between coronary plaque type and the presence of myocardial ischemia 
has previously been studied.23-25 Lin et al. included 163 low-to-intermediate risk 
symptomatic patients who underwent both CTA and SPECT MPI.25 Besides stenosis 
severity, mixed plaque was significantly associated with the presence of myocardial 
ischemia. Moreover, van Velzen et al. evaluated 514 patients with SPECT MPI and 
coronary CTA.23 The presence of mixed or calcified plaque independently predicted 
myocardial ischemia. In contrast, Bauer et al. focused on the relation between non-
calcified CAD on CTA and myocardial ischemia in 72 patients.24 It was demonstrated 
that coronary arteries with a perfusion defect in the corresponding vascular territory 
had significantly larger non-calcified plaque volumes, but there was no difference 
in calcified plaque volume. The underlying pathophysiological relation between 
coronary plaque composition and myocardial ischemia is unknown. Possible, mixed 
plaques with a relatively large plaque burden are prone to rupture, causing myocardial 
ischemia, whereas the more advanced stage of calcified plaque is relatively stable. 
Especially in a patient without baseline ischemia, rupture of a hemodynamically non-
significant plaque could cause onset of ischemia. However, the relation between CTA 
atherosclerosis parameters and progression of atherosclerosis has not been described 
earlier. Moreover, in the present study, no association could be established between 
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CTA coronary atherosclerosis and changes in myocardial ischemia. There was no 
significant difference in the different plaque types between patients with and without 
onset of new ischemia or progression of ischemia. Nor could a difference in the 
presence of non-obstructive CAD between both patient groups be established. More-
over, the CAC score was similar in both groups. The relative disagreement between 
atherosclerosis on CTA and ischemia on SPECT MPI could be caused by the fact that 
the two different modalities evaluate different manifestations of CAD. CTA only al-
lows assessment of coronary artery stenosis in the major epicardial coronary arteries. 
On the other hand, SPECT MPI visualizes perfusion defects which could be caused by 
either stenosis in a major epicardial coronary artery and/or by microvascular disease 
and endothelial dysfunction. However, it is well known that especially in diabetic 
patients, microvascular disease plays an important role in the onset of myocardial 
ischemia.6 
Limitations 
Some limitations need to be considered. First, a limited number of patients is in-
cluded. Second, patients who underwent revascularization were excluded, which 
may have affected results. And furthermore, additional SPECT parameters such as left 
ventricular ejection fraction, transient ischemic dilatation or ECG abnormalities were 
not incorporated in the current analysis.
Conclusions
The rate of progression of ischemia in high risk patients with diabetes without 
cardiac symptoms is limited. Few patients presented with new ischemia, whereas 
some patients show resolution of ischemia. Atherosclerosis parameters on CTA were 
not predictive of new onset ischemia or progression of ischemia.  Neither baseline 
characteristics, CAC score nor atherosclerosis parameters on CTA were predictive of 
the onset of new ischemia or were correlated with progression of ischemia. 
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Purpose: Diabetic patients with coronary artery disease (CAD) are often free of chest 
pain syndrome. A useful modality for non-invasive assessment of CAD is coronary 
computed tomography angiography (CTA). However, the prognostic value of CAD on 
coronary CTA in diabetic patients without chest pain syndrome is relatively unknown. 
Therefore, the aim was to investigate the long term prognostic value of coronary CTA 
in a large population diabetic patients without chest pain syndrome. 
Methods: Between 2005 and 2013, 525 diabetic patients without chest pain syn-
drome were prospectively included to undergo coronary artery calcium (CAC)-scoring 
followed by coronary CTA. During follow-up the composite endpoint of all-cause 
mortality, non-fatal myocardial infarction (MI) and late revascularization (>90 days) 
was registered. 
Results: In total, CAC-scoring was performed in 410 patients and coronary CTA in 
444 patients (431 interpretable). After median follow-up of 5.0(IQR 2.7-6.5) years 
the composite endpoint occurred in 65(14%) patients. Coronary CTA demonstrated a 
high prevalence of CAD (85%), mostly non-obstructive CAD (51%). Furthermore, pa-
tients with a normal CTA had an excellent prognosis (event-rate 3%). An incremental 
increase in event-rate was observed with increasing CAC-risk category or coronary 
stenosis severity. Finally, obstructive (50-70%) or severe CAD (>70%) was indepen-
dently predictive of events (HR=11.10[2.52;48.79](P=0.001), HR=15.16[3.01;76.36]
(P=0.001)). Obstructive (50-70%) or severe CAD (>70%) provided increased value 
over baseline risk factors.
Conclusion: Coronary CTA provided prognostic value in diabetic patients without 
chest pain syndrome. Most importantly, the prognosis of patients with a normal CTA 
was excellent.
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Introduction
Diabetes mellitus (DM) is a major and rapidly growing global health problem. In 
2013 DM was responsible for 8.4% of all-cause mortality in patients between 20-
79 years old and 10.8% of total health expenditure worldwide.1  Cardiovascular 
complications are the leading cause of mortality in diabetic patients.2 Accordingly, 
the European Society of Cardiology (ESC) classifies patients with DM as high risk for 
coronary artery disease (CAD).3 However, not all patients with DM have CAD and 
also diabetic patients with CAD are often free of chest pain syndrome.4 Coronary 
computed tomography angiography (CTA) is a useful modality for non-invasive as-
sessment of CAD.  Indeed, in diabetic patients without chest pain syndrome a high 
prevalence of CAD is present on coronary CTA.5-7 Potentially CTA could be used to 
risk stratify DM patients. However, the prognostic value of CAD on coronary CTA in 
these patients is relatively unknown. As a consequence, the value of coronary CTA for 
risk stratification of these patients is unestablished.8, 9 Therefore, the aim of this study 
is to investigate the long term prognostic value of coronary CTA in a large population 
of diabetic patients without chest pain syndrome.
Methods
Patients
The study population consisted of 525 diabetic patients without chest pain syn-
drome, referred from an outpatient diabetic clinic for assessment of cardiovascular 
risk between May 2005 and August 2013. The cardiovascular assessment include 
coronary artery  calcium (CAC) score and CTA to evaluate the presence and severity 
of CAD.5, 10 After enrolment in the prospective clinical registry, patients underwent 
a non-contrast CT for CAC-scoring followed by a contrast coronary CTA. Inclusion 
criteria consisted of confirmed diagnosis of DM type 1 or 2 (fasting plasma glucose 
level ≥126 mg/dL, use of oral glucose lowering medication or insulin) and absence of 
chest pain syndrome.11 Exclusion criteria were known or suspected coronary artery 
disease (CAD), previous coronary revascularization, cardiac arrhythmias, pregnancy 
and contraindications for the use of iodinated contrast media. 
Clinical data were prospectively entered into the departmental Cardiology Informa-
tion System (EPD-Vision©, Leiden University Medical Center, the Netherlands) and 
retrospectively analyzed. The Institutional Review Board of the Leiden University 
Medical Center approved this evaluation of clinically collected data, and waived the 




Patients were scanned using a 64-slice or 320-row multidetector scanner (64-slice: 
Aquillon 64, Toshiba Medical Systems, Otawara, Japan; 320-row: Aquillon ONE, 
Toshiba Medical System, Otawara, Japan). Scan-protocol was followed as previously 
described.12, 13 Post-processing of scans was performed with application of dedicated 
software (Vitrea FX 1.0, Vital Images, Minnetonka, MN, USA). Uninterpretable scans 
were excluded from the analysis.
CAC-scoring
CAC-scoring was performed according to the algorithm of Agatston. CAC-score was 
stratified into four risk categories: 0, 1-99, 100-399, ≥400.12 
Coronary CTA
All coronary CTAs were analysed by consensus of experienced observers according 
to the modified 17 segments American Heart Association (AHA) classification. 
First, each segment was assessed for interpretability. Segments were defined as 
uninterpretable in case of severe motion artefacts or low contrast resolution. Ad-
ditionally, segments with a diameter ≤1.5 mm were excluded.5 Second, interpretable 
segments were evaluated for stenosis. Stenosis was stratified into four categories: nor-
mal if no plaques were present on CTA, non-obstructive if the plaque covered <50%, 
obstructive if the plaque covered 50-70%, severe if the plaque covered >70% of the 
coronary artery lumen. If plaque was present, plaque composition was determined 
(calcified, mixed, and non-calcified). One type of plaque composition was assigned 
per segment. 
Follow-up
Follow-up data were retrospectively gathered by review of electronic medical re-
cords, blinded from CTA results, between December 2013 and February 2014, both 
the medical records of the department of cardiology and of the referring outpatient 
diabetic clinic have been analysed. Three endpoints were registered: all-cause mor-
tality, non-fatal myocardial infarction (MI), late revascularization. Non-fatal MI was 
defined based on criteria of typical chest pain, elevated cardiac enzyme levels and 
typical changes on the ECG.14 Late revascularization was defined as percutaneous 
coronary intervention (PCI) or coronary artery bypass grafting (CABG) after 90 days of 
scan acquisition.15 All revascularization procedures within 90 days were considered 
coronary CTA-driven. For the analysis a composite endpoint was constructed of all 
three endpoints.
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Statistical analysis
All continuous data (normally distributed, non-normally distributed) are presented 
as mean ±SD for reasons of uniformity. Categorical data are presented as absolute 
numbers and percentages. 
First, baseline characteristics were compared between patients with and without 
obstructive CAD (≥50%), similarly between patients with and without events. Second, 
results of both CAC-scoring and coronary CTA were compared between patients with 
and without events. Third, survival analyses were performed by the Kaplan-Meier 
method. Cumulative event rates for CAC-score and coronary stenosis were obtained 
by this method, using the composite endpoint. Note that these survival analyses were 
crude, because no corrections for baseline characteristics were performed. Fourth, 
the independent prognostic value of baseline characteristics, CAC-scoring and coro-
nary CTA was assessed. For this purpose univariate and multivariate Cox-regression 
analyses were performed. To avoid over fitting of the model a selection of univariate 
significant variables was entered into the multivariate model. 
All statistical tests were two-sided. Comparisons between groups were performed 
with the Independent-Samples T test or Mann-Whitney U test for continuous data and 
the χ2 test for categorical data. Comparisons of Kaplan-Meier curves were performed 
with the Log-Rank test. To compare the model fit of the multivariate Cox-regression 
models for CTA and CAC-score the -2 log likelihood was used. However, it should be 
noted that for non-nested models (i.e Model 2 vs Model 4), this only provides a crude 
comparison for which no P-values could be calculated. All statistical analyses were 
performed with SPSS software (Version 22.0, SPSS IBM Corp., Armonk, New York). A 
P-value <0.05 was considered statistically significant.
Results
Patients
The study population consisted of 525 patients. As depicted in Figure 1, 76(14%) 
patients were excluded from this analysis because of logistical reasons (i.e. patients 
who did not attend appointment). The results of 449 patients were available for the 
present analysis: 405 patients underwent both CAC-scoring and coronary CTA, 5 
patients underwent only CAC-scoring, 39 patients underwent only coronary CTA. In 
total, CAC-scoring was performed in 410 patients and coronary CTA in 444 patients. 
Mean age was 54±11 years, 265(59%) patients were male and median DM duration 










Only coronary CTA 
n=39 
 Both CAC-score + coronary CTA  
n=405 
No scans performed 
 because of logistical reasons 
n=76 
Figure 1. Flowchart of the study population.
Table 1. Baseline characteristics stratified according to coronary CTA results and events.












Age(years) 54±11 60±9 50±11 <0.001 59±10 53±11 <0.001
Male n(%) 265(59%) 101(69%) 154(54%) 0.004 47(72%) 218(57%) 0.018
BMI(kg/m2) 28.6±5.7 28.5±5.0 28.5±6.0 0.942 28.7±5.3 28.6±5.8 0.912
Hypertension† n(%) 145(33%) 65(44%) 72(26%) <0.001 28(43%) 117(31%) 0.051
Hypercholesterolemia‡ 
n(%)
162(36%) 68(46%) 85(30%) 0.001 33(51%) 129(34%) 0.009
Family history of CAD* 
n(%)
190(43%) 60(41%) 125(45%) 0.448 29(45%) 161(42%) 0.735
Smoker n(%) 101(23%) 41(28%) 59(21%) 0.114 23(35%) 78(21%) 0.008
DM-related risk factors



















NGSP (%) 7.8±1.5 7.9±1.6 7.7±1.5 0.211 8.0±1.7 7.7±1.5 0.287
IFCC (mmol/mol) 62±16 63±18 61±16 0.211 64±19 61±16 0.287
Serum creatinine 78±19 82±19 76±19 0.002 83±21 77±18 0.012




PVD n(%) 20(5%) 12(8%) 7(3%) 7(11%) 13(3%)
PNP n(%) 97(22%) 41(28%) 50(18%) 20(31%) 77(20%)
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Events
The composite endpoint of all-cause mortality, non-fatal MI and late revascularization 
occurred in 65(14%) patients. All-cause mortality occurred in 13(3%) patients and 
late revascularization in 52(12%) patients (PCI: 30 patients, CABG: 22 patients). Of 
the 52 patients who underwent revascularization, 27(52%) patients were referred to 
invasive coronary angiography because of new-onset angina, 20 (38%) patients had 
documented ischemia on a SPECT myocardial perfusion imaging (MPI) performed 
after CTA and 5 (10%) patients presented with new ischemia on SPECT MPI during 
follow up. Non-fatal MI did not occur. Early revascularization, which was excluded 
from the composite endpoint, occurred in 16(4%) patients (PCI: 13 patients, CABG: 
Table 1. (Continued)












PVD and PNP n(%) 26(6%) 14(10%) 12(4%) 6(9%) 20(5%)
DM-related treatment 0.578 0.083
Oral 131(29%) 47(32%) 79(28%) 21(32%) 110(29%)
Insulin 170(38%) 50(34%) 116(41%) 18(28%) 152(40%)
Oral and insulin 99(22%) 33(22%) 58(20%) 21(32%) 78(20%)
Medication 
Aspirin n(%) 99(22%) 47(32%) 46(16%) <0.001 27(42%) 72(19%) <0.001
ACE-inhibitors n(%) 155(35%) 73(50%) 73(26%) <0.001 34(52%) 121(32%) 0.001
ARB n(%) 36(8%) 10(7%) 25(9%) 0.464 6(9%) 30(8%) 0.715
Statins n(%) 248(56%) 97(66%) 138(49%) 0.001 45(69%) 203(53%) 0.018














LDL(mmol/l) 2.9±1.0 2.8±1.1 2.9±1.0 0.503 3.0±1.1 2.8±1.0 0.176
HDL(mmol/l) 1.4±0.5 1.4±0.5 1.5±0.5 0.062 1.4±0.5 1.4±0.5 0.729
Cholesterol/HDL ratio 3.6±1.5 3.7±1.4 3.6±1.6 0.594 3.8±1.3 3.6±1.5 0.310
Triglycerides(mmol/l) 1.7±1.2 1.7±1.1 1.6±1.2 0.462 1.8±1.2 1.6±1.1 0.262
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body 
mass index, CAD, coronary artery disease; DM, diabetes mellitus; eGFR, estimated glomerular filtra-
tion rate; HDL, high density lipoprotein; IFCC, International Federation of Clinical Chemistry; LDL, low 
density lipoprotein; MDRD, Modification of Diet in Renal Disease; NGSP, National Glycohemoglobin 
Standardization Program; PNP, polyneuropathy;  PVD, peripheral vessel disease.
Definitions: † Blood pressure ≥140/90 mmHg or treatment with antihypertensive medication; ‡ total 
cholesterol level >5.0mmol/L or use of cholesterol lowering medication; * presence of coronary artery 
disease in first-degree family members at age <55 years in men and <65 years in women.
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3 patients). Median follow-up was 5.0(IQR 2.7-6.5) years.  No patients were lost to 
follow-up.
Patients with events demonstrated a higher mean age (59±10 vs. 53±11(P<0.001)) 
and number of males (47(72%) vs. 218(57%)(P=0.018)) compared to patients without 
events. Furthermore, hypercholesterolemia (33(51%) vs. 129(34%)(P=0.009)), smoker 
(23(35%) vs. 78(21%)(P=0.008)) and overall DM-related complications (P=0.002) 
were more frequently observed in this group (Table 1). 
CAC-scoring
CAC-scoring was performed in 410 patients. Median CAC-score was 29(IQR 0-294). 
The distribution within the CAC-risk categories was as follows: CAC-score=0 in 
144(35%) patients, CAC-score=1-99 in 106(26%) patients, CAC-score=100-399 in 
67(16%) patients, CAC-score≥400 in 93(23%) patients. In total, CAC-score=0 and 
CAC-score≥1 were observed in respectively 35% and 65% of patients (Table 2). 
The results of CAC-scoring, stratified according to events, are depicted in Table 2. 
Patients with events demonstrated a higher median CAC-score compared to patients 
without events (543(IQR 141-1310) vs. 13(IQR 0-177)(P<0.001)). Moreover, patients 
with events were more often classified in a higher CAC-risk category (P<0.001).
Coronary CTA
Coronary CTA was performed in 444 patients, of which 13 were uninterpretable. 
The remaining results of 431 patients were used for the present analysis. A high 
prevalence of CAD (85%) was demonstrated on coronary CTA: non-obstructive CAD 
(<50%) in 219(51%) patients, obstructive CAD (50-70%) in 117(27%) patients, severe 
CAD (>70%) in 30(7%) patients. A normal CTA was observed in 65(15%) patients 
(Table 2).
The baseline characteristics, stratified according to coronary CTA results, are de-
picted in Table 1. Patients with obstructive CAD (≥50%) demonstrated a higher mean 
age (60±9 vs. 50±11(P<0.001)), number of males (101(69%) vs. 154(54%)(P=0.004)) 
and median diabetes duration (15(IQR 9-24) vs. 10(IQR 5-20)(P<0.001)) compared to 
patients with no or non-obstructive CAD (<50%). Furthermore, hypertension (65(44%) 
vs. 72(26%)(P<0.001)), hypercholesterolemia (68(46%) vs. 85(30%)(P=0.001)) and 
overall DM-related complications (P<0.001) were more frequently observed in this 
group. 
The results of coronary CTA, stratified according to events, are depicted in Table 2. 
Patients with events presented with more severe coronary stenosis compared to 
patients without events (P<0.001). Moreover, a higher mean number of plaques 
(9.7±4.4 vs. 7.7±5.7(P=0.002)), mean number of obstructive lesions (2.8±2.8 vs. 
0.6±1.4(P<0.001)) and mean number of severe lesions (0.3±0.8 vs. 0.1±0.4(P=0.009)) 
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were observed in this group. In addition, a higher mean number of calcified lesions 
(2.6±3.5 vs. 0.8±1.8(P<0.001)) and mixed lesions (3.0±3.0 vs.1.3±2.1(P<0.001)) 
were present in patients with events.
Kaplan-Meier analysis
The results of the Kaplan-Meier survival analyses, stratified according to CAC-score, 
are depicted in Figure 2 Panel A and B. Crude event-rate was lower in patients with 
CAC-score=0 compared to patients with CAC-score≥1 (5/144(3%) vs. 54/266(20%)
















CAC-score=0 144(35%) 5(9%) 139(40%)
CAC-score=1-99 106(26%) 7(12%) 99(28%)
CAC-score=100-399 67(16%) 12(20%) 55(16%)









No. of patients with normal CTA 
n(%) 65(15%) 2(3%) 63(17%)
No. of patients with non-obstructive 
CAD (<50%) n(%) 219(51%) 11(17%) 208(57%)
No. of patients with obstructive CAD 
(50-70%) n(%) 117(27%) 39(61%) 78(21%)
No. of patients with severe CAD 
(>70%) n(%) 30(7%) 12(19%) 18(5%)
Coronary plaques (stenosis)
No. of plaques 8.0±5.6 9.7±4.4 7.7±5.7 0.002
No. of non-obstructive lesions 7.0±5.3 6.9±4.1 7.1±5.4 0.724
No. of obstructive lesions 1.0±1.9 2.8±2.8 0.6±1.4 <0.001
No. of severe lesions 0.1±0.5 0.3±0.8 0.1±0.4 0.009
Coronary plaques (composition)
No. of calcified lesions 1.1± 2.2 2.6±3.5 0.8±1.8 <0.001
No. of mixed lesions 1.5±2.4 3.0±3.0 1.3±2.1 <0.001
No. of non-calcified lesions 0.9±1.5 1.3±2.2 0.8±1.4 0.067
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Figure 2. Kaplan-Meier curves for the composite endpoint (all-cause mortality, non-fatal MI, late re-
vascularization) according to CAC-score and coronary stenosis.
Panel A: event-free survival difference between patients with CAC-score=0 and CAC-score≥1  Pan-
el B: event-free survival difference between patients with CAC-score=0, CAC-score=1-99, CAC-
score=100-399 and CAC-score≥400  Panel C: event-free survival difference between patients with no 
or non-obstructive CAD (<50%) and obstructive CAD (≥50%). Panel D: event-free survival difference 




(P<0.001)) (Panel A). Additionally, an incremental increase in event-rate was observed 
with increasing CAC-risk category: 5/144(3%) for CAC-score=0, 7/106(7%) for CAC-
score=1-99, 12/67(18%) for CAC-score=100-399, 35/93(38%) for CAC-score≥400 
(P<0.001). Thus, event-rate was highest in patients with CAC-score≥400 (Panel B).
The results of the Kaplan-Meier survival analyses, stratified according to coronary 
stenosis, are depicted in Figure 2 Panel C and D. Crude event-rate was lower in pa-
tients with no or non-obstructive CAD (<50%) compared to patients with obstructive 
CAD (≥50%) (13/284(5%) vs. 51/147(35%)(P<0.001)) (Panel C). An excellent prog-
nosis was observed in patients with a normal CTA (event-rate 2/65(3%)). Of note, the 
2 patients with a normal CTA presented with complications not related to diabetes 
and died of a (presumably) non-cardiac course. Additionally, an incremental increase 
in event-rate was observed with increasing coronary stenosis severity: 11/219(5%) 
for non-obstructive CAD (<50%), 39/117(33%) for obstructive CAD (50-70%), 
12/30(40%) for severe CAD (>70%) (P<0.001). Event-rate was highest in patients 
with severe CAD (>70%) (Panel D). 
Cox-regression analysis
The results of univariate Cox-regression analyses for the prediction of events are de-
picted in Table 3 and Table 4. CAC-score≥100, obstructive (50-70%) or severe CAD 
(>70%), total number of plaques, number of plaques stratified to stenosis (obstructive, 
severe) and number of plaques stratified to plaque composition (calcified, mixed, 
non-calcified) were all significant univariate predictors of the composite endpoint 
(Table 4). 
The results of the multivariate Cox-regression analyses for the prediction of events 
are depicted in Table 5. To avoid over fitting of the model (limited number of events, 
n=65) only a selection of the univariate significant variables was entered into the mul-
tivariate model (i.e. age, male gender, smoker, CAC-risk category, coronary stenosis 
grade). The variable smoker was selected over hypertension and hypercholesterolemia, 
assuming it correlated less with age and male gender. Moreover, replacing smoking 
with either hypertension or hypercholesterolemia did not have a strong influence 
on the results. In the multivariate analyses, corrected for the selected baseline vari-
ables (Model 2), CAC-score≥100 was independently predictive of events. Moreover, 
CAC-score≥400 provided incremental prognostic value over CAC-score=100-399 
(HR=12.52[95%CI 4.29;36.54](P<0.001) vs. HR=5.13[95%CI 1.68;15.60](P=0.004)). 
Accordingly, obstructive (50-70%) or severe CAD (>70%) remained an independent 
predictor of events. The presence of severe CAD (>70%) provided incremental 
prognostic value over obstructive CAD (50-70%) (HR=15.16[95%CI 3.01;76.36]
(P=0.001) vs. HR=11.10[95%CI 2.52;48.79](P=0.001)).  Adding the CTA results tot 
Model 2 (including baseline variables and CAC-score) resulted in a significant change 
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in -2 log likelihood (17.60, P 0.001) (Model 3). Moreover, adding the CTA results to 
the baseline model resulted in a larger increase in the -2 log likelihood compared to 
the adding of the CAC-score (43.78 vs. 36.30) (Model 4). 









Family history of CAD 0.95[0.58;1.56] 0.846
Smoker 1.98[1.19;3.30] 0.008
DM-related risk factors
DM type 2 1.58[0.87;2.85] 0.132















Beta-blockers  2.29[1.20;4.39] 0.012
Calcium-antagonists 3.94[1.70;9.14] 0.001
Serum markers
Total cholesterol 1.23[0.99;1.54] 0.067
LDL 1.13[0.89;1.43] 0.317
HDL 0.92[0.55;1.54] 0.756
Cholesterol/HDL ratio 1.06[0.93;1.22] 0.364
Triglycerides 1.09[0.91;1.31] 0.364




The present study assessed the long term prognostic value of coronary CTA in a large 
prospective registry of diabetic patients without chest pain syndrome. Coronary 
CTA demonstrated high prevalence of CAD (85%), mostly non-obstructive. Most 
importantly, patients with a normal CTA had an excellent prognosis. Furthermore, an 
incremental increase in event-rate was observed with increasing coronary stenosis 
severity. Finally, obstructive (50-70%) or severe CAD (>70%) was independently 
predictive of events, with increased value over baseline risk factors (i.e. age, male 
gender, smoker). Moreover, the CAC-score demonstrated a similar independent 
predictive value for the occurrence of events. However,  the model including CTA 
performed better than the model with CAC-score, and CTA provided some additional 
value over the CAC-score. Although it should be noted that this was a crude analysis 













Coronary stenosis Overall <0.001
Normal CTA Ref. category
Non-obstructive CAD (<50%) 1.92[0.43;8.67] 0.397
Obstructive CAD (50-70%) 16.18[3.90;67.21] <0.001
Severe CAD (>70%) 29.03[6.40;131.73] <0.001
Coronary plaques (stenosis) 
No. of plaques 1.09[1.04;1.14] <0.001
No. of non-obstructive lesions 1.02[0.98;1.07] 0.375
No. of obstructive lesions 1.40[1.31;1.51] <0.001
No. of severe lesions 2.42[1.77;3.30] <0.001
Coronary plaques (composition)
No. of calcified lesions 1.22[1.14;1.30] <0.001
No. of mixed lesions 1.24[1.16;1.33] <0.001
No. of non-calcified lesions 1.17[1.04;1.31] 0.007
Abbreviations and definitions as in Table 2
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and that the present study was not designed to assess the difference in performance 
between CTA and CAC-score. 
CAC-score
Previous studies widely established the prevalence of CAC in diabetic patients 
without chest pain syndrome.16-18 The present study assessed the prognostic value of 
CAC by demonstrating CAC-score≥100 as independent predictor of events in diabetic 
patients without chest pain syndrome. Prior to our study, Raggi et al. investigated the 
prognostic value of CAC-scoring for all-cause mortality in asymptomatic individu-
als.19 In this study 10377 asymptomatic individuals were prospectively included to 
undergo electron beam computed tomography (EBCT): 903(9%) individuals with 
DM, 9474(91%) individuals without DM. This study, with mean follow-up of 5 years, 
demonstrated CAC as independent predictor of all-cause mortality in both diabetic 
and non-diabetic asymptomatic individuals. Moreover, Anand et al. investigated the 
prognostic value of EBCT for short term events in 510 asymptomatic patients with 
DM type 2.20 This study, with median follow-up of 2.2 years, demonstrated CAC-
score≥100 as independent predictor of cardiac death, MI, acute coronary syndrome 
(ACS), late coronary revascularization (>60 days after EBCT) and non-haemorrhagic 
stroke over established cardiovascular risk factors . Additionally, the PREDICT (pro-
spective evaluation of diabetic ischemic disease by computed tomography) study 
investigated the prognostic value of EBCT for cardiovascular events in 589 asymp-
tomatic patients with DM type 2.21 Cardiovascular events, which were defined as 
death due to MI or other cardiovascular causes, non-fatal MI, unstable angina, other 
objective evidence of CAD and stroke, occurred in 66(11%) patients after median 
follow-up of 4 years. In the multivariate analyses CAC-score≥101 was independently 
predictive of cardiovascular events. These findings were in line with the present study. 
Moreover, similar to the present study, incremental prognostic value was provided 
with increasing CAC-risk category. 
Coronary stenosis on CTA 
Several large cohort studies assessed the prevalence of CAD in the specific setting of 
diabetic patients without chest pain syndrome.6, 17, 22, 23  Similar to the present study, 
in these studies the majority of asymptomatic diabetic patients presented with CAD 
on coronary CTA (64-93 %). Accordingly, non-obstructive CAD (<50%) was most 
frequently observed (44-64%), whereas obstructive CAD (≥50%) was less prevalent 
(17-29%). 
Only a few studies assessed the prognostic value of coronary CTA in diabetic 
patients without chest pain syndrome.15, 22, 24 From the CONFIRM (coronary CT 
angiography evaluation for clinical outcomes: an international multicentre) registry 
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of 27125 patients, Min et al. selected 400 asymptomatic diabetic patients who under-
went coronary CTA.15 The prognostic value of CTA was investigated using the same 
composite endpoint as in the present study. Events occurred in 33(8%) patients after 
mean follow-up of 2.4±1.1 years: all-cause mortality in 13(3%) patients, non-fatal 
MI in 8(2%) patients, late revascularization in 12(3%) patients. In the multivariate 
analyses, corrected for selected variables (i.e. age, male gender, CAC-score), maximal 
stenosis severity, number of vessels with obstructive CAD (≥50%) and segment steno-
sis score (a marker of overall atherosclerosis extent) were independently predictive 
of events. Indeed, obstructive (50-70%) or severe (>70%) CAD provided prognostic 
value in the present study. Also Faustino et al. investigated the prognostic value of 
coronary CTA for cardiovascular events in 85 asymptomatic patients with DM type 
2.24 Cardiovascular events occurred in 10(11.8%) patients after median follow-up of 
48(IQR 18-68) months: cardiovascular death in 2(2.4%) patients, unstable angina 
in 1(1.2%) patients, stroke 7(8.4%) in patients. In the multivariate analyses, cor-
rected for univariate significant variables, absence of obstructive CAD (≥50%) was 
independently protective of events. Indeed, no or non-obstructive CAD (<50%) was 
not associated with increased risk for events in the present study. Most importantly, 
patients with a normal CTA had an excellent prognosis. Last, Park et al. investigated 
the prognostic value of coronary CTA for cardiovascular events in 557 asymptomatic 
Korean patients with DM type 2.22 Cardiovascular events were defined as cardiovas-
cular death, non-fatal MI, ACS requiring hospitalization and late revascularization (>6 
months after coronary CTA). More cardiovascular events and lower 3 year event-free 
survival rates were observed in patients with obstructive CAD (≥50%) compared to 
patients without obstructive CAD (<50%). Accordingly, in the present study a higher 
crude event-rate was observed in patients with obstructive CAD (≥50%) compared to 
patients with no or non-obstructive CAD (<50%). 
Coronary plaque composition on CTA
Multiple studies assessed plaque composition on coronary CTA in diabetic patients 
without chest pain syndrome. Comparable to the present study, the majority of these 
studies described an increased prevalence of mixed lesions in asymptomatic diabetic 
patients.6, 17, 25
The prognostic value of coronary plaque composition on coronary CTA for cardio-
vascular events in the specific setting of diabetic patients without chest pain syndrome 
has not been previously established. The present study demonstrated all coronary 
plaque compositions (calcified, mixed, non-calcified) as univariate significant predic-
tors of events. The prognostic value of calcified and mixed lesions was highest. These 
findings suggest an independent association between plaque composition and events. 
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However, the role of coronary plaque composition remains controversial. Gaem-
perli et al. demonstrated the prognostic value of coronary plaque composition in 220 
symptomatic patients.26  In contrast to the present study, mixed and non-calcified 
demonstrated highest predictive value for events. On the other hand, in the CONFIRM 
registry, including both symptomatic and asymptomatic patients with and without 
DM, calcified and mixed plaque provided the strongest predictive value.27 Further 
research is needed to understand the underlying pathophysiological mechanism of 
the different coronary plaque compositions. 
Single positron Emission Tomography (SPECT) Myocardial perfusion 
imaging (MPI)
The role of SPECT MPI for screening for silent ischemia in asymptomatic diabetic 
patients has been previously addressed.28, 29 Anand et al. included 510 asymptomatic 
diabetic patients of whom 180 patients underwent SPECT MPI.29 In those patients, 
the event-rate was significantly increased with increasing ischemic burden on SPECT 
MPI demonstrating the value for risk stratification. The most important study in this 
field was the DIAD (detection of Ischemia in Asymptomatic Diabetics) study.28 In this 
randomized controlled trial 1123 asymptomatic diabetic participants were random-
ized to SPECT MPI or no screening. After a mean follow-up of 4.8 years the incidence 
of cardiac events was higher in patients with significant MPI abnormalities. However, 
there was no significant prognostic benefit of screening. 
Clinical implications
The present observations demonstrate the prognostic value of CTA in diabetic patients 
without chest pain syndrome. Recent ESC guidelines indicate patients with DM as 
high risk for CAD (or very high risk if  ≥1 cardiovascular risk factor was present) 
irrespective of chest pain symptoms. Indeed, in the present study a great majority 
of patients presented with CAD on coronary CTA and the presence of obstructive 
(50-70%) or severe CAD (>70%) was associated with an impaired prognosis. Still, 
CAD was ruled-out in 15% of patients based on a normal CTA. Most importantly, the 
prognosis of these patients was excellent. 
The value of screening for CAD in high risk diabetic patients without chest pain 
syndrome was recently addressed by Muhlestein et al.30 In this trial, 900 asymp-
tomatic patients were randomized to CAD screening using coronary CTA or optimal 
medical treatment (OMT). The trial demonstrated no survival benefit from screening 
with coronary CTA. Therefore, this study does not support screening in all diabetic 
patients. Similarly, the American Diabetes Association position statement on cardio-
vascular disease and risk management only recommend screening using advanced 
cardiac testing in patients with cardiac symptoms or ECG abnormalities.31 However, 
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as also demonstrated in the present study, a large proportion of the patients had CAD 
on CTA and coronary CTA could identify patients with excellent prognosis. This sup-
ports the need to enrich the screening population to a high risk population who will 
mostly benefit from screening using coronary CTA. Especially since coronary CTA 
may lead to radiation exposure and may result in unnecessary invasive testing such as 
coronary angiography and revascularization procedures.31 Potentially, coronary CTA 
can provide a pivotal role in tailored therapy in these diabetic patients. Patients with a 
normal CTA have an excellent prognosis and could be treated conservatively (OMT), 
whereas patients with an abnormal CTA may benefit from additional non-invasive or 
invasive evaluation.
Limitations
Several limitations of the present study need to be considered. First, the present study 
was a single centre study. Second, the composite event-rate was relatively low. As a 
consequence, the study was underpowered to include all baseline risk factors into 
the multivariate model. Second, the endpoint mainly consisted of late revasculariza-
tion, therefore conclusions regarding hard endpoints are not justified based on this 
study. We cannot  rule out that, despite the wide time interval,  some referral bias 
has occurred in the patients who underwent late revascularization.  Moreover, it is 
possible that events that have occurred in other medical centres were missed in the 
analysis. Third, coronary CTA only visualizes coronary atherosclerosis and provides 
no information on the hemodynamic significance of coronary stenosis. 
Conclusion
Coronary CTA provided prognostic value in a large prospective registry of diabetic 
patients without chest pain syndrome. Most importantly, the prognosis of patients 
with a normal CTA was excellent. In addition, an incremental increase in event-rate 
was observed with increasing CAC-risk category and coronary stenosis severity. The 
highest event rate was observed in patients with severe CAD (>70%). Both CAC-score 
and coronary stenosis severity were independently predictive of events, after correc-
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Prognostic value of CTA in DM patients
The aim of this thesis was to explore the value of coronary computed tomography 
angiography in clinical practice. Specifically, the thesis focuses on the feasibility of 
quantitative assessment of coronary atherosclerosis on CTA. Additionally, the clinical 
value of coronary CTA in the specific setting of high risk diabetic patients without 
chest pain syndrome was established.
The general introduction in Chapter 2 of this thesis discusses the evolving role of 
cardiac CT in the diagnosis of patients with suspected CAD. An overview is provided 
of the performance of cardiac CTA and CAC score in the specific setting of patients 
with stable angina and patients presenting with acute chest pain at the emergency 
department. Furthermore, novel applications as myocardial perfusion and CT derived 
fractional flow reserve are discussed. 
Part 1
Part 1 of this thesis established the value of quantitative assessment of coronary ath-
erosclerosis on coronary CTA in clinical practice.
Chapter 3 provides an overview of the different imaging modalities for quantita-
tive assessment of coronary atherosclerosis and progression of coronary plaque. The 
clinical value of progression of atherosclerosis and corresponding medical therapy 
is discussed.
The value of QCT to assess coronary plaque constitution is assessed in Chapter 4-6. 
For this purpose the QCT datasets were registered based on anatomical landmarks 
with IVUS VH as reference standard. 
In Chapter 4 the ability of QCT to assess coronary plaque composition was as-
sessed. For this purpose 57 patients who had undergone CTA prior to IVUS VH were 
included. QCT was performed in all patients. CTA plaque volume was differentiated 
in 4 different plaque types: necrotic core, dense calcium, fibrotic and fibro-fatty tissue. 
The same parameters were derived from IVUS VH and compared. The performance 
of two different approaches for tissue characterization was evaluated. The first used 
fixed Hounsfield unit (HU) cut-off values to different the different components. The 
second used a dynamic threshold model, for which the HU threshold were adapted 
to the lumen HU intensity.  The different plaque types on QCT were well-correlated 
with IVUS VH. The dynamic threshold approach performed better, compared to the 
fixed threshold approach, as demonstrated by more narrow limits of agreement on 
the Bland–Altman analyses. Based on these results it was concluded that automatic, 
quantitative CTA tissue characterization is feasible using a dedicated software tool. 
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The relation between coronary atherosclerosis on QCT as compared to IVUS VH 
is further explored in Chapter 5. A major limitation of IVUS VH is the inability of the 
echo signal to penetrate coronary calcium. As a result, tissue located in the acoustic 
shadow behind calcium is difficult to classify. Using a novel algorithm this shadow 
can be automatically detected and quantified. The quantified volumes were added to 
the total volume of calcium to compensate for the expected underestimation of cal-
cium by IVUS VH. Indeed, by applying the novel algorithm, the agreement between 
IVUS VH and QCT for the assessment of coronary calcium improved. 
In Chapter 6 the ability of QCT to assess the Agatston coronary artery calcium 
score (CAC) was investigated. For this purpose 100 patients, 20 patients for each CAC 
category (i.e. 0, 1–99, 100–399, 400–999,  ≥1,000), were randomly selected. The 
Agatston CAC score on non-contrast CT was calculated manually, while the novel 
algorithm was used to automatically detect and quantify Agatston CAC score in con-
trast CTA images. The resulting Agatston CAC scores were validated against the non-
contrast images. The automatically computed CAC score showed a high correlation 
and intra-class correlation with non-contrast CT CAC score. Moreover, agreement 
within the CAC categories was good. It was concluded that fully automatic detection 
of Agatston CAC score on contrast CTA is feasible and showed high correlation with 
the non-contrast CT CAC score. This could imply a radiation dose reduction and time 
saving by omitting the non-contrast scan.
Previous studies have demonstrated the disagreement between significant stenosis 
on CTA and ischemia on SPECT MPI. Potentially, QCT can improve the correlation 
between stenosis severity and the presence of ischemia. Therefore, the aim of Chapter 
7 was to evaluate the association between QCT parameters of coronary artery lesions 
and the presence of myocardial ischemia on gated myocardial perfusion SPECT. Forty 
patients were included with known or suspected coronary artery disease who had 
undergone CTA and gated myocardial perfusion SPECT within 6 months. From the 
CTA datasets, vessel-based and lesion-based visual analyses were performed. Con-
secutively, lesion-based QCT was performed to assess plaque length, plaque burden, 
percentage lumen area stenosis and remodelling index. Subsequently, the presence 
of myocardial ischemia was assessed using the summed difference score (SDS ≥2) 
on gated myocardial perfusion SPECT. Myocardial ischemia was seen in 25 patients 
(62.5%) in 37 vascular territories. Coronary lesion length and quantitatively assessed 
significant stenosis were independently associated with myocardial ischemia. Both 
quantitative parameters had incremental value over baseline variables and traditional 
visual assessment of significant stenosis. It was concluded that QCT can possibly en-
hance assessment of CAD, which may be of potential use for identification of patients 
with myocardial ischemia.
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To evaluate the prognostic value of the severity, location and composition of CAD 
combined in a CTA risk score, the study of Chapter 8 was designed. The hypothesis 
was that a risk score incorporating all quantitative stenosis parameters allows for 
accurate risk stratification. Therefore, the purpose of this study was to determine if 
an automatic quantitative assessment of CAD using QCT combined into a single CTA 
risk score allows risk stratification of patients. In 300 patients QCT was performed 
to automatically detect and quantify all lesions in the coronary tree. Using QCT, 
the novel CTA risk score was calculated based on plaque extent, severity, composi-
tion, and location on a segment basis. During follow-up, the composite end point 
of all-cause mortality, revascularization, and nonfatal infarction was recorded. In 
127 patients with obstructive CAD (≥50% stenosis), 27 events were recorded, all in 
patients with a high CTA risk score. In conclusion, the present study demonstrated 
that a fully automatic QCT analysis of CAD is feasible and can be applied for risk 
stratification of patients with suspected CAD. The novel CTA risk score incorporating 
location, severity, and composition of coronary lesion may improve risk stratification, 
but this needs to be confirmed in larger studies. 
The aim of the study in Chapter 9 was to evaluate the feasibility of QCT for the as-
sessment of coronary atherosclerosis changes over time on serial CTA in patients with 
stable chest pain. For this study 53 patients clinically referred for the evaluation of 
chest pain who underwent a coronary CTA at the Rijnland Hospital. After a minimum 
of 2 years CTA was repeated to evaluate changes in coronary atherosclerosis over 
time. For accurate and reproducible assessment of CAD changes, all CTAs were quan-
titatively analysed using QCT. All parameters of dimension and composition of CAD 
were compared between patients to assess possible regression and progression of 
CAD. It was demonstrated that 32(60%) showed regression of coronary total atheroma 
volume whereas 21(40%) showed progression of coronary atheroma. Patients with 
progression of coronary atheroma had progression of all four plaque types. However, 
patients with regression demonstrated a regression of all plaque components except 
for dense calcium, for which progression was observed. This study demonstrated that 
the assessment of changes in CAD with QCT is feasible. Potentially QCT could be 
applied to assess the efficacy of anti-atherosclerotic therapy.
Part 2
Part 2 of this thesis discusses the value of CTA in high risk diabetic patients without 
chest pain syndrome. 
Chapter 10 primarily evaluated changes in myocardial ischemia on SPECT myo-
cardial perfusion imaging after 2 years in a cohort of high-risk patients with diabetes 
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without cardiac symptoms or known CAD. Secondly, this chapter assessed the value 
of baseline CTA-derived coronary atherosclerosis parameters to predict changes in 
myocardial ischemia. The population consisted of 100 high-risk patients with diabetes 
without cardiac symptoms referred for cardiovascular risk stratification. All patients 
underwent CAC scoring, CTA, and SPECT MPI. After 2 years of follow-up, SPECT MPI 
was repeated to evaluate potential progression of ischemia.  The rate of progression 
of ischemia in high-risk patients with diabetes without cardiac symptoms is limited. 
Few patients presented with new ischemia, whereas some patients showed resolution 
of ischemia. Atherosclerosis parameters on CTA were not predictive of new-onset 
ischemia or progression of ischemia.
Chapter 11 aims to investigate the long term prognostic value of coronary CTA in a 
large population of high risk diabetic patients without chest pain syndrome. 525 dia-
betic patients without chest pain syndrome were prospectively included to undergo 
coronary artery calcium (CAC)-scoring followed by coronary CTA. During follow-up 
the composite endpoint of all-cause mortality, non-fatal myocardial infarction and 
late revascularization (>90 days) was registered. After median follow-up of 5.0(IQR 
2.7-6.5) years the composite endpoint occurred in 65(14%) patients. Coronary CTA 
demonstrated a high prevalence of CAD (85%), mostly non-obstructive CAD (51%). 
Furthermore, patients with a normal CTA had an excellent prognosis (event-rate 
3%). An incremental increase in event-rate was observed with increasing CAC-risk 
category or coronary stenosis severity. Finally, obstructive (50-70%) or severe CAD 
(>70%) was independently predictive of events It was concluded that coronary CTA 
provided prognostic value in high risk diabetic patients without chest pain syndrome. 
Most importantly, the prognosis of patients with a normal CTA was excellent. 
Conclusions
The objective of this dissertation was to establish the value of QCT to further enhance 
the clinical applicability and accuracy of coronary CTA. The automatic characteriza-
tion of coronary atherosclerosis with QCT is feasible and correlates well with IVUS 
VH. However, further work is needed to provide quantification of coronary stents 
and coronary blood flow.  In the near future, the parameters of dimension and com-
position of coronary atherosclerosis will likely gain more clinical interest. It appears 
that coronary CTA can provide more clinically relevant information than the mere 
presence of coronary atherosclerosis or obstructive stenosis. Therefore, a novel CTA 
risk score was created incorporating detailed information on the location, severity 
and composition of atherosclerosis as assessed with QCT. This CTA risk score allows 
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accurate risk stratification of patients with suspected CAD. The work on this CTA risk 
score is continued to further validate the CTA risk score in external patient cohorts. 
In this thesis the feasibility of QCT to assess changes over time in coronary ath-
erosclerosis on CTA was explored. For clinical practice, disease progression (or 
regression) is an important variable which could be used to evaluate the efficacy 
of drugs, but also provide a more detailed insight in the natural history of coronary 
atherosclerosis on CTA. 
A drawback of coronary CTA is the fact that the hemodynamic significance of a le-
sion cannot be evaluated. In this thesis it was demonstrated that QCT provided better 
correlation with the presence of myocardial ischemia on SPECT MPI as compared to 
current visual assessment of coronary CTA.  
With regards to the specific setting of high risk diabetic patients without chest pain 
syndrome several conclusion can be derived from this thesis. First, if treated with 
optimal medical therapy, very few patients present with progression of myocardial 
ischemia. Second, the prognosis of these patients is good; the overall long-term event-
rate is limited. Especially diabetic patients without CAD on coronary CTA have an 
excellent prognosis. Even though the prognostic value of CTA was demonstrated in 
this thesis, it is unclear if screening using cardiac imaging influences the outcome 
of these patients. Additionally, cardiac CTA or CAC-score could help tailor medical 






Prognostic value of CTA in DM patients
Het doel van dit proefschrift was het bestuderen van de rol van computer tomografie 
(CT) coronairangiografie in de klinische praktijk. Het onderzoek van de thesis richt 
zich met name op de toepasbaarheid van een kwantitatieve analyse van coronairath-
erosclerose op CT coronairangiografie. Daarnaast wordt in dit proefschrift de klinische 
waarde van CT coronairangiografie in hoog-risico diabetes patiënten zonder angina 
pectoris klachten onderzocht.
De algemene introductie in Hoofdstuk 2 bespreekt de rol van cardiale CT in de 
diagnostiek van patiënten met verdenking op coronairlijden. Er wordt een overzicht 
geschetst van de waarde van cardiale CT en de coronair calcium score, in zowel 
patiënten met stabiele pijn op de borst, als patiënten met acute cardiale klachten die 
zich presenteren op de spoedeisende hulp. Daarnaast wordt ingegaan op nieuwe to-
epassingen van CT zoals myocardperfusie CT en ‘fractional flow reserve’ bepalingen 
op CT.
Deel 1
Deel 1 van dit proefschrift legt zich toe op de klinische toepasbaarheid van kwantita-
tieve analyse van atherosclerose op CT coronairangiografie. 
In hoofdstuk 3 wordt een overzicht geschetst van de verschillende beeldvorm-
ingstechnieken voor kwantificatie van coronairatherosclerose. Daarnaast wordt 
besproken hoe progressie van ziekte bepaald kan worden en wat de relatie is met 
medicamenteuze therapie. 
De waarde van QCT voor het bepalen van plaquecompositie werd bestudeerd in 
Hoofdstuk 4-6. Hiervoor werden de QCT datasets geregistreerd met de IVUS VH 
datasets op basis van anatomische herkenningspunten. 
In Hoofstuk 4 wordt gekeken naar de mogelijkheid om middels QCT de compositie 
van coronairatherosclerose op CT te bepalen. Hiervoor werden 57 patiënten geïnclu-
deerd die zowel CT coronairangiografie als IVUS VH hadden ondergaan. 
In alle patiënten werd QCT verricht. Plaquevolume werd gedifferentieerd in 4 
verschillende plaquetypes: necrotische plaque, ‘dense calcium’, fibreuze plaque en 
fibreus-vet weefsel. Dezelfde parameters werden bepaald in IVUS VH en vergeleken. 
Er werden twee verschillende algoritmes voor plaquedifferentiatie gebruikt. De eerste 
methode gebruikt vaste (‘fixed’) HU afkapwaardes. De tweede methode gebruikt een 
dynamisch algoritme, waarbij de HU afkapwaardes worden aangepast aan de intens-
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iteit van het lumen. De differentiatie tussen de verschillende plaquetypes middels 
QCT toonde een goede correlatie met IVUS VH. Het dynamische algoritme presteerde 
beter, zoals bleek uit smallere Bland-Altman ‘limits of agreement’. Op basis van deze 
resultaten werd geconcludeerd dat middels QCT, automatische kwantificatie van 
verschillende plaquetypes mogelijk is. 
De relatie tussen coronairatherosclerose op QCT en op IVUS VH wordt verder 
onderzocht in Hoofdstuk 5. Een belangrijke beperking van IVUS VH is het feit 
dat het echosignaal niet doordringt door coronair calcium. Hierdoor ontstaat een 
akoestische schaduw, waarbinnen plaquekarakterisatie moeilijk is. Middels een 
nieuw algoritme werd deze akoestische schaduw gedetecteerd en gekwantificeerd. 
Deze gekwantificeerde volumina werden meegenomen met de totale hoeveelheid 
calcium. Hiermee werd getracht te compenseren voor de verwachte onderschatting 
van coronair calcium op IVUS VH. Het bleek dat het toepassen van dit akoestische 
schaduwalgoritme de overeenkomst tussen IVUS VH en QCT voor het bepalen van 
coronair calcium verbeterde.
In Hoofdstuk 6 wordt de mogelijkheid om met QCT de Agatston coronair calcium 
(CAC) score te bepalen in contrast-CT datasets onderzocht. Hiervoor werden 100 
patiënten random geselecteerd uit verschillende CAC score categorieën (0, 1–99, 
100–399, 400–999, ≥1,000).. Een nieuw algoritme werd gebruikt om automatisch de 
CAC score te detecteren en kwantificeren in contrast-CT datasets. Deze CAC score 
werd gevalideerd met de Agatston CAC-score bepaald uit non-contrast CT datasets, 
zoals nu klinisch gebruikt wordt. De automatisch bepaalde CAC score uit contrast CT 
had een hoge correlatie en intra-class correlatie met de CAC score uit non-contrast 
CT. Daarnaast was er een goede overeenstemming binnen de verschillende CAC 
categorieën. Op basis hiervan werd geconcludeerd dat automatische detectie van 
de CAC score op contrast CT mogelijk is en een goede correlatie heeft met de non-
contrast CAC score. Mogelijk leidt het klinisch toepassen van dit algoritme tot een 
reductie van de stralingbelasting voor de patiënt en tijdswinst omdat het verrichten 
van een non-contrast scan niet langer nodig is.
Eerdere studies hebben laten zien dat er een beperkte overeenkomst is tussen de 
aanwezigheid van een obstructieve stenose op CT en de aanwezigheid van myo-
cardischemie op ‘single-photon emission CT’ SPECT. Mogelijkerwijs kan QCT deze 
correlatie verbeteren. 
In hoofdstuk 7 wordt daarom de relatie onderzocht tussen QCT parameters van 
coronairatherosclerose en de aanwezigheid van myocardischemie op SPECT. Veertig 
patiënten werden geïncludeerd die zowel CT coronairangiografie als SPECT hadden 
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ondergaan, binnen een tijdsinterval van 6 maanden. De CT coronairangiografie da-
tasets werden eerst visueel geanalyseerd, per vat en per laesie. Vervolgens werd QCT 
verricht van elke laesie in de coronairvaatboom, om plaquelengte, ‘plaqueburden’, 
percentage stenosegraad en ‘remodellingindex’ te bepalen. Daarnaast werd de aan-
wezigheid van myocardischemie bepaald aan de hand van de ‘summed difference 
score’. In totaal presenteerde 25 (62.5%) patiënten zich met myocardischemie in 
37 stroomgebieden. Zowel stenosegraad als plaque-lengte was onafhankelijk gecor-
releerd aan de aanwezigheid van myocardischemie. Beide kwantitatieve parameters 
hadden toegevoegde waarde bovenop baseline patiëntkarakteristieken en visueel 
bepaalde stenosegraad. Geconcludeerd werd dat QCT mogelijk een verbeterde 
bepaling van atherosclerose op CT mogelijk maakt en dus mogelijk geschikt kan zijn 
voor het beter identificeren van patiënten met myocardischemie. 
In hoofdstuk 8 wordt gekeken naar de prognostische waarde van een CTA-risicoscore 
die de ernst, locatie en compositie van coronairlijden op CTA combineert in één getal. 
De hypothese was dat een dergelijke score die meerdere kwantitatieve atherosclerose 
parameters samenvoegt in een getal, gebruikt kan worden voor risicostratificatie van 
patiënten. Het doel van deze studie was om te bepalen of een CTA risico score op 
basis van automatische kwantitatieve analyse van coronairlijden met QCT, risico-
stratificatie van patiënten mogelijk maakt. In 300 patiënten werd QCT verricht voor 
het automatisch detecteren en kwantificeren van alle coronairstenosen in de coro-
nairvaatboom. Een nieuwe CTA-risicoscore werd gecreëerd die een weergave geeft 
van de totale atherosclerose belasting van een patiënt. Deze score is de optelsom van 
de locatie, ernst en compositie van atherosclerose per coronairsegment. Gedurende 
follow-up werden de volgende eindpunten geregistreerd: sterfte, myocardinfarct en 
late-revascularizatie (>90 dagen). In de 27 patiënten met obstructief coronairlijden 
(≥50% stenose) vonden 27 events plaats, allen in patiënten met een hoge CTA risico 
score. Deze studie liet zien dat een volledig automatische analyse van coronairlijden 
op CT coronair angiografie middels QCT mogelijk is en gebruikt kan worden voor 
risicostratificatie van patiënten. Daarnaast toonde deze studie aan dat een nieuwe 
CTA-risicoscore die verschillende parameters van atherosclerose in één getal samen-
vat, nauwkeurige risicostratificatie van patiënten mogelijk maakt. De exacte klinische 
waarde van deze score moet echter nog worden bevestigd in grotere studies. 
In de studie beschreven in Hoofdstuk 9, wordt gekeken naar de mogelijkheid om 
middels QCT veranderingen in coronairatherosclerose op seriële CT coronair an-
giografie te meten. Hiervoor werden 53 patiënten met stabiele angina geïncludeerd. 
Deze patiënten waren verwezen voor klinische evaluatie van pijn op de borst middels 
CT in het Rijnlandziekenhuis. Na minimaal 2 jaar werd de CT coronair angiografie 
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herhaald, om de verandering in coronairatherosclerose in de tijd te bepalen. Om de 
veranderingen zo accuraat mogelijk te bepalen werd alle CT data geanalyseerd met 
QCT. Parameters van dimensie en compositie van atherosclerose werden vergeleken 
om te bepalen of er progressie of regressie van atherosclerose was. In 32 patiënten 
(60%) was er regressie van het totale atheromavolume, terwijl 21 patiënten (40%) 
progressie van atheroma hadden. Patiënten met progressie hadden progressie van 
alle vier verschillende plaque componenten. Patiënten met regressie van ziekten had-
den regressie van alle plaquecomponenten, behalve calcium. Middels deze studie 
werd aangetoond dat het bepalen van progressie van atherosclerose mogelijk is met 
QCT. Mogelijk kan QCT in de toekomst worden gebruikt voor het bepalen van de 
effectiviteit van anti-atherosclerose therapie. 
Deel 2
Deel 2 van deze thesis bespreekt de waarde van CT coronair angiografie in hoog- 
risico diabetespatiënten zonder angina pectoris klachten.
Hoofdstuk 10 is een evaluatie van veranderingen in myocardischemie op SPECT in 2 
jaar tijd, in een cohort diabetes patiënten zonder cardiale klachten of bekend coro-
nairlijden. Daarnaast wordt in dit hoofdstuk gekeken naar de waarde van parameters 
van atherosclerose op CT om veranderingen in myocardischemie te voorspellen. De 
patiënten populatie bestond uit 100 hoog risico patiënten zonder cardiale klachten 
die waren verwezen voor cardiovasculaire risico analyse. Alle patiënten kregen 
een CAC-score, CT coronairangiografie en SPECT myocardperfusie scintigrafie op 
baseline. Na 2 jaar werd SPECT myocardperfusie scintigrafie herhaald om eventuele 
progressie van myocardischemie vast te stellen. Het aantal patiënten met toename van 
ischemie was zeer beperkt. Slechts weinig patiënten presenteerden zich met nieuwe 
ischemie, terwijl andere patiënten afname van ischemie lieten zien. Atherosclerose 
parameters op CT coronairangiografie waren niet gerelateerd aan veranderingen in 
myocardischemie. 
In hoofdstuk 11 wordt de prognostische waarde onderzocht van CT coronair an-
giografie in een groot cohort diabetes patiënten zonder cardiale klachten. In totaal 
werden 525 patiënten geïncludeerd, die zowel een CAC score als een CT coronai-
rangiografie ondergingen. Gedurende follow-up werd gekeken naar sterfte, myocar-
dinfarct en late-revascularisatie (>90dagen). Na een mediane follow-up van 5 (IQR 
2.7-6.5)  jaar, trad een event op in 65(14%) patiënten. CT coronairangiografie toonde 
een hoge prevalentie van coronairlijden (85%), met name niet obstructief (51%). De 
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prognose van patiënten met een normale CT was zeer gunstig (incidentie 3%). Er 
was een toename in incidentie van events met toenemende CAC-score of ernst van 
coronairstenose. Daarnaast had de aanwezigheid van obstructief of ernstig coronair-
lijden onafhankelijke voorspellende waarde voor het optreden van events. Op basis 
hiervan werd geconcludeerd dat CT coronairangiografie voorspellende waarde heeft 
in diabetes patiënten zonder cardiale klachten. Met name de prognose van patiënten 
zonder coronairlijden op CT is uitstekend.
Conclusies
Dit proefschrift onderzoekt de waarde van QCT voor het verder verbreden van 
klinische toepasbaarheid en verhogen van diagnostische waarde van CT coronairan-
giografie.  Automatisch karakterisatie van coronairatherosclerose is mogelijk en toont 
een goede correlatie met IVUS VH. In de toekomst is meer onderzoek nodig om ook 
kwantificatie van stents en coronaire bloedstroom mogelijk te maken. 
Waarschijnlijk krijgen kwantitatieve parameters van afmetingen en plaque samen-
stelling in de toekomst meer klinische waarde. CT coronairangiografie faciliteert meer 
dan alleen analyse van de aanwezigheid van atherosclerose of obstructieve stenose. 
Daarom werd in dit proefschrift een nieuwe CT risico score ontwikkelend op basis 
van QCT, welke informatie over de locatie, compositie en ernst van coronairathero-
sclerose samenvoegt in een score. Deze CTA risico score kan gebruikt worden voor 
risicostratificatie van patiënten met verdenking op coronairlijden. Verder onderzoek 
zal worden gedaan om de klinische waarde van deze CT risico score verder te beves-
tigen in externe patiëntcohorten. 
In deze dissertatie is ook gekeken naar de mogelijkheid om met QCT veranderingen 
in atherosclerose over de tijd te kwantificeren. Dit zou in de toekomst klinisch goed 
toepasbaar zijn voor het meten van de effectiviteit van antiarteriosclerose therapie. 
Ook zou deze techniek meer inzicht kunnen verschaffen over het natuurlijk beloop 
van coronairatherosclerose. 
Een nadeel van CT coronairangiografie is het feit dat deze techniek geen inzicht ver-
schaft in thermodynamische consequenties van coronairstenosen. Dit proefschrift laat 
zien dat QCT een betere correlatie heeft met de aanwezigheid van myocardischemie 
op SPECT in vergelijking tot reguliere visuele analyse van CT coronairangiografie. 
Met betrekking tot de klinische setting van hoog risico diabetes patiënten zonder 
angina pectoris kunnen op basis van dit proefschrift twee dingen worden gecon-
cludeerd. Ten eerste: indien patiënten met diabetes een accurate farmacologische 
behandeling krijgen, is het aantal patiënten dat zich presenteert met toename van 
myocardischemie zeer beperkt. Ten tweede is de prognose van deze patiënten goed. 
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De lange termijn overleving, laat weinig events zien. Met name diabetes patiënten 
zonder coronairlijden op CT coronairangiografie hebben een goede prognose. Hoewel 
dit proefschrift de prognostische waarde van CTA heeft bevestigd, is vooralsnog niet 
duidelijk of het doen van beeldvorming in deze patiënten groep invloed heeft op 
overleving en uitkomst. Mogelijk kan CT coronairangiografie of coronair calcium 
score in de toekomst worden gebruikt voor het individualiseren van medicamenteuze 
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